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Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world 
(1). In 2008, there were an estimated 21,650 new cases of ovarian cancer and 15,520 deaths due to 
this disease in the United States (2). In the top 10 of leading cancer types for estimated new cancer 
cases and cancer related deaths, ovarian cancer was ranked 8th and 5th respectively (2). 
Approximately 75% of patients are diagnosed with evidence of metastatic spread beyond the 
ovaries, defined as International Federation of Gynecology and Obstetrics (FIGO) stages Ill and IV. 
The presentation of the disease at these late stages is due to the lack of specific early symptoms and 
effective screening methods. The standard treatment of patients with advanced stage ovarian 
cancer is surgical debulking followed by the combination of a platinum compound and paclitaxel (3). 
Initial response rates for advanced ovarian cancer are over 80% (4;5). Despite this high initial 
response rate, most patients with advanced stage disease will experience a recurrence and, 
depending at the time between primary treatment and recurrence, frequently acquired drug­
resistant disease (3). Consequently, the 5-year survival rate of patients with advanced disease is only 
about 30% (2). In the past decade, many studies have been performed using different classes of 
chemotherapy agents in various dosages, combinations and schedules in an effort to improve 
survival. These strategies did lead to a significant improvement of 5-year, but only marginal 
improvement of overall survival of patients with advanced ovarian cancer (6). 
Carcinogenesis and tumor behavior of ovarian cancer is thought to result from an accumulation of 
genetic changes (7;8). When these changes are better understood, it should be possible to identify 
new subgroups of ovarian cancer patients that may benefit from novel first-line experimental 
approaches. 
This thesis aims to gain more insight into the biology of ovarian cancer relating to survival and 
chemo-resistance using gene expression microarrays. 
Contents of the thesis 
Nowadays, microarray technology enables us to characterize ovarian tumors at the molecular level. 
For an individual sample the expression levels of thousands of genes can be determined 
simultaneously, thus allowing identification of gene expression profiles associated with distinct 
phenotypes. In chapter 2 a literature overview is presented of microarray studies that investigated 
prognostic and/or predictive gene expression profiles in advanced stage ovarian cancer. 
Furthermore, the methodological difficulties in prognostic ovarian cancer microarray studies are 
summarized. Finally, new strategies are described, which might enable us to define new molecular 
subgroups within advanced stage ovarian cancer at the level of biological pathways. 
Measuring transcript abundance by quantitative real-time PCR (qRT-PCR) is the most commonly 
used method for validating microarray data of a smaller set of genes and is especially useful when 
only few cells are available (9;10). Besides being a powerful technique qRT-PCR suffers from certain 
pitfalls, with inappropriate data normalization as the most important problem. At this moment, 
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housekeeping genes are the gold standard to normalize the mRNA fraction. However, the well­
known variation in gene expression of commonly used housekeeping genes will add noise to an 
experiment and could ultimately lead to misinterpretation of the results (11-13). In chapter 3 we 
used a large set of expression data from 13,629 published gene arrays of human tissues and 
investigated the abundance and stability in gene expression levels in order to identify the most 
stable housekeeping genes. 
As discussed in chapter 2, a variety of studies have employed gene expression profiling to classify 
ovarian carcinomas in clinically relevant subtypes. These studies provided valuable first clues to 
molecular changes in serous ovarian cancer that might be exploited to develop new treatment 
strategies. However, most studies were of relatively limited size and the number of overlapping 
genes in the identified profiles was minimal. Although identification of gene expression profiles 
associated with clinically relevant subtypes in ovarian cancer is important, knowledge is now rapidly 
emerging on how genes interact in pathways, networks and complexes. This new information allows 
one to unravel the cellular pathways determining the biological behavior of ovarian cancer. In 
chapter 4 the aim was to develop a gene expression profile associated with overall survival in 
advanced stage serous ovarian cancer, to assess the association of pathways and transcription 
factors with overall survival, and to validate our identified profile and pathways/transcription factors 
in an independent set of ovarian cancers. According to a randomized design, profiling of 157 
advanced stage serous ovarian cancers was performed in duplicate using "'35,000 70-mer 
oligonucleotide microarrays. A continuous predictor of overall survival was built taking into account 
well-known issues in microarray analysis, such as multiple testing and overfitting (14;15}. In addition, 
a functional class scoring analysis was utilized to assess pathways/transcription factors for their 
association with overall survival. The prognostic value of genes that constitute our overall survival 
profile was validated on a fully independent, publicly available data set of 118 well-defined primary 
serous ovarian cancers. Furthermore, a functional class scoring analysis was performed on this 
independent data set to assess the overlap in pathways/transcription factors identified in our data 
set. 
As described above, acquired resistance to platinum-based chemotherapy is a major hurdle in the 
treatment of epithelial ovarian cancer. Chemotherapy is thought to select for cells displaying a 
resistant phenotype, so pre- and post-chemotherapy samples obtained from the same patient 
provide a unique opportunity to study the effects of chemotherapeutic treatment on gene 
expression, while excluding noise caused by differences in patient and tumor characteristics. In 
chapter 5, in order to identify genes and pathways associated with chemo-resistance, we profiled 9 
paired stage Ill/IV serous ovarian cancers obtained prior to and shortly after 3-6 cycles of platinum­
based chemotherapy according to a randomized design using "'35,000 70-mer oligonucleotide 
microarrays. A paired t-test was applied to identify genes differentially expressed between pre-and 
post-chemotherapy samples. In addition, the prognostic impact of the identified genes was 
evaluated in the set of 157 profiled stage Ill/IV serous ovarian cancers described in chapter 4. 
Furthermore, utilizing Gene Set Enrichment Analysis (GSEA) enabled us to integrate all available 
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genomic information into functional sets according to pre-defined biological pathways. Finally, we 
validated some of our results with RT-PCR and immunohistochemistry on ovarian tumor tissue 
microarrays. 
It has been hypothesized that the net expression of a gene is regulated by the combined effects of 
various transcriptional system regulators {TSRs) {16-18). However, characterizing the complexity of 
regulation of the transcriptome is a major challenge. In chapter 6 we obtained microarray 
expression data of 17,550 human samples hybridized to HG-U133A or HG-U133 Plus 2.0 Genechips 
{Affymetrix, Santa Clara, California, USA) from the Gene Expression Omnibus (19). These data sets 
contained a wide range of heterogeneous tissues (primary patient material, cell lines, normal 
tissues, etc.) and covered a multitude of different experimental conditions {transfected/transduced, 
stimulated or treated cells, etc.). Principal Component Analysis {PCA) on this large data set provided 
us with a global picture of the dynamics of gene expression on different levels of transcriptional 
regulation. 
Finally, findings in this thesis are summarized and future perspectives are discussed in chapter 7. 
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Chapter 2 
Abstract 
Ovarian cancer is a heterogeneous disease with respect to histopathology, molecular biology, and 
clinical outcome. In advanced stages, surgery and chemotherapy result in an approximately 25% 
overall 5-year survival rate, pointing to a strong need to identify subgroups of patients that may 
benefit from targeted innovative molecular therapy. This review summarizes: (a) microarray 
research identifying gene-expression profiles in ovarian cancer; (b) the methodological flaws in the 
available microarray studies; and (c) applications of pathway analysis to define new molecular 
subgroups. Microarray technology now permits the analysis of expression levels of thousands of 
genes. So far seven studies have aimed to identify a genetic profile that can predict survival/clinical 
outcome and/or response to platinum-based therapy. To date, the clinical evidence of prognostic 
microarray studies has only reached the level of small retrospective studies, and there are other 
issues that may explain the non-reproducibility among the reported prognostic profiles, such as 
overfitting, technical platform differences, and accuracy of measurements. We consider pathway 
analysis a promising new strategy. The accumulation of small differential expressions within a 
meaningful molecular regulatory network might lead to a critical threshold level, resulting in ovarian 
cancer. Microarray technologies have already provided valuable expression data for classifying 
ovarian cancer and the first clues about which molecular changes in ovarian cancer could be 
exploited in new treatment strategies. Further improvements in technology as well as in study 
design, combined with pathway analysis, will allow us to detect even more subtle tumor expression 
differences among subgroups of ovarian cancer patients. 
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Introduction 
Ovarian carcinoma is the leading cause of death from gynecological malignancies in the western 
world (1). Its high death rate is a result of the fact that most patients (> 60%) are diagnosed at an 
advanced stage of disease (2). Debulking surgery followed by platinum-based chemotherapy 
schemes is considered standard care for these patients (3). However, despite an initial response rate 
of 65% - 80% to first-line chemotherapy, most ovarian carcinomas relapse. Acquired resistance to 
further chemotherapy is generally responsible for treatment failure, resulting in an overall 5-year 
survival rate of only 10% - 30% for late-stage ovarian cancer (2). Classic clinicopathological factors, 
such as age, stage, residual tumor after first laparotomy, differentiation grade, histiotype, and 
response to chemotherapy, are important prognostic markers {3), but it is not possible to select 
optimal chemotherapy for an individual patient based on these factors. 
Ovarian cancer is thought to result from an accumulation of genetic changes (4). When these 
changes are better understood, it should be possible to identify new subgroups of ovarian cancer 
patients. This may identify patients benefiting in the future from novel first-line experimental 
approaches when having a high chance of resistance to standard first-line chemotherapy. 
Furthermore, insights might be provided into tumor aggressiveness and drug resistance, yielding 
potential new molecular targets for therapy. However, to date, there exist no such therapies that 
are proven and used in ovarian cancer, and it is still speculative that there will be {5;6). The speed of 
elucidating this insight is hampered by the relatively low incidence of and the substantial molecular 
heterogeneity among ovarian cancer subtypes {2;4). The prognostic and/or predictive value of 
several single molecular markers has been evaluated in ovarian cancer {5;7). To date, gene­
expression patterns have also been used to classify ovarian carcinomas into clinically relevant 
subtypes {Figure 1). However, none of these single molecular markers or predictor sets of genes 
have been clinically implemented, mainly because their reliability and validity have not yet been well 
established. 
In this review we summarize: (a) microarray research identifying gene-expression profiles in ovarian 
cancer; (b) the methodological flaws in ovarian cancer microarray studies; and (c) applications of 
pathway analysis to define new molecular subgroups. 
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Figure 1. Gene expression patterns can be used to classify ovarian 
carcinomas into clinically relevant subtypes. 
Microarray studies in ovarian cancer 
Studies on the role of single molecular markers have shown ovarian carcinogenesis to be a complex 
process, multifactorial in nature, and associated with genetic abnormalities in multiple gene 
families. Microarray technology now permits analysis of expression levels of thousands of genes and 
is widely used to identify prognostic gene-expression profiles for all sorts of cancer. Several studies 
using DNA microarrays to determine gene-expression profiles in ovarian cancer cell lines or ovarian 
carcinomas have been reported. The specific aims of the separate studies are listed in 
supplementary Table S1. Most have tried to identify diagnostic markers by comparing ovarian 
cancers or ovarian cancer cell lines with normal ovarian epithelium. Ovarian cancer cell line models 
were mostly used to identify genes related to drug resistance. Recently, we published a study on 
drug resistance in four ovarian cancer cell lines, which differed only in their degree of cisplatin 
resistance (8). We identified 315 genes associated with cisplatin resistance. Many studies profiling 
ovarian tumors have searched for genes associated with classical clinical prognostic factors, or drug 
resistance, to identify molecular clues to prognosis and treatment efficacy. So far, seven microarray 
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studies have looked at prognostic and/or predictive genes and gene profiles for predicting individual 
disease outcome in advanced ovarian cancer (9-15). Three studies aimed to predict survival/clinical 
outcome. Spentzos et al. used 34 tumor samples to identify a 115-gene profile {14). When applied to 
a validation set of 34 samples, the profile distinguished patients with a favorable overall survival 
(median, 30 months versus not yet reached; log-rank p = .004). The profile consists of 70 genes 
overexpressed in the unfavorable outcome group and 45 genes underexpressed in the favorable 
group. Berchuck et al. tried to identify gene-expression patterns using classification tree and linear 
discriminant models that reflected patient survival by profiling tumors from 54 advanced-stage 
patients (9). Survival was < 3 years in 30 cases and > 7 years in 24 cases. They presented 26 genes 
used in tree and linear discriminant models of short-term versus long-term survival, including three 
genes involvea in classification trees and 23 genes appearing in 15 or more leave-one-out linear 
discriminant models. They were also able to confirm that the identified set of genes associated with 
survival in their l inear discriminant models held their prognostic value in the set of independent 
tumors profiled by Spentzos et al. (14). 
Instead of studying overall survival using expression profiles, Hartmann et al. tried to predict which 
women were at risk for early (< 21 months) versus late (> 21 months) relapse after initial 
chemotherapy (12). They identified a 14-gene profile predictive for early recurrence by profiling 79 
advanced-stage, high-grade tumors. In addition to these three prognostic studies, four other studies 
tried to identify a profile predictive of response to platinum-based therapy. Spentzos et al. 
discovered a 93-gene profile predictive of pathological complete response to chemotherapy by 
profiling 24 tumors from patients who had undergone second-look surgery (15). This profile was also 
able to distinguish between cancers in a validation series of patients with favorable versus 
unfavorable overall survival. Their prognostic 115-gene profile for overall survival, described above, 
was determined from the same data but, surprisingly, showed no gene overlap with the 93-gene 
profile associated with predicting response to chemotherapy. Combining both profiles yielded better 
prognostic discrimination than either profile alone. Helleman et al. identified a nine-gene profile 
using microarray and reverse transcription-polymerase chain reaction (RT-PCR) that was able to 
classify tumors from 24 patients according to their response to platinum-based therapy (13). Using 
RT-PCR, this nine-gene set predicted platinum resistance in an independent validation set of 72 
patients. However, in contrast to Spentzos et al., who assessed response pathologically, they 
assessed a clinical response according to World Health Organization criteria (15). They further 
defined non-responders as patients whose tumors showed progression, whereas Spentzos et al. 
considered all the patients whose tumors showed no pathological complete response as non­
responders (15). The differences in definition of response to chemotherapy may be one reason for 
the low number of genes shared by the two profiles. In a preliminary study, Crijns et al. labeled 
samples from 157 patients with advanced ovarian cancer with Cy5 and Cy3 (10). They identified a 
53-gene Cy5 predictor set and a 76-gene Cy3 predictor set for response to chemotherapy. The two 
predictor sets had 32 genes in common. Misclassification rates for the original CyS and Cy3 datasets 
were validated with a phenotype randomization test and were significantly better than random, 
confirming the relevance of the new predictor sets for response to chemotherapy. Dressman et al. 
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developed an expression model with 1,727 genes that predicts response to platinum-based therapy 
using a training set of 83 advanced-stage serous ovarian cancers and tested it on a 36-sample 
validation set (11). A prediction accuracy of 78% in the validation set was achieved. In parallel, 
expression signatures defining the status of oncogenic signaling pathways were evaluated. In 
patients with platinum-resistant disease they identified expression signatures consistent with 
activation of Src and Rb/E2F pathways. Several genes reported in the prognostic and predictive 
profile studies described above (such as those encoding T-lymphocyte maturation-associated 
protein, heat shock protein 27, SRD5Al, lysophospholipase II, plasminogen activator inhibitor type 1, 
BAX, platelet-derived growth factor receptor, fibronectin, connective tissue growth factor) are 
known to affect the malignant phenotype (16-25). This suggests that gene-expression profiling can 
indeed be used to define prognosis and yield mechanistic insights into ovarian carcinogenesis and 
chemoresista nee. 
Methodological difficulties of prognostic ovarian cancer 
microarray studies 
So far, the clinical evidence of prognostic microarray studies (as well as prognostic studies on single 
markers) has only reached level 3 (small retrospective studies) on a scale of 5 (low) to 1 (high) (26). 
These studies therefore encounter the same methodological difficulties as prognostic studies on 
single molecular markers. However, in ovarian cancer microarray studies, there are other reasons 
that may explain the limited overlap between the prognostic profiles. 
Overfitti ng 
In ovarian cancer microarray studies, the problem of sample size becomes even more important, as 
overfitting, that is, finding a discriminatory pattern by chance may occur when large numbers of 
potential predictors are used to discriminate among a small number of outcome events (27;28). A 
complex multivariate analysis may very well result in a perfect prognostic profile for the dataset at 
hand, but perform poorly on independent datasets. Because the numbers of samples included in the 
seven prognostic and/or predictive microarray studies are all of limited size (range, 24-157) in 
comparison with the numbers of features on the microarrays, they are all at risk for overfitting. The 
Hartmann et al. study, identifying a 14-gene profile, is a striking example where overfitting might 
have occurred (12). They proposed that their final model classified 40 of 51 samples correctly (78%; 
p < .001). This high classification accuracy was probably achieved by using all 51 samples to fit the 
model. They also reported a classification accuracy of 86% (p < .05) for their model on an 
independent test set of 28 samples, but we feel this should be interpreted with caution. The authors 
called this test set independent, but it was actually used to select the best-performing prediction 
model out of 100 and thus introduced additional degrees of freedom for fitting a model. 
Multiple Microarray Platforms 
Multiple array platforms vary in the kind of probes they use (short-oligonucleotide, long­
oligonucleotide, cDNA, etc.), the production method (in situ polymerization, spotting, microbeads, 
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etc.), and the labeling method. For microarrays to be reliable tools, they must possess probes that 
hybridize with high sensitivity and specificity. The seven studies to find prognostic and/or predictive 
gene profiles for predicting individual disease outcome in advanced ovarian cancer used different 
types of microarray platforms. One major advantage of oligonucleotide arrays over cDNA arrays is 
that there is less possibility of probe mix-ups (29;30}. Oligonucleotide arrays can be synthesized in 
situ or synthesized ex situ and attached to a derivative substrate. Affymetrix (Affymetrix, Santa 
Clara, CA) and Agilent (Agilent Technologies, Palo Alto, CA) are both commercial platforms that rely 
on the in situ synthesis of probes. Affymetrix oligonucleotide arrays consist of 25-mer probes 
contrasting with the longer 60-mer probes employed by Agilent. Short oligonucleotides should, in 
theory, provide the greatest discrimination between related sequences, but the longer 60-mer 
probes are more tolerant of sequencing mismatches and thus more suitable for the analysis of 
highly polymorphic regions. Furthermore, when 60-mers instead of 25-mers are used, the sensitivity 
is enhanced, partly because of the larger area available for hybridization. Only recently, a novel 
array platform was developed on the basis of randomly assembled arrays of beads in wells (31). 
Following random assembly, the location and identity of each bead, bearing a gene-specific probe 
sequence, were determined via a sequential decoding process. Advantages of this approach are the 
dense packing that can be achieved and that there are multiple copies of each sequence-specific 
bead in an array. Randomness minimizes the effects of spatially localized artifacts and redundancy 
increases the precision and robustness of measurements. These factors combine to increase 
accuracy. Another advantage is that only 100 ng of input RNA is necessary. 
The problem of non-reproducibility of prognostic profiles related to the technical differences 
described above has been addressed by several studies, which drew different conclusions (32-45). 
Some studies found that the concordance of results across expression analysis platforms was low in 
contrast to other studies that concluded the opposite. A study comparing the Affymetrix and 
lllumina (lllumina Inc., San Diego, CA) arrays showed that agreement was very high, particularly for 
genes that were predicted to be differentially expressed between two tissue types (33). That study 
further demonstrated that the agreement was strongly correlated with the level of gene expression 
and concordance was superior when probes on both platforms could be identified as being likely to 
target the same set of transcripts of a given gene. 
Signa l-to-Noise Ratio 
The intensities observed from ovarian cancer microarray experiments do not simply represent the 
relative gene-expression level. They are composed of signal (gene-expression level) and 
experimental noise (46;47). Each stage in the course of a microarray experiment is a source of 
experimental noise, for example sample collection, sample labeling and hybridization, and the 
analysis and explanation of microarray data {30). The number of genes expected to be differentially 
expressed within a single tissue type between two classes of interest is probably small, and the 
differences in expression may not be large in relation to experimental noise (47). Because the 
samples used in the seven prognostic ovarian cancer profile studies described above were mainly 
composed of the serous histological type, it may be difficult to identify the relevant genes from 
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among the numerous noise genes. As such, confirmation and validation of genome-wide microarray 
results using additional methods such as real-time quantitative RT-PCR remain critical steps. 
Applying pathway analysis to define new molecular subgroups 
So far, profiling of ovarian cancer tissue has enabled classification of discrete subsets of ovarian 
cancers to predict outcome or response to chemotherapy. Ultimately, one would like to use 
expression profiles to better understand the biological pathways involved in oncogenesis. Several 
novel strategies have recently been proposed to identify relevant pathways linked to expression 
signatures. Bild et al. experimentally generated expression signatures that reflect the activation of 
various oncogenic signaling pathways (48). Initially, they brought primary human mammary 
epithelial cell cultures (HMECs) to quiescence. Subsequently, the HMECs were infected with 
adenovirus expressing either human c-Myc, activated H-Ras, human c-Src, human E2F3, or 13-
catenin. Quiescent cells were used because many of the pathways of interest, such as apoptotic or 
proliferative pathways, would be inactive. The activation states of the five defined pathway 
signatures were simultaneously analyzed in advanced-stage ovarian carcinomas, among other tumor 
types. The ovarian cancers exhibited a dominant pattern of 13-catenin and Src deregulation, either 
elevated or diminished. Notably, the co-deregulation of Src and 13-catenin identified a population of 
patients with very poor survival compared with other pathway clusters. They also showed that 
signatures for Ras and Src pathway activation accurately predicted the in vitro sensitivity of a broad 
range of human tumor cell lines to drugs targeting the mutational activated versions of these 
proteins. Potti et al. used in vitro drug sensitivity data obtained in cell lines coupled with Affymetrix 
microarray data to develop gene-expression signatures that predict sensitivity to chemotherapeutic 
drugs {docetaxel, topotecan, doxorubicin, etoposide, 5-fluorouracil, paclitaxel, and 
cyclophosphamide) (49). They integrated the chemotherapy response signatures with signatures of 
oncogenic pathway deregulation to identify new therapeutic strategies. Regression analysis showed 
a relationship between phosphatidylinositol 3-OH {Pl3)-kinase pathway deregulation and docetaxel 
resistance, indicating a potential relevance of future use of a Pl3-kinase inhibitor in this docetaxel­
resistant subgroup. Several other studies generating expression signatures representing deregulated 
pathways made use of mouse tumor models or cells stably transformed by the loss of a tumor­
suppressor gene or the expression of an oncogene {50-54). These strategies have the advantage of 
being more reflective of the oncogenic phenotype compared with the acute expression of an 
oncogene with an adenovirus. On the other hand, the limitation of steady-state expression is the 
extent to which the steady-state obscures the direct effects of a single pathway and begins to merge 
several pathways. In contrast to experimentally derived signatures Subramanian et al. describe a 
computational approach called gene set enrichment analysis {52). Genes that are differentially 
expressed between two phenotypic classes are compared according to rank against a large 
collection of pathway data and other categorizations {functional groupings). This is done to 
determine enrichment for one or more of these functional groupings. Functional groupings a re 
made according to known pathway databases such as Kyoto Encyclopedia of Genes and Genomes 
{KEGG), cytogenetic loci, or other relevant functional groupings data. A drawback of this approach is 
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the reliability of functional groups defined by these databases and the fragmented knowledge about 
them. For ovarian cancer, a similar approach was applied by Donninger et al. using PathwayAssist 
(lobion Informatics, LLC, La Jolla, CA), a commercially available program (55). Based on the 
expression results and PathwayAssist, a signaling pathway associated with tumor cell migration, 
spread, and invasion was identified as being activated in advanced ovarian cancer. Mougeot et al. 
also performed microarray analysis with the aim of identifying molecular interaction networks 
defining tumor growth (56). Hierarchical clustering identified groups of tissues reflective of low 
malignant potential/early cancer onset and possible precancerous stages involving small-molecule, 
cytokine, and/or hormone-dependent feedback responses specific to the pelvic reproductive system 
and a priori-initiated tumor suppression mechanisms. They also established a protein/protein 
interaction database using the Biomolecular Interaction Network Database and Cytoscape 2.1 
(57;58). This associated database was used to build and visualize molecular regulatory networks 
integrating small but significant changes in gene expression. 
Discussion 
In ovarian cancer, the use and potential of conventional chemotherapeutic drugs seem to have 
reached a ceiling. Chemotherapeutic drugs used differently can still clearly improve survival. 
Armstrong et al. recently showed that i.p. cisplatin and paclitaxel resulted in a higher survival rate, 
48% versus 38%, at 60 months in stage Ill patients in comparison with i.v. paclitaxel (59). Although 
this is a clear improvement in this group of patients over i.v. treatment, it also shows that there is 
still ample room for improvement. In the future we would like to have more patient-tailored 
therapy, in which molecularly different subtypes are treated with specific drugs. 
Microarray technologies have already provided valuable expression data for classifying ovarian 
cancers based on gene profiling. However, both at the level of study performance as well as at the 
level of technology used, there is room for further improvement. The low signal-to-noise ratio often 
seen in microarray experiments can generally be improved by synthesizing multiple copies of the 
(same) probe. Chou et al. showed that accurate gene-expression measurement can be achieved with 
multiple probes per gene, and fewer probes are needed if longer probes rather than shorter probes 
are used (60). To further reduce error, standards for reporting microarray data have been 
established: minimum information about a microarray experiment {MIAME) (61). This standard 
contains information required to easily interpret the microarray data so that the results derived 
from its analysis can be independently verified. Mcshane et al. recently formulated the REporting 
recommendations for tumor MARKer prognostic studies (REMARK) to provide relevant information 
on how to perform good prognostic studies and to encourage transparent and complete reporting 
so that the usefulness of the data can be judged by outsiders (62). As concluded in all prognostic 
microarray studies, the prognostic value of gene profiling in ovarian cancer must be further 
evaluated in additional, large prospective studies to reach levels 2 or 1 for clinical evidence (26). 
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However, microarray analyses or studies, mainly providing lists of significant genes with p-values, 
are insufficient to fully understand the etiology of ovarian cancer. For example, a single gene that is 
significantly up- or down-regulated does not necessarily have any physiological impact on the 
growth of ovarian cancer. Physiological effects will depend on the relative distribution of the gene 
product and its interaction with other genes. If the progression of ovarian cancer depends on the 
accumulation of small significant changes in expression, it will be necessary to place these significant 
genes in gene regulatory networks to reveal whether molecular pathways are deregulated. Such an 
analysis should provide insight into which molecular pathways contribute to the development and 
clinical outcome of ovarian cancer. Moreover, it may indicate which components of these associated 
pathways can be used as therapeutic targets. In the future, it will be necessary to extend and correct 
our knowledge of molecular regulatory networks to be able to identify the molecular pathways 
involved in tumor progression with greater reliability. 
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Abstract 
For accurate and reliable gene expression analysis, normalization of gene expression data against 
housekeeping genes (reference or internal control genes) is required. It is known that commonly 
used housekeeping genes (e.g. ACTB, GAPDH, HPRT1, and 82M) vary considerably under different 
experimental conditions and therefore their use for normalization is limited. We performed a meta­
analysis of 13,629 human gene array samples in order to identify the most stable expressed genes. 
Here we show novel candidate housekeeping genes (e.g. RPS13, RPL27, RPS20 and OAZ1) with 
enhanced stability among a multitude of different cell types and varying experimental conditions. 
None of the commonly used housekeeping genes were present in the top 50 of the most stable 
expressed genes. In addition, using 2,543 diverse mouse gene array samples we were able to 
confirm the enhanced stability of the candidate novel housekeeping genes in another mammalian 
species. Therefore, the identified novel candidate housekeeping genes seem to be the most 
appropriate choice for normalizing gene expression data. 
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Introduction 
Measuring transcript abundance by real-time reverse transcription PCR (RT-PCR) has become the 
method of choice due to its high sensitivity, specificity and broad quantification range for high­
throughput and accurate expression profiling of selected genes (1). RT-PCR is the most commonly 
used method for molecular diagnostics, validating microarray data of a smaller set of genes and is 
especially useful when only a small number of cells is available (2-6). Besides being a powerful 
technique RT-PCR suffers from certain pitfalls, with inappropriate data normalization as the most 
important problem. Various strategies have been applied to control gene expression results. 
Standardization of the amount of cells is for instance a problem when tissue samples are used. 
Quantification of total RNA is difficult when only minimal RNA quantities are available. More 
importantly, it measures the total RNA fraction of a sample, which consists for only a relatively small 
percentage (<10%) of mRNA and predominantly of rRNA molecules. A drawback to the use of 18S or 
28S rRNA molecules as control genes is the abovementioned imbalance between mRNA and rRNA 
fractions (7). In addition, it has been shown that certain biological factors and drugs may affect rRNA 
transcription (8;9). Finally, those approaches still do not take a correction for the efficiency of 
enzymatic reactions into account. At this moment housekeeping genes are the gold standard to 
normalize the mRNA fraction. However, the known considerable variation in gene expression of 
commonly used housekeeping genes will add noise to an experiment and could ultimately lead to 
erroneous results (10-12). This even resulted in strategies to control for the instability by using sets 
of control genes and calculation of normalization factors using statistical algorithms (1;12;13). In 
order to identify the most stable expressed housekeeping genes we used a large set of expression 
data from 13,629 published human gene arrays and investigated the abundance and stability in gene 
expression levels. We validated the human results in mice using a set of 2,543 published mouse 
gene arrays. 
Results and discussion 
A candidate housekeeping gene was defined as a gene with the most stable expression, i.e. a gene 
with a small coefficient of variation (CV) and a maximum fold change < 2 (MFC, the ratio of the 
maximum and minimum values observed within the dataset). In addition, a mean expression level 
lower than the maximum expression level subtracted with 2 standard deviation (SD) was a 
prerequisite for a candidate housekeeping gene. The expression levels of 13,037 unique genes in the 
set of 13,629 diverse samples were used. Table 1 shows the identified top 15 candidate 
housekeeping genes (Table S1 shows CVs of all 13,037 unique genes). All 15 genes had a CV beneath 
the 4% level and a standard deviation below 0.49. Moreover, the MFCs ranged from 1.41 (RPL27) to 
1.99 (RPS12), reflecting the minor variation in expression of those candidate housekeeping genes 
within the large dataset. Thirteen of these top 15 genes encode for ribosomal proteins involved in 
protein biosynthesis. The distribution of the expression levels is given in Figure 1. 
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Next, we studied the expression levels of commonly used housekeeping genes (e.g. ACTB, GAPDH, 
HPRT1 and 82M). The expression levels of those commonly used housekeeping genes fluctuated 
dramatically (Table 2). The MFC ranged from 1.91 (ACTB) to 15.15 (ALOOA). Moreover, for only one 
of 12 commonly used housekeeping genes (ACTB) the CV was beneath the 5% level, reflecting the 
highly variable levels of those commonly used housekeeping genes within our large dataset. 
Remarkably, none of the classical housekeeping genes ranked among the top 50 identified candidate 
housekeeping genes. The distribution of expression levels of commonly used housekeeping genes is 
depicted in Figure 2. 
Table 1. Top 15 candidate housekeeping genes identified in 13,629 samples. 
Gene symbol Name Mean SD CV (%) MFC Rank 
RPS13 ribosomal protein S13 12.82 0.3 2.59 1.61 1 
RPL27 ribosomal protein L27 12.70 0.4 2.73 1.41 2 
RPS20 ribosomal protein S20 12.81 0.4 2.90 1.67 3 
RPL30 ribosomal protein L30 13.08 0.4 3.22 1.99 4 
RPL13A ribosomal protein L13A 13.01 0.4 3.29 1.83 5 
RPL9 ribosomal protein L9 12.95 0.4 3.36 1.68 6 
SRP14 signal recognition particle 14k0a 11.45 0.4 3.46 1.48 7 
RPL24 ribosomal protein L24 12.50 0.5 3.65 1.54 8 
RPL22 ribosomal protein L22 11.94 0.4 3.68 1.91 9 
RPS29 ribosomal protein S29 12.86 0.5 3.69 1.93 10 
RPS16 ribosomal protein S16 12.48 0.5 3.73 1.62 11 
RPL4 ribosomal protein L4 12.43 0.5 3.76 1.63 12 
RPL6 ribosomal protein LG 12.22 0.5 3.76 1.65 13 
OAZl ornithine decarboxylase antizyme 1 11.88 0.5 3.78 1.51 14 
RPS12 ribosomal protein S12 12.90 0.5 3.82 1.99 15 
CV, indicates the coefficient of variation and equals the standard deviation divided by the mean (expressed as a 
percentage). MFC, indicates the maximum fold change, i.e. the ratio of the maximum and minimum values 
observed within a dataset. The ranking is based upon three criteria: CV, a MFC <2 and a mean value lower than 
the maximum value with 2 standard deviation (SD) subtracted. 
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Figure 1. Expression distribution of the top 15 candidate housekeeping genes. 
Table 2. Ranking of 12 commonly used housekeeping genes identified in 13,629 samples. 
Gene 
symbol Name Mean SD CV (%) MFC Rank 
ACTB 13-actin 13.00 0.6 4.88 1.91 57 
GAPDH 
glyceraldehyde-3 phosphate 
12.83 0.7 5.75 6.37 139 
dehydrogenase 
LDHA lactate dehydrogenase A 12.09 0.7 5.92 2.21 168 
82M 13-2-microglobulin 12.75 0.8 5.97 4.01 176 
PGAM1 phosphoglycerate mutase 11.14 0.8 6.87 2.03 413 
ALDOA aldolase A 11.94 0.9 7.74 15.15 767 
PGK1 phosphoglycerate kinase 10.08 0.8 8.17 2.19 996 
HPRT1 hypoxanthine phosphoribosyl-transferase 9.29 0.9 9.94 2.48 2193 
TUBA1 a-tubulin 9.04 1.3 14.15 2.87 4921 
VIM vimentin 11.65 1.9 16.01 5.83 6016 
PFKP phosphofructokinase 8.89 1.6 17.93 6.25 7019 
G6PD glucose-6 phosphate dehydrogenase 7.27 1.7 23.86 5.78 9707 
CV, indicates the coefficient of variation and equals the standard deviation divided by the mean (expressed as a 
percentage}. The ranking of these commonly used housekeeping genes among all 13,037 unique tested genes is 
based on the CV. 
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To demonstrate the feasibility of the use of these novel candidate housekeeping genes, we created 
for 5 of the top 15 candidate housekeeping genes primers (i.e. RPL27, RPL30, OAZ1, RPL22 and 
RPS29). We tested with PCR for desired product length and specificity; no pseudogenes were 
amplified (Figure 3 shows the PCR results). To validate the enhanced stability of the identified novel 
candidate housekeeping genes we used another mammalian model system, i.e. the mouse. The 
expression levels of 21,377 unique genes in a set of 2,543 diverse mouse samples were used. 
0 10 10 15 0 10 15 0 10 15 
1 �Ll □ - W: 1 
0 5 10 15 0 5 10 15 0 5 10 15 0 S 10 15 
Figure 2. Expression distribution of 12 commonly used housekeeping genes in 13,629 human samples. 
RPL27 OAZ1 RPL30 RPS29 RPL22 
L S B S B S B S B S B L 
Figure 3. PCR results of 5 novel candidate housekeeping genes. S 
indicates sample, cDNA of a HL-60 leukemic cell line was used for 
all primers, B indicates the blanc {H2O} and L indicates the 100 
base pair ladder {Fermentas). 
The novel candidate housekeeping genes identified in the human data set also showed stability in 
expression in mouse arrays (Table 3). Also in mouse expression arrays genes encoding for ribosomal 
proteins are the most stable expressed ones. So, the stability in expression of the identified 
candidate housekeeping genes was confirmed in another species. Our results clearly reveal novel 
candidate housekeeping genes with a more stable expression in different cellular and experimental 
contexts in comparison to frequently used housekeeping genes (e.g. ACTB, GAPDH and HPRn, On 
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the basis of a definition of ubiquitous and stable expression, our results indicate however that no 
single gene qualifies as a 'real' housekeeping gene. GAPDH and ACTB were used as single control 
genes in more than 90% of the cases in high impact journals (11). Commonly used control genes are 
historical carryovers and were considered good references for many years in techniques where a 
qualitative change was being measured, because these genes are expressed at relatively high levels 
in nearly all cells. However, the advent of RT-PCR placed the emphasis on quantitative change, and 
asks for a re-evaluation of the use of these historical housekeeping genes. 
Table 3. The variation in expression of the candidate housekeeping genes in mice. 
Gene symbol SD CV (%) MFC 
RPS29 0.26 1.92 1.26 
RPL4 0.39 2.95 1.34 
OAZ1 0.43 3.42 1.34 
RPL13A 0.50 3.89 1.36 
RPL6 a.so 3.90 1.30 
SRP14 0.56 5.22 1.40 
RPL24 0.63 6.10 1.59 
RPL27 0.74 6.16 1.53 
RPS13 0.73 6.34 1.50 
RPL9 0.57 6.41 1.56 
RPL22 0.76 6.42 1.46 
RPS16 0.80 6.46 1.49 
RPS12 0.83 7.01 1.49 
RPS20 1.01 8.61 1.57 
RPL30 0.87 8.97 3.80 
CV indicates the coefficient of variation and equals the standard deviation divided by the mean (expressed as a 
percentage). MFC indicates the maximum fold change, i.e. the ratio of the maximum and minimum values 
observed within a dataset. 
Here we show for the first time a genome wide evaluation of candidate housekeeping genes by a 
meta-analysis of more than 13,000 samples. Interestingly, the identified candidate novel 
housekeeping genes do not vary much in terms of functionality; they are predominantly ribosomal 
proteins involved in protein biosynthesis. Therefore, experimenters that tinker with this specific 




Using meta-analysis we were able to find candidate housekeeping genes with a much lower level of 
variance in expression across tissue types and experimental conditions than commonly used 
housekeeping genes. Our identified candidate housekeeping genes can be applied in (nearly) all 
future RT-PCR experiments without any restrictions. 
Materials and methods 
Microarray expression data of 13,629 publicly available samples hybridized to Affymetrix HG-U133A 
and HG-U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, Ca.) were downloaded from the Gene 
Expression Omnibus (14). This set of samples comprises gene expression data of a wide variety of 
different tissues (e.g. primary patient material, cell lines, diseased as well as normal tissues, stem 
cells etc. ) and varying experimental conditions (e.g. transfected/transduced cells, cytokine 
stimulated, cells under hypoxic conditions, ultraviolet treated cells, cells treated with 
chemotherapeutics or non cytotoxic drugs etc. ). Probesets that were available on both platforms 
were converted to official gene symbols, averaging expression values of multiple probesets targeting 
the same gene. Next, quantile normalization was applied to the log2 transformed expression values 
(15). For each gene the CV of the expression was calculated. The CV equals the standard deviation 
divided by the mean (expressed as a percentage). The CV is used as a statistic for comparing the 
degree of variation between genes, even if the mean expressions are drastically different from each 
other (16). The calculated CVs for all genes were ranked. In addition, the MFC was calculated to 
reflect the minor variation in expression of those candidate housekeeping genes within the large 
dataset. For validation 2,543 publicly available mouse samples hybridized to Affymetrix Mouse 
Genome 430 2.0 GeneChips (Affymetrix) were downloaded from the Gene Expression Omnibus (14). 
Again, this validation set comprises a wide variety of different mouse tissues and varying 
experimental conditions. 
Table 4. Primer sequences of 5 candidate housekeeping genes. 
Gene Base 
symbol Forward Reverse pairs T 
RPL27 ATCGCCAAGAGATCAAAGATAA TCTGAAGACATCCTTATTGACG 123 60 
RPL30 ACAGCATGCGGAAAATACTAC AAAGGAAAATTTTGCAGGTTT 158 60 
OAZ1 GGATCCTCAATAGCCACTGC TACAGCAGTGGAGGGAGACC 150 60 
RPL22 TCGCTCACCTCCCTTTCTAA TCACGGTGATCTTGCTCTTG 250 60 
RPS29 GCACTGCTGAGAGCAAGATG ATAGGCAGTGCCAAGGAAGA 213 60 
Forward and reverse indicate the specific primers; base pairs, the product length and T, the annealing 
temperature given as 0C. 
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Total RNA was extracted with Absolutely RNA Miniprep Kit (Stratagene, Amsterdam, The 
Netherlands), and reverse transcribed to cDNA with random hexamer and RevertAidTM M-MuLV 
Reverse Transcriptase (Fermentas, Burlington, Ontario, Canada) according to the manufacturer's 
protocols. Table 4 shows primer sequences for RPL27, RPL30, OAZ1, RPL22 and RPS29. The same 
annealing temperature (i.e. 60 uC) and number of cycles (i.e. 25) was used for all primers. The PCR 
products were analyzed by electrophoresis in a 1.0% agarose gel. 
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Ovarian cancer has a poor prognosis due to  advanced stage at presentation and either intrinsic or 
acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials 
with different combinations and sequences of classic cytotoxic drugs indicate that further significant 
improvement in prognosis by this type of drugs is not to be expected. Currently a large number of 
drugs, targeting dysregulated molecular pathways in cancer cells have been developed and are 
introduced in the clinic. A major challenge is to identify those patients who will benefit from drugs 
targeting these specific dysregulated pathways. The aims of our study were (1) to develop a gene 
expression profile associated with overall survival in advanced stage serous ovarian cancer, (2) to 
assess the association of pathways and transcription factors with overall survival, and (3) to validate 
our identified profile and pathways/transcription factors in an independent set of ovarian cancers. 
Methods and F indings 
According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was 
performed in duplicate using ~35,000 70-mer oligonucleotide microarrays. A continuous predictor of 
overall survival was built taking into account well-known issues in microarray analysis, such as 
multiple testing and overfitting. A functional class scoring analysis was utilized to assess 
pathways/transcription factors for their association with overall survival. The prognostic value of 
genes that constitute our overall survival profile was validated on a fully independent, publicly 
available dataset of 118 well-defined primary serous ovarian cancers. Furthermore, functional class 
scoring analysis was also performed on this independent dataset to assess the similarities with 
results from our own dataset. An 86-gene overall survival profile discriminated between patients 
with unfavorable and favorable prognosis (median survival, 19 versus 41 mo, respectively; 
permutation p-value of log-rank statistic = 0.015) and maintained its independent prognostic value 
in multivariate analysis. Genes that composed the overall survival profile were also able to 
discriminate between the two risk groups in the independent dataset. In our dataset 17 /167 
pathways and 13/111 transcription factors were associated with overall survival, of which 16 and 12, 
respectively, were confirmed in the independent dataset. 
Conclusions 
Our study provides new clues to genes, pathways, and transcription factors that contribute to the 
clinical outcome of serous ovarian cancer and might be exploited in designing new treatment 
strategies. 
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Introduction 
Ovarian carcinoma is the leading cause of death from gynecologic malignancies in the Western 
world (1). Debulking surgery followed by platinum-based chemotherapy is considered standard of 
care for patients with advanced stage ovarian cancer, but despite an initial response rate of 65%-
80% to first-line chemotherapy, most patients will relapse with drug-resistant disease (2). 
Consequently, the 5-y survival rate of patients with advanced-stage disease is only about 5%-30% 
(3). 
To date, a variety of studies have employed gene expression profiling to classify ovarian carcinomas 
in clinically relevant subtypes (4-9). These studies provided valuable first clues to molecular changes 
in serous ovarian cancer that might be exploited in new treatment strategies. However, most studies 
were of relatively limited size and the number of overlapping genes in the identified profiles was 
minimal. Although identification of gene expression profiles associated with clinically relevant 
subtypes in ovarian cancer is important, knowledge is now rapidly emerging on how genes interact 
in pathways, networks and complexes; this new information allows us to unravel the cellular 
pathways determining the biological behavior of ovarian cancer, and these pathways might be 
successfully targeted with drugs. 
The aim of our study was to (1) develop a gene expression profile associated with overall survival in 
advanced-stage serous ovarian cancer, (2) assess the association of pathways and transcription 
factors with overall survival, and (3) validate our profile and identified pathways/transcription 
factors in a fully independent, publicly available dataset of serous ovarian cancers. 
Materials and methods 
Patients and Tumor Samples 
The study population consisted of 157 consecutive patients with advanced-stage serous ovarian 
cancer operated on by a gynecologic oncologist from the University Medical Center Groningen 
(UMCG, Groningen, The Netherlands) in the period 1990 - 2003. All patients were treated according 
to Dutch guidelines, which are based on the International Federation of Gynecology and Obstetrics 
(FIGO) guidelines (10;11). Standard treatment included cytoreductive surgery followed by platinum­
based chemotherapy (in combination with paclitaxel after 1996). For follow-up, patients were seen 
every 3 mo for the first 2 y. Thereafter, follow-up visits had an interval of 4 mo in the third year, 6 
mo in the fourth and fifth year, and once a year in the sixth to tenth year. A follow-up visit 
comprised a general physical and gynecologic examination. CA125 serum levels were also routinely 
determined. 
Overall survival was calculated from the date of primary surgery to the date of last follow-up (right­
censored) or to the date of death due to ovarian cancer. Patients who died from intercurrent 
disease were right-censored at the time of death. All tumor samples were obtained at primary 
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surgery prior to chemotherapy, flash frozen in liquid nitrogen, and stored at -80 °C. Samples were 
confirmed to comprise tumor cells {median percentage tumor cells: 70%, interquartile range: 50% -
80%), as examined after hematoxylin and eosin staining of frozen sections. Patients gave informed 
consent for collection and storage of tissue samples in a tissue bank for future research. All relevant 
patient data were retrieved and transferred into an anonymous, password-protected, database. The 
patients' identity was protected by study-specific, unique patient codes and their true identity was 
only known to two dedicated data managers. According to Dutch regulations, these precautions 
meant no further institutional review board approval was needed {http://www.federa.org/). 
RNA extraction and ampl ification 
Total RNA from tumor samples was subjected to cesium chloride density gradient 
ultracentrifugation {Roche, Almere, The Netherlands). After total RNA samples had been given 
DNAse treatment {Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA 
using a dinucleotide primer set {D11S875) specific for genomic DNA (12). mRNA was linearly 
amplified by in vitro transcription using T7 RNA polymerase {Megascript T7 kit) (13). 
Quality/integrity of total and amplified mRNA {cRNA) was checked by spectrophotometric analysis 
(criterion: UV 260/280 ratio >1.8 for each sample), and/or agarose gel electrophoresis. 
Microarray experiments 
Two randomly selected cRNA samples were hybridized together on the arrays for intensity-based 
instead of ratiobased analysis of the microarray data (14). All cRNA samples (1.5 lg) were labeled 
with ULS-CyS and ULS-Cy3 label (BIOKE, Leiden, The Netherlands) and hybridized to ~3s,000 70-mer 
two-color oligonucleotide microarrays (~35,000 Operon v3.0 probes), manufactured by The 
Netherlands Cancer Institute {Amsterdam, The Netherlands, http://microarrays.nki.nl). Because 
each tumor sample was profiled once with CyS and once with Cy3, there was one replicate of the 
whole experiment. Samples were hybridized according to a randomized design {Figure Sl) to 
prevent systematic biases such as those caused by batch effects or technical variation that can be 
introduced during labeling, hybridization, and scanning (15-17). After randomization of the 
processing order of the arrays from different batches, CyS- and Cy3-labeled cRNA samples were 
randomly placed onto the arrays. Arrays were scanned and expression values were calculated. The 
MIAME-compliant microarray data are available at http://www.ncbi.nlm.nih.gov/geo/ under 
accession number GSE13876. 
Quantitative Rea l Time-PCR 
Total RNA from 31 specimens, previously extracted, isolated and used for the microarray study, was 
reverse transcribed into cDNA using MMLV reverse transcriptase and hexameric random primer 
pd(N)6 {lnvitrogen, Breda, The Netherlands). The profile of the reverse transcription reaction was 10 
min at 25°C, 50 min at 37°C and 15 min at 70°C. Quantitative real-time PCR {qRT-PCR) was 
performed on 12 ng of cDNA. Applied Biosystems Taqman Gene expression assays, and Taqman 
Universal PCR master mix (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) were used 
to perform qRT-PCR on FGFBP1 {Hs00183226_ml, Applied Biosystems), TMEM45A 
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(Hs01046616_ml, Applied Biosystems), FKBP7 (Hs00383941_ml, Applied Biosystems), CCL28 
(Hs00955110_ml, Applied Biosystems) and the house-keeping gene GAPDH (Hs02758991_gl, 
Applied Biosystems), which is among the most constantly expressed mRNAs (18). All reactions were 
performed in 384 well plates in triplicate using an ABI PRISM 7900 HT Sequence Detection System. 
PCR reaction conditions were as follows: Step 1: S0°C for 2 minutes, Step 2: 95°C for 10 minutes, 
Step 3: 50 cycles of 95°C for 15 seconds followed by 60°C for 1 minute. We used the comparative 
threshold cycle (Ct) method to calculate the expression of the gene of interest relative to GAPDH in 
each sample by subtracting the mean Ct value of GAPDH from the mean Ct value of each gene, 
obtaining the �Ct value. 
Statistica l Methods 
Quantile normalization was applied to logrtransformed CyS and Cy3 intensities (19). The goal of the 
quantile normalization is to equalize the distribution of expression values for each array in a set of 
arrays: (1) expression values of each microarray were sorted, (2) median intensity in each rank 
across the microarrays was computed, and (3) each expression value was replaced by the median 
intensity at its rank. 
Principal components analysis (PCA) was performed for quality control. It has been shown that the 
most significant principal component for a gene expression data matrix is frequently a constant 
pattern, which dominates the data (20). So, the first principal component explaining the largest part 
of the variation could be considered variation that the arrays have in common (13;21). Next, 
correlation with the first principal component was calculated for each individual array (factor 
loading). Factor loadings of the first principal component for an individual array can be seen as a 
quality index, as arrays of lesser quality would have lower or distinctly different correlations than 
arrays of good quality. Samples with a factor loading with the first principal components of less than 
2 times the standard deviation from the mean were excluded as their hybridizations were 
considered to be of low quality (13;21). Operon V3.0 probe identifiers (""35,000) were converted to 
official gene symbols using probe annotations provided by The Netherlands Cancer Institute 
(http://microarrays.nki.nl//download/files/operon_hs_060614.xls). A description of the annotation 
methodology used by The Netherlands Cancer Institute is provided on their Web site 
(http://microarrays.nki.nl/services/blastdata.html). We have only used those oligonucleotides that 
specifically respond in a BLAST search with a single hit on a gene. Expression values of multiple 
oligonucleotide probes targeting the same gene (identical gene symbol) were averaged, resulting in 
a total of 15,909 unique genes for further analysis. Subsequently, expression data obtained from 
CyS- and Cy3-labeled samples of the same tumor were averaged (mean correlation 0.93 ± standard 
deviation 0.04). Microarray analyses were performed with the software package BRB Array Tools 
3.6.0, developed by the Biometric Research Branch of the US National Cancer Institute 
(http://linus.nci.nih.gov/BRB-ArrayTools.html). 
Survival prediction. An overall survival profile was built using the supervised principal components 
method (22). For each iteration of the complete cross-validation, 10% of the cases were omitted, 
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and a subset of genes was selected that correlated with overall survival at a significance level of p < 
0.001 for the remaining cases. The significance of each gene was measured based on a univariate 
Cox proportional hazards regression of survival time versus the log expression level. Next, PCA was 
performed to reduce the dimensionality of this selected subset of genes. Principal components 
(PCs), which are linear additions of weighted gene expression signals, were constructed in such a 
way that the first PC explained the largest amount of variance in our dataset and each subsequent 
PC explained the largest amount of the remaining variance while remaining uncorrelated with the 
previously constructed PC. Cox proportional hazards model was fitted to the data (with 10% of cases 
omitted) using the first five PCs as predictor variables, providing a regression coefficient (weight) for 
each principal component. The regression coefficients in combination with the first five PCs were 
used to calculate the predictive index for each sample. The 10% omitted test cases were classified as 
high or low risk based on whether their predictive index was above or below the median of the 
predictive indices for the 90% of cases in the training set. This entire procedure was repeated, 
leaving out a different 10% of cases until each case had been omitted exactly once and the cross­
validated risk groups were determined for all cases. So the cross-validated risk group for each case 
was determined based on a predictor model that did not use that case in any way in its construction. 
Kaplan-Meier survival curves were plotted for the predicted overall survival risk classes (high or low) 
giving a fair representation of the value of the expression profiles for predicting overall survival risk 
and the log-rank statistic was computed. To assess the significance of the log-rank statistic and the 
degree of overfitting, a phenotype permutation test based on 1,000 permutations was performed 
(23). Survival data were randomly shuffled among the cases and the entire cross-validation process 
described above was repeated. For each random reshuffling, the process was repeated, new cross­
validated Kaplan-Meier survival curves created, and the log-rank statistic for the random shuffling 
was computed, providing a null-distribution of the log-rank statistic. The tail area of this null 
distribution beyond the log-rank statistic obtained from the real data was the permutation 
significance level for testing the null hypothesis of no relation between the expression data and 
overall survival. A graphical representation of the survival prediction method is given in Figure 52. 
The genes that are selected as univariately associated with survival will differ for each iteration of 
the cross-validation, because the entire predictor development process must be repeated from the 
beginning for each new cross-validated training set. The final gene set (profile) presented in the 
results was selected when the supervised principal components method was applied to the full 
dataset with no samples omitted. 
Furthermore, to evaluate whether our profile provides more accurate predictions than that 
provided by standard clinicopathological covariates we performed a multivariate analysis using Cox 
proportional hazards regression. 
Pathway and transcription factor analysis. Functional gene set enrichment analysis was performed 
as described by Pavlidis et al. (24). Predefined gene sets were analyzed to indicate which contained 
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more genes correlated with overall survival than would be expected by chance. First a univariate Cox 
proportional hazards p-value was computed for all 15,909 unique genes. Then p-values of a subset 
of genes belonging to a functional set were summarized by the LS and KS summary statistics. For a 
set of n genes, the LS statistic is defined as the mean negative natural logarithm of single gene p­
values. The KS statistic is defined as the maximum difference between i/n and Pi, where Pi is the ith 
smallest p-value. This is the Kolmogorov-Smirnov statistic for testing if the p-values are of uniform 
distribution. The statistical significance of a functional gene set containing n genes is evaluated by 
computing the empirical distribution of these summary statistics in random samples of n genes. A 
total of 167 functional gene sets reported in the Kyoto Encyclopedia of Genes and Genomes {KEGG) 
database and 111 reported in the Transcriptional Regulatory Element Database {TRED) were 
analyzed (25;26). 
External validation. To establish that our profile was associated with prognosis in an independent 
set of serous ovarian cancers, we used publicly available microarray data {4;5;27). Available 
clinicopathologic characteristics of the 118 patients as reported previously are summarized in Table 
Sl. Differences in microarray platforms {Operon V3 versus Affymetrix HU133A) meant that direct 
application of our prediction model on this independent dataset was not feasible (28). The platforms 
differ, for example, in the reporter systems {short versus long oligonucleotides), labeling techniques, 
and hybridization protocols. Furthermore, many probes from the two platforms assigned to the 
same gene symbol are in fact detecting different splicing variants. Therefore, the genes composing 
our profile, but not the prediction rule, were generalizable to the independent dataset using a 
previously described methodology (29). Probe sets from the Affymetrix HU133A microarray related 
to the genes in our profile were selected. Subsequently, we applied the survival prediction method, 
with cross-validation and permutation testing as described above, to assess the performance of a 
classifier for the independent dataset based only on these selected probes; however, this time a 
significance threshold of 0.9999 was used to ensure that all selected probes representing genes 
from our survival profile were used in each iteration of the cross-validation. Furthermore, functional 
class scoring analysis for pathways and transcription factors as described above using all available 
probes was also performed on this independent dataset to compare results {24). 
Oncogenic pathway activation analysis. Recently, Bild et al. experimentally generated expression 
signatures that reflect the activation of various oncogenic signaling pathways, and provided 
software to assess the activation status in individual expression profiles (27). We used these publicly 
available expression profiles and software to assess the activation probability of the c-Myc, H-Ras, c­
Src, E2F3, and �-catenin pathway in our 157 ovarian tumor samples. For each pathway we divided 
the tumor samples into a group with an activation probability p < 0.5 and a group with activation 
probability p > 0.5. Next, Kaplan-Meier survival curves were plotted for both groups and the log-rank 
statistic computed. A significant log-rank statistic would indicate an association between the 
activation status of the oncogenic pathway and overall survival. Furthermore, to assess the 
combined effect of the five oncogenic pathways on overall survival, we applied average linkage 
hierarchical clustering according to the uncentered correlation measure on the activation 
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probabilities. Kaplan-Meier survival curves were plotted for the top two clusters and the log-rank 
statistic was computed. 
Results 
Patient characteristics 
Clinicopathologic characteristics of the 157 platinum-treated patients with serous ovarian cancer are 
summarized in Table 1. For the whole group the median overall survival time was 21 mo (range 1-
234 mo), and the 5-y overall survival rate was 27%. 
Gene expression profi le associated with overa l l  surviva l 
Eighty-six genes were found to correlate with overall survival by univariately fitting Cox proportional 
models at an alpha of 0.001. In Table 2 each gene is listed with its p-value, cross-validation support, 
hazard ratio (HR), and description. Univariate p-values, HR, and false discovery rates (FDRs) for all 
15,909 genes are given in Table S2. The FDR associated with a row of the table is an estimate of the 
proportion of the genes with univariate p-values less than or equal to the one in that row that 
represent false positives (30). Figure lA shows the Kaplan-Meier survival curves for the cross­
validated risk groups predicted to have above (n = 83) or below (n = 74) median risk of death due to 
ovarian cancer. Table S3 contains the necessary weights and final prediction rule to calculate the 
predictive index for a sample based on the expression signals of the identified 86 genes. As 
mentioned in the methods section the cross-validated risk group for each case was determined 
based on a predictor model that did not use that case in any way in its construction. The low-risk 
group had a median survival of 41 mo, whereas the high-risk group had a median survival of 19 mo 
(p = 0.0014, log-rank). The permutation test based on 1,000 permutations resulted in a p-value of 
0.0015, indicating that the chance that such a log-rank static is based on overfitting is small. Table 3 
shows the distribution of several prognostic factors as a function of risk assignment based on our 86-
gene overall survival profile. Age, stage, grade, debulking status, and chemotherapy regimens 
showed no difference in distribution between the predicted low- and high-risk groups. In addition to 
our overall survival profile, only the amount of residual tumor after primary surgery (p = 0.0003; HR 
= 2.34) showed a prognostic value for overall survival in univariate analysis. In multivariate analysis 
our overall survival profile (p = 0.008; HR = 1.94; 95% confidence interval [Cl] 1.19-3.16) and 
debulking status (p = 0.006; HR = 2.44; 95% Cl 1.30-4.60) both maintained independent prognostic 
significance (Table 4). 
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Table 1. Patient Characteristics (n = 157) 
Characteristic Category or Measure n or Value Percentage 
Age, y Median (range) 60 (21-84} 
Survival, mo Median (range) 21 (1-234) 
Stage (FIGO) IIIA 2 1.3 
1 1 1B 6 3.8 
I I IC 125 79.6 
IV 24 15.3 
Grade Well differentiated 14 8.9 
Moderately differentiated 45 28.7 
Poorly differentiated 82 52.2 
Undifferentiated 3 1.9 
Unknown 13 8.3 
Debulking status Complete debulking 22 14 
< 2 cm 21 13.4 
c!: 2 Cm 100 63.7 
Positive, size unknown 9 5.7 
Unknown 5 3.2 
Chemotherapy Carboplatin 2 1.2 
Cyclophosphamide/carboplatin 88 56.1 
Cyclophosphamide/cisplatin 12 7.6 
Paclitaxel/cisplatin 7 4.5 
Paclitaxel/carboplatin 48 30.6 
Ascites < 1 L  49 31.2 
c!: l l  71 45.2 
Unknown 37 23.6 
All patients received platinum-based chemotherapy postoperatively. 
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Table 2. Genes Composing the Overall Survival Profile. 
Gene %CV Hazard 
symbol p-Value Supporta Ratio Description 
AAK1 0.000645 40 0.48  AP2 associated kinase 1 
ACSM1 0.000361 60 0.27 
Acyl-CoA synthetase medium-chain family 
member 1 
AGPAT7 0.000418 60 0.33 
1-Acylglycerol-3-phosphate O-acyltransferase 
7 (lysophosphatidic acid acyltransferase, eta) 
AIPL1 0.000989 30 0.38 
Aryl hydrocarbon receptor interacting protein-
like 1 
ATPSD 0.000133 90 0.52 
ATP synthase, H+ transporting, mitochondrial 
Fl complex, delta subunit 
BAX 0.000964 so 0.39 BCL2-associated X protein 
BRSK1 0.000981 30 0.63 BR serine/threonine kinase 1 
C10orf80 0.000407 40 0.35 Chromosome 10 open reading frame 80 
C14orf121 0.000105 90 0.26 Chromosome 14 open reading frame 121 
Clor/151 0.000116 90 0.58 Chromosome 1 open reading frame 151 
C1orf159 0.000228 70 0.30 Chromosome 1 open reading frame 159 
Clor/198 0.000785 30 1.61 Chromosome 1 open reading frame 198 
C1orf68 0.000348 so 0.47 Chromosome 1 open reading frame 68 
C1QTNF3 0.000106 90 1.75 
Clq and tumor necrosis factor related protein 
3 
C20orf32 0.000699 40 0.58 Chromosome 20 open reading frame 32 
CACNA18 0.000027 100 0.32 
Calcium channel, voltage-dependent, N type, 
alpha 1B subunit 
CACNG6 0.000154 80 0.40  
Calcium channel, voltage-dependent, gamma 
subunit 6 
CCDC135 0.000232 70 0.30 Coiled-coil domain containing 135 
CCL28 0.000749 40 1.48 Chemokine (C-C motif) ligand 28 
CDH19 0.000493 40 0.45 Cadherin 19, type 2 
CDYL2 0.000987 20 0.49 Chromodomain protein, Y-like 2 
CES2 0.000256 60 0.39 Carboxylesterase 2 (intestine, liver) 
CNTFR 0.00071 40 0.45 Ciliary neurotrophic factor receptor 
CPE 0.000651 40 1.42 Carboxypeptidase E 
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Table 2. Continued. 
Gene %CV Hazard 
symbol p-Value Suppore Ratio Description 
CRYBB1 0.000473 50 0.34 Crystallin, beta Bl 
0D82 0.000937 40 0.64 
Damage-specific DNA binding protein 2, 
48kDa 
FEZ1 0.000451 50 2.20 
Fasciculation and elongation protein zeta 1 
(zygin i} 
FGFBP1 0.000525 50 0.73 Fibroblast growth factor binding protein 1 
FGFR10P2 0.000428 50 1.77 FGFRl oncogene partner 2 
FKBP7 0.000042 100 2.90 FK506 binding protein 7 
GCM1 0.000638 40 0.41 Glial cells missing homolog 1 (drosophila} 
GNAZ 0.000256 70 0.32 
Guanine nucleotide binding protein (G 
protein}, alpha z polypeptide 
HIPK1 0.00044 70 0.20 Homeodomain interacting protein kinase 1 
ITGB7 0.000023 100 0.39 lntegrin, beta 7 
JAK2 0.000811 60 0.41 Janus kinase 2 (a protein tyrosine kinase} 
KDELR2 0.000566 40 1.73 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 2 
K/AA0141 0.000283 60 0.51 KIAA0141 
KLF12 0.00045 50 2.71 Kruppel-like factor 12 
KLHL7 0.000842 40 2.49 Kelch-like 7 (drosophila) 
KRT10 0.000802 40 1.80 
Keratin 10 (epidermolytic hyperkeratosis; 
keratosis palmaris et plantaris) 
KYNU 0.000342 80 0.49 Kynureninase (L-kynurenine hydrolase) 
LIN28 0.000089 100 2.12 Lin-28 homolog (C. elegans) 
LRRC17 0.000691 40 1.51 Leucine-rich repeat containing 17 
LRSAM1 0.000397 60 0.38 
Leucine-rich repeat and sterile alpha motif 
containing 1 
METTL4 0.000828 40 0.46 Methyltransferase like 4 
MFAP2 0.000198 80 1.77 Microfibrillar-associated protein 2 
MUTYH 0.000619 40 0.34 MutY homolog (E. coli) 
MXD1 0.000057 100 0.40 MAX dimerization protein 1 
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Table 2. Continued. 
Gene %CV Hazard 
symbol p-Value Supporta Ratio Description 
NANOS1 0.000275 70 1.80 Nanos homolog 1 (drosophila) 
NCR2 0.000425 80 0.35 Natural cytotoxicity triggering receptor 2 
ODF4 0.000094 80 0.43 Outer dense fiber of sperm tails 4 
OR10A3 0.000023 90 0.49 
Olfactory receptor, family 10, subfamily A, 
member 3 
OR2AG1 0.000435 60 0.41 
Olfactory receptor, family 2, subfamily ag, 
member 1 
OR4C15 0.000931 40 0.40 
Olfactory receptor, family 4, subfamily c, 
member 15 
OR5185 0.00062 40 0.47 
Olfactory receptor, family 51, subfamily 8, 
member s 
OR51/1 0.000042 100 0.63 
Olfactory receptor, family 51, subfamily I, 
member 1 
OR6F1 0.000866 30 0.40 
Olfactory receptor, family 6, subfamily F, 
member 1 
OR9G9 0.000512 40 0.45 
Olfactory receptor, family 9, subfamily G, 
member 9 
OSGEPL1 0.000443 so 2.05 O-sialoglycoprotein endopeptidase-like 1 
OSM 0.000645 40 0.62 Oncostatin M 
PKHD1 0.000882 20 0.32 
Polycystic kidney and hepatic disease 1 
(autosomal recessive) 
PPAP28 0.000695 40 1.39 Phosphatidic acid phosphatase type 28 
PPCDC 0.000021 100 0.34 Phosphopantothenoylcysteine decarboxylase 
PRELP 0.00043 50 1.34 
Praline/arginine-rich end leucine-rich repeat 
protein 
PTCH2 0.0002 80 0.43 Patched homolog 2 (drosophila) 
PTPRN2 0.000265 60 0.43 
Protein tyrosine phosphatase, receptor type, N 
polypeptide 2 
RIN1 0.000285 70 0.44 Ras and Rab interactor 1 
RIT1 0.000282 70 1.91 Ras-like without CAAX 1 
SC02 0.000263 70 0.46 
SCO cytochrome oxidase deficient homolog 2 
(yeast) 
SEPN1 0.000093 100 0.40 Selenoprotein N, 1 
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Table 2. Continued. 
Gene %CV Hazard 
symbol p-Value Supporta Ratio Description 
S/GLEC8 0.000838 20 0.48 Sialic acid binding lg-like lectin 8 
SMPD2 0.000049 90 0.47 
Sphingomyelin phosphodiesterase 2, neutral 
membrane (neutral sphingomyelinase) 
SPATA13 0.000631 so 0.46 Spermatogenesis associated 13 
SPATA18 0.000139 80 0.38 
Spermatogenesis associated 18 homolog 
(rat) 
SYT11 0.000838 40 1.69 Synaptotagmin XI 
TMEM150 0.000425 40 0.30 Transmembrane protein 150 
TMEM45A 0.000288 70 1.49 Transmembrane protein 45A 
TRO 0.000051 100 2.17 Trophinin 
TRPV4 0.000999 10 0.53 
Transient receptor potential cation channel, 
subfamily V, member 4 
TUBB4 0.00071 30 0.43 Tubulin, beta 4 
WDR7 0.000086 100 0.26 WO repeat domain 7 
WNT16 0.000828 30 0.48 
Wingless-type MMTV integration site family, 
member 16 
ZBT88 0.000324 80 2.26 Zinc finger and 8TB domain containing 8 
ZNF12 0.000588 30 2.05 Zinc finger protein 12 
ZNF521 0.000281 70 1.50 Zinc finger protein 521 
ZNF569 0.000197 80 2.49 Zinc finger protein 569 
0%CV Support indicates the percentage of the cross-validation training sets in which the gene was selected. 100% 
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Figure 1. Kaplan-Meier Survival Curves for the Patients Predicted to Have Above or Below Median Risk of Death 
Due to Ovarian Cancer (A) Present study, median survival of 19 mo versus 41 mo (p = 0.0014, log-rank), 
permutation p-value = 0.015. (B) Dressman et al. (5), median survival of 33 mo versus 108 mo (p < 0.0001, log­
rank), permutation p-value = 0.007. 
QRT-PCR va l idation of the overa l l  surviva l profi le 
To validate the overall survival profile, we performed qRTPCR for 31 total RNA samples that had 
been included in the microarray analysis. Four genes, i.e., FGFBP1, FKBP7, TMEM45A, and CCL28, 
that differ in percentage cross-validation support were arbitrarily selected from the 86-gene overall 
survival profile. Relative expression levels for each gene were correlated with the corresponding 
microarray signal intensities. A strong correlation between qRT-PCR and microarray signal intensities 
was observed for all four genes (Figure 2). 
I ndependent va l idation of the overa l l  surviva l profi le 
Because of the different microarray platforms used, our predictor model could not be directly tested 
on the independent serous ovarian cancer dataset. Instead we identified 97 probes on the HU133A 
platform, targeting 57 out of the 86 unique genes from our overall survival profile. These probes 
were used to build a survival profile as described above. Figure 18 shows the Kaplan-Meier survival 
curves for the patients from the independent dataset predicted to have above or below median risk 
of death due to ovarian cancer. This low-risk group had a median survival of 108 mo, whereas the 
high-risk group had a median survival of 33 mo (p < 0.0001, log-rank). The permutation p-value of 
the log-rank test statistic between the two risk groups, based on 1,000 permutations, was p =  0.007. 
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Table 3. Association between the Overall Survival Profile and Clinicopathologic Characteristics. 
Characteristic Subcategory Low Risk (n = 74) High Risk (n = 83) 
p-Value 
n or Value % n or Value % 
Age Median, years 60 60 
Survival Median, months 41 19 
Stage (FIGO) I I IA 2 2.7 0 0 0.128 
1 1 18  1 1.4 5 6 
IIIC 62 83.8 63 75.9 
IV 9 12.2 15 18.1 
Grade 
Well 
9 12.2 5 6 0.104 
differentiated 
Moderately 




43 58.1 39 47 
Undifferentiated 0 0 3 3.6 
Unknown 6 8.1 7 8.4 
Debulking Complete 
12 16.2 10 12.1 0.237 
status debulking 
< 2 cm 10 13.5 11 13.3 
� 2 cm 48 64.9 52 62.7 
Positive, size 
1 1.4 8 9.6 
unknown 
Unknown 3 4.1 2 2.4 
Chemotherapy 
Non paclitaxel-
44 59.5 58 69.9 0.115 
based 
Paclitaxel-based 30 40.5 25 30.1 
p-Values for stage, grade, debulking status,and chemotherapy were derived from the Pearson Chi-square test. p-
Value for age was derived from the t-test. FIGO, International Federation of Gynecology and Obstetrics. 
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Table 4. Prognostic Value of the Overall Survival Profile Adjusted for Debulking Status, Stage, 
Grade, Age, and Ascites by Cox Proportional Hazards Regression. 
Prognostic Factor 
OSP 
Stage (Ill vs. IV) 
Debulking status (residual tumor < vs > 2 cm) 
Grade {I vs 1 1/ 1 1 1 )  
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Figure 2. Scatter Plots Showing the Microarray Expression Signal Versus the .1Ct Obtained by qRT-PCR for Four 
Individual Genes. Genes are FGFBP1, FKBP7, TMEM45A, and CCL28 from our overall survival profile . .1Ct of the 
gene is obtained by subtracting the mean Ct value of GAPDH from the mean Ct value of the gene. Both axes are 
on log2 scale. 
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Pathways and transcription factors associated with 
overa l l  surviva l 
As input for the survival gene set analysis, significance levels based on 
univariate Cox proportional hazards regression of survival time versus the log 
expression level for all 15,909 genes were used. KEGG pathways and 
transcription factors associated with overall survival in our dataset and that 
of Dressman et al. (5) are shown in Tables 5 and 6, respectively. In our 
dataset 17/167 pathways and 13/111 transcription factors were associated 
with overall survival, of which 16 and 12, respectively, were confirmed in the 
independent dataset from Dressman et al. (5). Table S4 shows univariate p­
values and hazard ratios for genes that form part of the 17 pathways 
associated with overall survival in our dataset. 
Oncogen ic pathway activation 
Figure 3 shows a heatmap of the predicted activation status for the five 
oncogenic pathways in our 157 ovarian tumor samples. Red indicates a high 
probability of activation and green indicates a low probability of activation. 
None of the five oncogenic pathways showed a significant log-rank statistic 
for the Kaplan-Meier survival curves between the group of ovarian tumor 
samples with an activation probability p < 0.5 and the group with an 
activation probability p < 0.5. The five Kaplan-Meier curves and the 
associated log-rank p-values are shown in Figure S3. After clustering the 
samples on their activation probabilities for the five oncogenic pathways 
combined, the top two clusters showed no significant difference between 
their Kaplan-Meier survival curves (Figure S4). 
Figure 3. Heatmap Showing Predicted Probabilities of Pathway Activation for the Five 
Oncogenic Pathways Pathways are c-Myc, H-Ras, c-Src, E2F3, and b-catenin in our 157 
ovarian tumor samples. Red indicates a high probability of activation and green 
indicates a low probability of activation. The probabilities of pathway activation were 
clustered according to the uncentered correlation measure. On the right of the figure 
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Table 5. KEGG Pathways with More Genes Correlated with Overall Survival than Expected by 
Chance as Identified in the Present Study and in the Dressman et al. (5) Dataset. 
Present Dressman 
KEGG Pathway Pathway Description Study et al. (5) 
hsa00190 Oxidative phosphorylation X X 
hsa00230 Purine metabolism X X 
hsa01430 Cell communication X X 
hsa04020 Calcium signaling pathway X X 
hsa04060 Cytokine-cytokine receptor interaction X X 
hsa04110 Cell cycle X X 
hsa04310 Wnt signaling pathway X X 
hsa04360 Axon guidance X X 
hsa04510 Focal adhesion X X 
hsa04514 Cell adhesion molecules (CAMs) X X 
hsa04530 Tight junction X X 
hsa04630 Jak-STAT signaling pathway X X 
hsa04650 Natural killer cell mediated cytotoxicity X X 
hsa04670 Leukocyte transendothelial migration X X 
hsa04810 Regulation of actin cytoskeleton X X 
hsa04910 Insulin signaling pathway X X 
hsa04020 MAPK signaling pathway X 
Pathways that are significant at the nominal 0.005 level of the LS permutation test or KS permutation test are 
fisted. The following pathways are associated with survival only in the study of Dressman et al. (5): Co/orecta/ 
cancer, Pyrimidine metabolism, Tryptophan metabolism, Glycerophospholipid metabolism, Glycan structures -
biosynthesis 1, Ribosome, PPAR signaling pathway, Phosphatidyfinositol signaling system, Neuroactive ligand­
receptor interaction, Apoptosis, TGF-beta signaling pathway, VEGF signaling pathway, ECM-receptor interaction, 
Adherens junction, Gap junction, Antigen processing and presentation, Toll-like receptor signaling pathway, 
Hematopoietic cell lineage, B cell receptor signaling pathway, Long-term potentiation, Long-term depression, 
GnRH signaling pathway, Adipocytokine signaling pathway, Epithelial cell signaling in Helicobacter pylori 
infection, One carbon pool by Jo/ate, Methane metabolism, Glycosphingolipid biosynthesis - ganglioseries, 
G/ycosphingo/ipid biosynthesis - globoseries, Hedgehog signaling pathway, Glycan structures - biosynthesis 2, 
Neurodegenerative disorders, Regulation of autophagy. 
58 
Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer 
Table 6. Transcription Factor Gene Sets with More Genes Correlated with Overall Survival than 
Expected by Chance as Identified in the Present Study and in the Dressman et al. (5) Dataset. 
Present Dressman 
Factor Name Accession Number Study et al. (S) 
C/EBPalpha T00105 X X 
CREB T00163 X X 
E2F-1 T01542 X X 
E2F-4 T01546 X X 
c-Ets-1 T00112 X X 
AP-1 T00029 X X 
c-Myb T00137 X X 
CTF-1 T00176 X X 
NF-kappaB(-like) T00591 X X 
Spl T00759 X X 
AP-2alphaA T00035 X X 
p53 T00671 X X 
E2F-2 T01544 X 
Transcription factor gene sets that are significant at the nominal 0.005 level of the LS permutation test or KS 
permutation. The following transcription factor gene sets are associated with survival only in the study of 
Dressman et al. (5), ATF-1, Egr-1, ER-alpha, PEA3, H/F-1, POU2F1, PPAR-gammal, RAR-alphal, RAR-beta, Re/A, 
Sp3, PU.1, USF1, USF2, NF-/l6-2. 
Discussion 
In this study on tumors of a large series of well-documented advanced-stage serous ovarian cancer 
patients we identified a gene expression profile that reflects patients' overall survival. Our overall 
survival profile maintained independent prognostic significance in multivariate analysis. Moreover, 
expression of the genes that composed our overall survival profile also held their prognostic value in 
an independent dataset processed at a different institution using a different microarray platform. 
Finally, in addition to individual genes, we were also able to reproducibly identify and validate KEGG 
pathways and TRED transcription factors associated with overall survival. 
Limited overlap with respect to individual genes, as observed in comparable studies in other tumor 
types, was also found between our overall survival profile and those reported in three previous 
ovarian cancer microarray studies (4;8;31). 
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Non-reproducibility of prognostic profiles between different microarray studies in the same tumor 
type can be attributed to a variety of methodological issues (23;32). Our study specifically pays 
attention to methodological principles such as randomization and replication. Thus, confounding 
effects are avoided and unbiased estimation of differential expression levels is provided. The three 
studies mentioned above did not include a replication of the experiment (4;8;31). In contrast to 
these studies, by using supervised PCA to build prognostic profiles, we could consider survival a 
continuous parameter, and patients were thus not forced into subgroups that might not be 
biologically meaningful. Categorizing patients a priori into a "low risk" and "high risk" subgroup 
based on survival times might cause any future predictions based on this model to be suspect when 
underlying, unidentified, biologically different subgroups have considerable overlap in survival 
times. 
Our overall survival profile contains several interesting genes (Table 2) that offer potential insight 
into mechanisms associated with tumor behavior. The overall validity of our approach is confirmed 
by the observation that for some of the genes in our profile, earlier studies that utilized non-array­
based methodologies already indicated their relevance in ovarian cancer. For example, high 
expression of the proapoptotic BAX gene was associated with improved prognosis in our study. 
Previously, a similar relation between BAX expression and response to chemotherapy and overall 
survival in ovarian cancer was reported by others (9;33-35). likewise, in our study, high expression 
of Ras inhibitor 1 (RIN1) and low expression of Ras-like without CAAXl (R/Tl) were associated with 
better overall survival, which is in agreement with previous work by others showing that activated 
Ras contributes to the maintenance and growth of ovarian carcinomas (36). In addition to these 
already known relevant genes in ovarian cancer our study reveals also multiple new genes with a 
possible impact on tumor behavior in ovarian cancer. For example OSM, JAK2, and CNTFR are 
components of the Jak/STAT signaling pathway, which can stimulate cell proliferation, 
differentiation, cell migration, and apoptosis (37). OSM has individually been identified as a potent 
suppressor of tumor cell proliferation and inducer of differentiation in multiple tissues (38). FGFBPl 
and FGFRl interact with fibroblast growth factors FGFl and FGF2, and it has been suggested that the 
fibroblast growth factors could serve as the angiogenic switch in human cancer {Czubayko, 1997 36 
/id;Grand, 2004 2087 /id;Wu, 1991 2030 /id}. Apart from having prognostic impact our analysis also 
sheds light on previous unknown possible 'druggable' targets in ovarian cancer; FKBP7, with the 
highest hazard ratio for individual genes in our study, appears to be especially of interest because 
FKBPs can be targeted with mTOR inhibitors (42). 
Although individual genes such as those described above may prove to be relevant for tumor 
behavior, it is often not known in ovarian and other cancers whether large fold-changes in individual 
genes will have more biological relevance than will smaller but coordinated fold-changes in a set of 
genes along a single pathway. Analysis of our microarray data by integration of genes into functional 
gene sets according to well-known biological pathways and transcription factors enabled us to 
consider all available genomic information rather than only genes passing a certain significance 
threshold, thus providing extra clues to which signaling pathways and transcription factors 
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contribute to the clinical outcome of ovarian cancer. Bonome et al. (31) recently also identified 
possible signaling events (pathways). However, by using classical over-representation analysis of 
functional gene sets within only a small subset of genes (57 probes) associated with overall survival, 
the authors disregarded most of the genomic information available (31). 
Our pathway analysis, which to our knowledge has not been applied to ovarian cancer array 
datasets previously, revealed 17 pathways to be related to survival, of which 16 were validated in 
the independent dataset. As previously mentioned, there is usually only limited overlap with respect 
to individual genes between the prognostic profiles previously published in (ovarian) cancer (43). In 
contrast, integrating genes in functional gene sets according to pathways and transcription factors in 
this study resulted in considerable overlap between our dataset and the independent dataset with 
respect to prognostic impact. Our results therefore indicate that assessment of prognostic profiles is 
more robust by determination of coordinated expression of several signaling pathways than of 
expression of individual genes. 
Thus in the present study, cell cycle, Wnt, Jak-STAT, and MAPK pathways, playing a role in apoptosis, 
proliferation, differentiation, and/or cell cycle, were identified as having a role in ovarian cancer; 
consistent with these results, aberrant signaling of each of these pathways has been proposed as 
contributing to ovarian carcinogenesis (44-48), again indicating the strength of our approach. Novel 
therapeutic options are currently being explored that act on several signaling pathways that we 
found to be associated with overall survival in ovarian cancer. For example, Basica et al. recently 
described activation of Wnt signaling in ovarian and breast cancer cell lines and showed that Wnt 
antagonists dramatically altered the biological behavior of these cells (49). A blocking antibody 
against FZD10, a cell membrane receptor for Wnt, was shown to have strong antitumor effect in 
xenografted tumors overexpressing FZD10 {50;51). As in our study, a dysregulated Wnt pathway 
and, more specifically, overexpression of FZD10 and FZD7 (another member of the Wnt cell-surface 
receptor family) were related to worse prognosis, so this FZD10 blocking antibody may have clinical 
potential by inhibiting the autocrine Wnt signalling pathway in ovarian cancer. 
Our transcription factor analysis also implicated several transcription factors (Table 5) in ovarian 
cancer. With different methodologies A2P-2alpha and c-Ets-1 have previously been associated with 
poor prognosis in ovarian cancer (52-54). Similarly, E2F transcription factors, members of the C/EBP 
family, and CREB were demonstrated to play an important role in ovarian carcinogenesis (55-58). 
With the exception of p53, most transcription factors are presently difficult to target. Our 
transcription factor analysis demonstrated a positive prognostic impact for p53 as an "activated" 
transcription factor. In tumor cell lines activation of wildtype p53 can be induced by the small 
molecule nutlin-3, which antagonizes the function of the natural inhibitor of wild-type p53 MDM2, 
resulting in enhanced apoptosis or cell cycle arrest (59;60). In combination, these observations 
tempt one to speculate on a possible role for nutlin-3 in overcoming resistance to chemotherapy, 
especially in those ovarian cancers with a less activated p53 {59;61). 
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A limitation of functional gene set enrichment analysis as performed in our study, however, is its 
inability to assess the activation status of identified pathways in an individual tumor sample. This 
gap is potentially filled by the strategy described by Dressman et al. (5) and Bild et al. (27) (see also 
Materials and Methods: Oncogenic pathway activation analysis). In this study we assessed the 
activation status of five oncogenic signaling pathways in 157 ovarian tumor samples based on the 
activation observed in a mammalian cell line following transfection of adenovirus expressing human 
c-Myc, activated H-Ras, human c-Src, human E2F3, or b-catenin. Bild et al. showed in a series of 153 
samples that activated E2F3, bcatenin, and c-Src pathways were associated with poor overall 
survival in ovarian cancer (27). None of these five oncogenic pathways showed a significant 
association (as individual pathways and/or in combination) with overall survival in our dataset (see 
Figures 53 and S4). Our results therefore indicate that analysis of pathway activation status until 
now is not very robust and cannot be easily exchanged between different studies, as was recently 
also described by others (62). 
In this study the prognostic impact of 57 genes from our profile was validated within the 
independent dataset from Dressman et al. (5), providing stronger evidence than before that these 
genes are important in the biological behavior of ovarian tumors. Platform differences did not allow 
one-to-one exact validation of the underlying predictive algorithm. Therefore, the clinical usefulness 
of our overall survival predictor needs further validation. With regard to the reproducibility issues 
between different microarray platforms, it seems likely that in the future an array-based prognostic 
tool will be based on a single platform. So, our study might be considered a phase II study in which 
we constructed a genetic profile associated with overall survival within the whole group of 157 
patients according to statistical principles such as cross-validation and permutation testing (63). As 
described above, such a study provides valuable clues about the mechanisms underlying tumor 
behavior and clues with respect to potential drug development targets (genes, pathways, etc). To 
further evaluate the prognostic impact of our profile for individual patients, prospective studies 
need to be performed. Another important issue that needs to be addressed in such studies is the 
impact of intra-tumor heterogeneity on reproducibility. Using a combination of microsatellite 
analysis and SNP analysis Khalique et al. recently showed that intra-tumor heterogeneity is a 
common feature within epithelial ovarian cancer (64). 
In conclusion, our study provides new, validated insights into molecular changes in genes, pathways, 
and transcription factors that are relevant for ovarian cancer behavior and that should therefore be 
exploited in the search for new treatment strategies towards patient-tailored therapy. In the future, 
pathway activation analysis in individual tumors may guide the choice of targeting drugs in ovarian 
cancer patients (65;66), but its methodology needs to become more robust before clinical relevance 
can be envisioned. 
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Figure S1. Diagram Showing the Randomization Design. 
Table S1. Patient Characteristics (n = 118) 
Characteristic Category or Measure n or Value 
Age, y (tN = 52) Median (range) 60 (33-79) 
Survival, mo (tN = 118) Median (range) 34 (1-185) 
Stage (FIGO) (tN = 117) I l l  98 
IV 18 
Grade (tN = 115) Well differentiated 4 
Moderately differentiated 55 
Poorly differentiated 55 
Undifferentiated 1 
Debulking status (tN = 118) Optimal, < 1 cm 63 










Available Clinicopathologic Characteristics of the 118 Patients as Reported by Dressman et al. (5). Abbreviations: 
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Figure 53. Kaplan-Meier Survival Curves for the Five 
Oncogenic Pathways between the Group of Ovarian Tumor 
Samples with an Activation Probability p < 0.5 and the 
Group with an Activation Probability p > 0.5. 
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Figure 54. Kaplan-Meier Survival Curves of the Top Two 
Clusters after Clustering the Samples on their Activation 
Probabilities for the Five Oncogenic Pathways Combined. 
Table S2. Overall Survival-Related Univariate p­
Values, HR, and FDR for all 15,909 Genes. Found at 
doi:10.1371/journal.pmed.1000024.st002 {1.5 MB 
XLS). 
Table S4. Univariate p-Values and Hazard Ratios for 
Genes that Form Part of the 17 Pathways Associated 
with Overall Survival in Our Dataset. Found at 




Table S3. Weights and Final Prediction Rule to Calculate the Predictive Index for a Sample Based 
on the Expression Signals of the Identified 86 Genes. 
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Weights and Final Prediction Rule to Calculate the Predictive Index for a Sample Based on the Expression Signals 
of the Identified 86 Genes. A new sample is predicted as high (low) risk if its prognostic index is larger than 
(smaller than or equal to) 0.008756. The prognostic index can be computed by the simple formula I;w, X; + 
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Resistance to platinum-based chemotherapy is a major problem in the treatment of ovarian cancer 
and more insight in its underlying biology is needed. The aim of the present study was to identify 
genes and pathways associated with platinum resistance. 
Experimenta l design 
Nine paired stage Ill/IV serous ovarian cancers obtained at primary surgery and after chemotherapy 
were profiled using oligonucleotide microarrays. Differentially expressed genes were identified using 
a paired t-test. Gene set enrichment analysis {GSEA) was performed to identify pathways associated 
with platinum resistance. The prognostic impact of identified genes and pathways was evaluated in 
a validation set of 157 previously profiled stage Ill/IV serous tumors. Further validation was 
performed by qRT-PCR and immunostaining of tissue microarrays for proteasome subunit MBl {n = 
115) and IGF-lR {n = 165), as representatives of the proteasome and IGF-lR pathways. 
Resu lts 
Differential expression between pre- and post-chemotherapy samples was observed for 272 genes, 
of which 24 were also associated with survival in the validation set. Moreover, high expression of 
genes up-regulated in post-chemotherapy samples was associated with poor overall survival. GSEA 
revealed well-known and novel pathways enriched in pre- or post-chemotherapy samples, such as 
the proteasome and IGF-lR pathways. Several of these pathways were also associated with survival 
in the validation set. lmmunostaining independently validated the association of MBl expression 
with poor and IGF-lR expression with improved survival. 
Conclusion 
Our study provides novel and validated insights into genes and pathways associated with 
chemoresistance in ovarian cancer which deserve to be further explored as possible therapeutic 
targets. 
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Introduction 
Resistance to platinum-based chemotherapy is a major obstacle in the treatment of patients with 
advanced stage epithelial ovarian cancer (1). Despite a response rate of 70-80% to first-line 
chemotherapy, the majority of patients will eventually die of platinum-resistant disease resulting in 
five-year survival rates of only 25-30%. To improve the efficacy of existing drugs and to identify 
novel targets for therapy, more insight in the molecular changes underlying chemoresistance is 
pivotal. 
Chemotherapy is thought to select for cells displaying a resistant phenotype, so pre- and post­
chemotherapy samples obtained from the same patient provide a unique opportunity to study the 
effects of chemotherapeutic treatment on gene expression, while excluding noise caused by 
differences in patient and tumor characteristics. However, the majority of ovarian cancer patients 
do not routinely undergo interval or second look surgery after first-line chemotherapy, so such 
samples are rarely available. 
The aim of the present study was to identify genes and pathways associated with chemoresistance 
in a homogeneous group of nine paired pre- and post-chemotherapy serous ovarian cancer samples. 
In addition, we explored the prognostic value of the identified genes and pathways in a large dataset 
of 157 primary advanced stage serous cancers previously profiled in our institution (2). Finally, we 
independently validated our findings using qRT-PCR and immunohistochemical staining of tissue 
microarrays (TMAs). 
Materials and methods 
Patients and Tumor Samples 
The study population consisted of 9 patients with previously untreated stage Ill/IV serous ovarian 
cancer for whom paired tumor samples were available from both primary surgery as well as surgery 
performed after three or six cycles of chemotherapy. Tumor samples were obtained at the 
University Medical Centre Groningen (Groningen, the Netherlands) between 1990 and 2003. All 
patients were treated with primary cytoreductive surgery followed by platinum-based 
chemotherapy (3). Post-chemotherapy samples were obtained at surgery performed maximally six 
weeks after three or six cycles of chemotherapy. Intervention or second look surgery was only 
performed in patients regarded as responding to chemotherapy. Tumor samples were snap frozen in 
liquid nitrogen, and stored at -80 °C. The median percentage of tumor cells was 70% (range 50-80%). 
Patients gave informed consent for collection and storage of tumor samples in a tissue bank for 
future research. Relevant patient data were retrieved and transferred into an anonymous, 
password-protected, database. Patients' identity was protected by study-specific, unique patient 
codes and their true identity was only known to two dedicated data managers. According to Dutch 




Microa rray experiments 
RNA extraction and amplification was performed as described previously (2). Samples were 
hybridized to 70-mere oligonucleotide microarrays ("'35,000 Operon v3.0 probes) as part of a larger 
study (2) using a randomized design to prevent systematic biases (4-6}. Tumor samples were profiled 
multiple times with a minimum of two hybridizations per sample (supplementary methods). Arrays 
were scanned with the Affymetrix GMS428 (Affymetrix, Santa Clara, CA) and expression values were 
calculated by Bluefuse software (BlueGnome, Cambridge, UK). Raw microarray data and 
accompanying clinical data are available at http://www.ncbi.nlm.nih.gov/geo/. 
Preprocessing of microarray data 
Quantile normalization was applied to log2 transformed Cy5 and Cy3 intensities (7). Subsequently, 
principal components analysis was performed for quality control (2). Based on this approach one 
sample was excluded (supplementary Figure 1), leaving 54 samples for further analysis. Next, 
Operon V3.0 probe identifiers were converted to official gene symbols using probe annotations 
provided by the Netherlands Cancer Institute (NKI}. We have only used those oligonucleotides that 
specifically BLAST with a single hit on a gene. Expression values of multiple probes targeting the 
same gene (identical gene symbol) were averaged, resulting in a total of 15,909 unique genes for 
further analysis. Subsequently, expression data obtained from multiple hybridizations of the same 
tumor sample were averaged resulting in 9 paired pre- and post-chemotherapy profiles. For a more 
detailed description, see supplementary methods. 
Class comparison between pre- and post-chemotherapy samples 
Class comparison was performed using the software package BRB Array Tools 3.6.0, developed by 
the Biometric Research Branch of the US National Cancer Institute (http://linus.nci.nih.gov/BRB­
ArrayTools.html). Differentially expressed genes were identified using a paired t-test with a 
significance threshold of p < 0.01. The significance of individual genes was determined using a 
univariate permutations test based on 10,000 permutations. Average linkage hierarchical clustering 
using the Euclidean distance metric was performed using CLUSTER and TREEVIEW software (8). 
Gene Set Enrichment Ana lysis (GSEA) 
GSEA was performed with the software package GSEA 2.0, developed by the Broad Institute of MIT 
and Harvard (9). Ranked expression data for all 15,909 genes were compared against a large 
collection of functional gene sets to determine if there was enrichment of one of these gene sets in 
pre- or post-chemotherapy samples. The GSEA analysis was separately performed two times with a 
total of 166 gene sets as reported in the Kyoto Encyclopedia of Genes and Genomes database 
(KEGG}, and 174 gene sets as reported in the Biocarta database (http://www.biocarta.com) (10}. The 
statistical significance of enrichment was determined using a randomization test based on 1,000 
gene permutations. Furthermore, for each functional set the false discovery rate (FDR) was 
calculated. As an example, a FDR < 0.25 indicates that the result is expected to be valid 3 out of 4 
times. We use FDR's because in an explorative investigation we aim at generating interesting 
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hypotheses and drive further research, rather than claim definite results (9). For a more detailed 
description, see supplementary methods. 
Leading-edge subset analysis 
The leading-edge subset is defined as the subset of genes in a functional gene set that appears high 
up in the ranked list of 15,909 genes at, or before, the point where the running enrichment score 
reaches its maximum deviation from zero. The genes within this subset can be interpreted as the 
most important in the enrichment of the functional gene set. Leading-edge subsets were 
determined in those functional gene sets that showed a significance level of p < 0.05 in GSEA. 
Subsequently, the overlap between leading-edge subsets from significantly enriched functional gene 
sets from the two databases was determined. Using this approach, genes could be identified that 
belonged to more than one identified pathway and might be considered key genes. 
Impact of identified genes and pathways on overal l  surviva l 
For genes with differential expression between pre- and post-chemotherapy samples we 
determined the correlation with survival within a data set of 157 advanced stage serous ovarian 
cancers previously profiled by our group (2). The significance of each gene was determined by a 
univariate Cox proportional hazards regression of survival time versus the log expression level. 
Genes were selected at a threshold of p < 0.05. This resulted in a subset of genes that were both 
differentially expressed between paired pre- and post-chemotherapy samples and significantly 
correlated with overall survival. Based on fold-changes, this subset was divided into genes that were 
up-regulated or down-regulated in post-chemotherapy samples. This allowed us to evaluate the 
prognostic impact of these genes in primary tumors. 
This subset of genes in combination with the supervised principal components method was utilized 
to construct a predictor model that is capable of assigning risk classes to individual patients (11). To 
give a fair representation of the capability of this model to predict survival risk we applied internal 
10-fold cross validation (12). In addition, we performed a permutation test based on 1,000 
permutations to assess to what degree our model was influenced by overfitting (12). Additionally, 
we performed GSEA on the 157 previously profiled ovarian cancers to determine the association 
between identified pathways and overall survival. For a more detailed description, see 
supplementary methods. 
Quantitative RT-PCR 
Differential gene expression was validated using 24 RNA samples previously used for microarray 
analysis (2). Total RNA, previously extracted for the microarray analysis, was reverse transcribed into 
cDNA as previously described (2). Quantitative RT-PCR (qRT-PCR) was performed on 1.2 ng of cDNA 
using Taqman Gene expression assays and Taqman Universal PCR master mix (Applied Biosystems, 
Nieuwerkerk a/d IJssel, the Netherlands) on CRSP2 (Hs00426717 _ml), EGR2 (Hs00166165_ml), 
LHXl (Hs00232144_m1), UBLCPl (Hs00376791_m1) and the housekeeping gene GAPDH 
(Hs02758991_gl) (13). All reactions were performed in triplicate using an ABI PRISM9 7900 HT 
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Sequence Detection System according to previously described cycling conditions (2). To calculate the 
relative expression for each gene, the mean CT value for GAPDH was subtracted from the mean CT 
value for the gene of interest (comparative threshold cycle [LlCT] method). 
lmmunohistochemical sta in ing for MBl and IGF-lR 
lmmunohistochemical staining for the proteasome subunit MBl and IGF-lR was performed on 
TMAs. TMAs were constructed using primary tumor tissues from all consecutive epithelial ovarian 
cancer patients treated by gynecological oncologists from the University Medical Centre Groningen 
between May 1985 and April 2003. Paraffin-embedded tumor tissue was available for 232 patients. 
Detailed information regarding the patient population and TMA construction has been described 
previously (14;15). 
lmmunohistochemical staining for the proteasome subunit MBl was performed in 232 stage I/IV 
primary ovarian cancers as part of a previously published study (15). For the present study, we 
analyzed the prognostic value of MBl immunostaining in all 115 patients presenting with stage Il l/IV 
serous disease. lmmunostaining for IGF-lR was newly performed in 165 stage Ill/IV tumors. This 
cohort included 115 patients evaluated for MBl staining and in addition all consecutive epithelial 
ovarian cancer patients with stage Il l/IV serous tumors treated between April 2003 and August 
2006. 
Four µm sections taken from the array block were deparaffinized in xylene and dehydrated with 
alcohol. Antigen retrieval was performed by boiling slides in a microwave in citrate buffer (pH 6.0) 
for 15 min. Endogenous peroxidase was blocked by incubating the slides in 3% hydrogen peroxide 
for 30 min. Sections were incubated with primary antibodies (polyclonal rabbit anti-MBl [Novus 
Biologicals, dilution 1:10] and polyclonal rabbit anti-lGF-lR [Cell Signaling #3027, dilution 1:1501) 
overnight at 4 2c. Detection was by a goat anti-mouse/rabbit secondary antibody conjugated with a 
peroxidase labeled polymer (DAKO EnVision+ system, DAKO, Glostrup, Denmark). Peroxidase activity 
was visualized by incubating the slides with 3,3-diaminobenzidine substrate (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and sections were counterstained with hematoxylin. As a negative 
control, a serial section was processed with replacement of primary antibody by rabbit lgG. Normal 
tissue derived from first trimester placenta served as a positive control (16). The intensity of 
immunostaining was evaluated by two independent observers blinded to the clinical data. MB-1 was 
scored as described previously (15). For IGF-1R, tumors showing moderate or strong membrane 
and/or cytoplasmic staining were considered to show positive expression (17). A more detailed 
description of statistical analyses performed is provided in the supplementary methods. 
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Results 
Patient cha racteristics 
We profiled paired specimens from 9 patients with advanced stage serous ovarian cancer. Median 
age was 53 years (range 42 - 66). Differentiation grade was moderate in three cases (33.3%) and 
poor in six cases (66.6%). All patients had residual tumor lesions with a diameter > 2cm after their 
first laparotomy and were treated with platinum-based chemotherapy. Median progression free and 
overall survival times were 10 months (range 4-18 months) and 13 months (range 6-30 months), 
respectively. 
Class comparison and hierarchical c lustering 
Hierarchical clustering of paired tumor samples based on the expression of all 15,909 genes showed 
that pre- and post-chemotherapy samples from the same patient tended to cluster together, 
indicating that differences between pre- and post-chemotherapy samples are relatively small 
compared to differences between patients (Fig. 1A). Based on a paired t-test, a total of 272 genes 
that were differentially expressed between pre- and post-chemotherapy samples were identified (p­
value < 0.01). Subsequent clustering based on 272 differentially expressed genes revealed a 
segregation of pre- and post chemotherapy samples except for samples F and H (Fig. 1B). 
Figure 1. Dendrograms showing results of hierarchical clustering based on 
a/1 15,909 genes (A) and 272 differentially expressed genes (B). 
Biologica l pathway ana lysis 
GSEA using pathway definitions from Biocarta revealed 2 pathways enriched in post-chemotherapy 
samples, whereas 12 pathways were enriched in pre-chemotherapy samples (Table 1, Fig. 2A and B). 
Four pathways, including the proteasome pathway in post-chemotherapy samples and the IGF-1R, 
ERK and Ras pathways in pre-chemotherapy samples, showed enrichment with a FDR < 0.25. Using 
KEGG pathway definitions, GSEA identified 23 enriched pathways of which eight were enriched in 
post-chemotherapy samples and 15 in pre-chemotherapy samples (Table 2, Fig. 2C and D). Eight 
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pathways had a FDR of < 0.25. The oxidative phosphorylation and proteasome pathways even 
showed a FDR of < 1.0-7. Leading edge analysis revealed key regulatory genes common to the 
identified pathways, such as AKT2 and PIK3R2 for Biocarta pathways and MAP2K1 for KEGG 
pathways {Supplementary table 2). 
Table 1. Results of gene set enrichment analysis using pathway definitions from Biocarta 
Pathway p-value FDR* Enriched in 
Proteasome pathway** < 0.001 0.13 post 
p53 hypoxia pathway 0.021 0.73 post 
IGF-lR pathway 0.002 0.13 pre 
ERK pathway 0.002 0.08 Pre 
RAS pathway 0.004 0.12 Pre 
MET pathway** 0.02 0.43 Pre 
IL-2 RB pathway 0.021 0.48 Pre 
SRC RPTP pathway 0.028 0.68 Pre 
HCMV pathway 0.032 0.48 Pre 
ACH pathway 0.036 0.56 Pre 
AKT pathway 0.037 0.48 Pre 
CXCR4 pathway 0.037 0.43 Pre 
IGF-1 pathway**  0.04 0.39 Pre 
FM LP pathway 0.048 0.58 Pre 
* FDR: False discovery rate 
** Associated with a worse prognosis in the validation set 
*** Associated with a relatively favorable prognosis in the validation set 
Impact on overa l l  surviva l 
To assess the prognostic value of the 272 genes that were differentially expressed between pre- and 
post-chemotherapy samples, univariate survival analysis was performed in 157 primary advanced 
stage serous carcinomas previously profiled in our institution (2). Of these 272 genes, 24 genes 
showed a significant correlation with overall survival {Table 3). Further analysis to unravel the 
possible relationship between up- or down-regulated genes after chemotherapy and prognosis of 
primary tumors clearly showed that high expression of genes up-regulated in post-chemotherapy 
samples was associated with poor overall survival in the validation set. 
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Table 2. Results of gene set enrichment analysis using pathway definitions from KEGG 
Pathway p-value FDR* Enriched in 
Oxidative phosphorylation <1.0-7 <1.0-7 post 
Proteasome pathway** <1.0-7 < 0.01 post 
Valine, leucine and isoleucine degradation 0.015 0.64 post 
Snare interactions in vesicular transport 0.017 0.46 Post 
Antigen processing and presentation 0.033 0.52 Post 
Fatty acid metabolism 0.039 0.53 Post 
Pathogenic E. Coli infection 0.039 0.47 Post 
Pyrimidine metabolism 0.042 0.35 Post 
Glycine, serine and threonie metabolism <1.0-7 0.13 Pre 
Neuroactive ligand receptor interaction*** <1.0-7 0.13 Pre 
Taste transduction 0.002 0.25 Pre 
Prostate cancer 0.006 0.24 Pre 
Gamma Hexachlororcyclohexane degradation 0.006 0.13 Pre 
Focal adhesion 0.007 0.41 Pre 
TGF beta pathway** 0.01 0.28 Pre 
Acute myeloid leukemia 0.011 0.25 Pre 
Small cell lung cancer 0.011 0.29 Pre 
Chronic myeloid leukemia 0.014 0.29 Pre 
Cytokine-cytokine receptor Interaction*** 0.016 0.46 Pre 
Notch pathway 0.02 0.25 Pre 
Type II diabetes mellitus 0.022 0.22 Pre 
Calcium pathway*** 0.023 0.45 Pre 
Jak STAT pathway*** 0.043 0.47 Pre 
Endometrial cancer 0.048 0.38 Pre 
* FDR: False discovery rate 
** Associated with a worse prognosis in the validation set 
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Figure 2. The most enriched pathways in GSEA based on Biocarta pathways in pre- and post-chemotherapy 
samples (A and B, respectively), and based on KEGG pathways (C and D, respectively). 
Table 3. Differentially expressed genes that showed a significant association with survival in the 
validation set 
Gene symbol p-value Hazard ratio Fold change (post/pre) 
TRIM9 0.0091 0.52 0.70 
DHX33 0.0112 0.52 0.71 
ENPP6 0.0254 0.67 0.72 
RTKN 0.0384 0.57 0.73 
NTSR1 0.0294 0.69 0.74 
AIM1 0.0147 0.57 0.74 
EGR2 0.0297 0.59 0.77 
CYP2S1 0.0426 0.61 0.77 
CBLB 0.0328 0.58 0.78 
SEPN1 0.0001 0.40 0.80 
WDR218 0.0234 0.56 0.81 
KLF3 0.0399 1.57 0.82 
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Table 3. Continued 
Gene symbol p-value Hazard ratio Fold change (post/pre) 
DDX31 0.0224 0.43 0.90 
PAOX 0.0021 0.37 1.12 
OR683 0.006 2.02 1.20 
HAX1 0.0146 1.90 1.23 
RNF7 0.0146 1.52 1.25 
ZNF433 0.0248 1.54 1.28 
TMEM16K 0.0067 1.68 1.38 
VPS45 0.0042 1.73 1.38 
NOB1 0.0347 0.71 1.42 
C10orf89 0.0078 1.45 1.43 
STARD3NL 0.003 1.49 1.66 
CSRP2 0.0118 1.32 2.00 
Subsequently, a predictor model was constructed based on the expression of the 24 genes identified 
in the previous analysis. Figure 3 shows Kaplan-Meier survival curves for cross-validated risk groups 
predicted to have a low (n = 42), median (n = 39) or high (n = 76) risk of death due to ovarian cancer. 
Median survival time was 42 months for the low risk group, 29 months for the median risk group 
and 17 months for the high-risk group (p-value log rank test = 0.011). The predictor maintained its 
prognostic value for patients in the high-risk group (HR = 2.1, 95%CI 1.20-3.81, p = 0.01) when 
entered into a multivariate model correcting for FIGO stage and residual tumor after primary 
surgery (Figure 3). 
Additionally, we performed GSEA to evaluate the prognostic impact of the identified pathways 
enriched in pre- or post-chemotherapy samples. GSEA using Biocarta pathway definitions revealed 
that the insulin-like growth factor I (IGF-1), MET and proteasome pathways were associated with a 
worse prognosis (Table 1 and Supplementary table 3). KEGG pathways associated with poor overall 
survival included the proteasome and transforming growth factor � (TGF-�) pathway, while several 
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Figure 3. Kaplan-Meier survival curves for patients with a low, medium 
and high predicted risk of death due to ovarian cancer. 
Results of qRT-PCR 
To validate that microarray expression measurements reflect true differences in expression, 4 genes 
differentially expressed between pre- and post-chemotherapy samples were selected for qRT-PCR 
analysis (CSRP2, EGR2, LHX1 and UBLCP1). Two of these genes (CSRP2 and EGR2) also showed an 
association with overall survival in the independent data set. First, relative expression levels for each 
gene were correlated with the corresponding microarray signal intensity. A strong correlation 
between �CT values obtained from qRT-PCR and microarray signal intensities was observed for 
three out of four genes {Supplementary figure 2: R = -0.80 for CSRP2, R = -0.38 for EGR2, R = -0.68 
for LHX1 and R = -0.78 for UBLCP1). In order to investigate whether qRT-PCR signal intensities could 
also be used to discriminate between pre- and post-chemotherapy samples, a paired samples t-test 
was performed. This analysis revealed that relative expression of UBLCP1 significantly differed 
between samples obtained prior to and following chemotherapeutic treatment (p = 0.11 for CSRP2, 
p = 0.88 for EGR2 and p = 0.61 for LHX1 and p = 0.017 for UBLCP1). 
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lmmunohistochemica l sta in ing for M Bl and IGF-lR 
Based on GSEA results showing that the proteasome pathway is  highly enriched in  post­
chemotherapy samples and in addition is related to poor overall survival, we assessed the 
prognostic value of expression of the proteasome subunit MBl in 115 stage Ill/IV serous cancers 
which were part of a previously published study in 232 stage I-IV ovarian cancers (15). 
Clinicopathological characteristics are summarized in Supplementary Table 4. Nuclear MB1 
expression was present in 68/112 (60.7%) evaluable tumors, while cytoplasmic staining was 
observed in 80/112 (71.4%) evaluable tumors. No relationships between nuclear or cytoplasmic 
MBl expression and patient age (p = 0.44 and p = 0.56, respectively), differentiation grade (p = 0.096 
and p = 0.27, respectively) or residual tumor after primary debulking surgery (p = 1.00 for both) were 
found. In univariate survival analysis nuclear, but not cytoplasmic MB1 staining was related to poor 
disease-specific survival (p = 0.005 and p = 0.055, respectively). Multivariate analysis confirmed that 
nuclear MBl staining was related to poor disease-specific survival independent of patient age, 
differentiation grade and debulking status (Supplementary table 5: HR 1.84, 95%CI 1.02-3.32, p = 
0.044). 
In addition to M81 immunostaining, we performed immunohistochemical staining for IGF-1R in 165 
stage Ill/IV cancers based on GSEA results that suggested enrichment of the IGF-1R and JGF-1 
pathways in pre-chemotherapy samples (Fig. 4 and Supplementary Table 4). Positive expression of 
JGF-1R occurred in 80/160 (50%) evaluable tumors, and was not associated with patient age (p = 
1.00), differentiation grade (p = 0.22) and residual tumor after primary surgery (p = 0.38). Univariate 
survival analysis showed that high expression of JGF-1R was related to an improved progression free 
survival, while no relationship between /GF-1R expression and disease-specific overall survival was 
found (Fig. 4). In multivariate analysis, JGF-1R expression no longer predicted disease outcome 
(Supplementary Table 5). 
Discussion 
In this study, we identified 272 genes that were most differentially expressed between 9 paired 
stage Ill/IV serous tumor samples obtained at surgery prior to and following platinum-based 
chemotherapy. From these 272 genes, a subset of 24 genes was univariately associated with overall 
survival in a large validation series of 157 advanced stage ovarian tumors. Moreover, high 
expression of genes up-regulated in post-chemotherapy samples was associated with poor overall 
survival in the validation set. A predictor model based on these 24 genes was capable of reflecting 
patients' overall survival, and held its significance in multivariate analysis. Using GSEA, we identified 
both well-known and novel pathways contributing to chemoresistance, several of which were also 
associated with survival in the validation series. Finally, we validated our results using qRT-PCR and 
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Figure 4. Results of immunohistochemical staining for IGF-1R. A) Kaplan Meier survival curves for progression free 
and overall survival. B) Representative examples of weak, moderate and strong staining intensity. Tumors 
exhibiting moderate or strong immunostaining were considered to show positive /GF-1R expression. 
Our study was performed based on the assumption that genes showing altered expression levels in 
the post-chemotherapy samples are related to platinum resistance. Higher frequency of platinum 
resistance of ovarian cancer cells after chemotherapy can be attributed to re-growth of either 
quiescent primary tumor cells that are relatively resistant to chemotherapy from the start due to 
their low proliferation rate (i.e. stem cell like cells), or drug-resistant clones that have progressively 
acquired genetic and/or epigenetic changes during chemotherapeutic treatment (1). These 
alterations can encompass cellular stress mechanisms and pro-survival routes that are temporarily 
induced following platinum treatment, as well as permanently changed genes due to genetic and/or 
epigenetic modifications. 
By assessing the impact of the genes differentially expressed between pre- and post-chemotherapy 
samples on overall survival within a different data set we were able to provide stronger evidence 
which genes might influence disease outcome. Among the 24 genes also associated with overall 
survival there are several genes previously described to be involved in (ovarian) carcinogenesis and 
tumor progression, indicating the validity of our approach. RNF7 is one of the interesting genes up­
regulated in post-chemotherapy samples. RNF7 was first identified as a stress-responsive gene that 
plays a role in ubiquitination and subsequent degradation of caspase 3, c-Jun and HIF-la, thereby 
protecting tumor cells from apoptosis (18-20). Consistent with results of the present study, high 
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RNF7 RNA expression was shown to be an independent predictor of poor survival in non-small cell 
lung cancer (21). Among the genes downregulated in post-chemotherapy samples EGR2 is of 
potential interest. Using cDNA microarrays, EGR2 was identified as a component of the PTEN 
pathway and was shown to be downregulated in ovarian cancer cell lines compared to 
corresponding normal ovarian tissues (22). Functional studies revealed that EGR2 functions as a key 
mediator of PTEN-induced growth inhibition and cell cycle arrest, making it an attractive target for 
(gene) therapy (22;23). 
Although the individual genes described above may certainly prove to be relevant for tumor 
behavior, it is not known whether large fold changes in individual genes have more biologic 
relevance than more subtle but orchestrated fold changes in a set of genes belonging to a single 
pathway (9;24). GSEA facilitates the interpretation of microarray data by identifying pathways 
underlying platinum resistance and has the important advantage of considering all the genes in an 
experiment rather than only genes passing a certain (arbitrary) significance threshold (9). In contrast 
to our previous work in which we used the LS/KS statistics taking in account only p-values (2), we 
have now ranked our gene list considering both p-values and fold changes between pre- and post­
chemotherapy samples. Consequently, our results do not only reveal pathways that are deregulated 
when comparing pre- and post-chemotherapy samples, but in addition show if genes belonging to a 
pathway exhibit higher expression levels in pre- or post-chemotherapy samples based on their 
enrichment. Using GSEA, several interesting pathways were identified that may provide starting 
points for further research. 
GSEA revealed that the proteasome pathway was highly enriched in pre-chemotherapy samples and 
that enrichment in the validation series was associated with overall survival. These findings were 
further validated by assessing the prognostic value of the proteasome subunit MB1 in 115 advanced 
stage serous carcinomas which were part of a previously published series (15). Consistent with GSEA 
results, this analysis revealed that nuclear MB1 staining was independently associated with poor 
disease-specific survival (15). The ubiquitin-proteasome pathway is crucial for intracellular protein 
turnover (25), so increased activity of this pathway in post-chemotherapy samples might simply be a 
reflection of cellular stress and increased protein metabolism following platinum treatment. 
However, as this pathway has been shown to control the levels of proteins important for cell-cycle 
progression and induction of apoptosis in malignant cells, deregulation may also contribute to 
resistance to anticancer therapy (25;26). Indeed, a recent study showed that specific inhibitors of 
the proteasome prevent down-regulation of the cisplatin transporter hCTRl, thereby enhancing 
drug uptake and apoptosis of ovarian cancer cell lines (27). Unfortunately, clinical trials combining 
proteasome inhibitors with chemotherapy for the treatment of recurrent/refractory ovarian cancer 
have shown only modest efficacy, while especially neurotoxicity was considerable (28-30). Currently, 
new generation proteasome inhibitors are being developed, which hopefully will result in more 
effective and less toxic treatment options for ovarian cancer patients (31). Alternatively, it has been 
shown that deregulated proteasome activity contributes to the anticancer activity of HDAC 
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inhibitors, suggesting that these inhibitors might represent a novel therapeutic strategy in tumors 
showing aberrant proteasome activity (32). 
Results from gene set enrichment analysis suggest that deregulation of genes belonging to the IGF 
axis contributes to platinum resistance and survival of ovarian cancer patients. Gene set enrichment 
revealed that the JGF-1R pathway was enriched in pre-chemotherapy samples, whereas deregulated 
IGF-1 signaling was shown to influence overall survival. In agreement with our present results, 
Spentzos et al demonstrated that IGF axis gene expression patterns can be used to predict prognosis 
of epithelial ovarian cancer patients (33). The IGF axis is well known for its role in malignant 
transformation, tumor progression and resistance to a wide range of anticancer therapies (34). 
Several strategies targeting the IGF system, such as monoclonal antibodies and small molecules, 
have been developed and are currently being tested in clinical trials (35). Recently, it has been 
shown that acquired platinum resistance of ovarian cancer cell lines is associated with autocrine JGF-
1 signaling and hyperactivation of the JGF-1R signaling pathway (36). In order to validate results of 
our pathway analysis and more precisely define the potential role of IGF-1R signaling in ovarian 
tumor tissues, we performed immunohistochemical staining for its key receptor IGF-1R in a large 
series of 165 advanced stage serous ovarian tumors. Our results showed that 50% of ovarian cancers 
show high expression of the JGF-R, rendering the receptor an attractive therapeutic target. In 
agreement with results from pathway analysis, univariate survival analysis revealed that tumors 
exhibiting enhanced IGF-1R expression have a longer progression free survival, which however did 
not translate into a better overall survival. Further research is needed to gain insight in the 
activation status of the IGF axis in ovarian cancer and the role for IGF-1R and/or other components 
of the IGF axis such as the insulin receptor in platinum resistance. 
Until now, only two studies have investigated chemoresistance using post-chemotherapy tumor 
samples (37;38). With respect to individual genes, there was little overlap between the genes 
identified in our present study and those identified in previous publications. Non-reproducibility of 
results is a well-known phenomenon in microarray studies and can be attributed to various 
methodological issues, such as the use of different microarray platforms (39). In the present study, 
we have paid specific attention to methodological issues by using a randomized hybridization design 
and performing multiple hybridizations per tumor sample. In this way, a more reliable and unbiased 
estimate of gene expression levels is provided. In addition, we used paired tumor samples 
representing a homogenous patient population with regard to clinicopathological characteristics and 
limited time between last chemotherapy and the second laparotomy to maximally 6 weeks. 
None of the 24 genes that were associated with overall survival in the present study were part of the 
86-gene overall survival profile in our previous study (2). Several reasons may account for this 
apparent discrepancy. First, the present study aimed to identify genes associated with 
chemoresistance while our previous investigation focused on overall survival, which is influenced by 
many factors besides response to chemotherapy. Secondly, because relevant genes were first 
selected on the basis of differential expression between pre- and post-chemotherapy samples, we 
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used a less strict significance threshold in survival analysis (p < 0.05). As a result, none of the 24 
genes associated with survival in the present study reached the significance level required for 
incorporation in the 86-gene profile. 
To further investigate the importance of the identified genes and pathways, several approaches can 
be envisioned. Firstly, the expression and clinical relevance of the identified genes can be 
determined using immunohistochemical staining or comparable methods in large cohorts of ovarian 
cancer patients. Secondly, studies in ovarian cancer cell lines to assess the functionality and 
therapeutic potential of the identified pathways should be performed and are currently underway in 
our laboratory. In addition, human tumor slices provide a powerful tool to test the efficacy and 
toxicity of agents targeting the identified pathways (40). 
In conclusion, our study provides novel insights into genes and pathways that contribute to platinum 
resistance in ovarian cancer and therefore deserve to be further validated and explored as possible 
therapeutic targets. 
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Patients and tumor samples 
The study population consisted of 9 patients with previously untreated stage Ill/IV serous 
carcinomas for whom paired tumor samples were available from both primary surgery as well was 
surgery performed after three or six cycles of chemotherapy. Tumor samples were collected at the 
University Medical Centre Groningen (Groningen, the Netherlands) between 1990 and 2003. All 
patients were treated with primary cytoreductive surgery followed by platinum-based 
chemotherapy (1). Post-chemotherapy samples were obtained at surgery performed maximally six 
weeks after three or six cycles of chemotherapy. Intervention or second look surgery was only 
performed in patients regarded as responding to chemotherapy. Tumor samples were snap frozen in 
liquid nitrogen, and stored at -80 °C. The median percentage of tumor cells was 70% (range 50 -
80%). Patients gave informed consent for collection and storage of tumor samples in a tissue bank 
for future research. Relevant patient data were retrieved and transferred into an anonymous, 
password-protected, database. Patients' identity was protected by study-specific, unique patient 
codes and their true identity was only known to two dedicated data managers. According to Dutch 
regulations, these precautions meant no further institutional review board approval was needed 
(http://www.federa.org). 
Microarray experiments 
RNA extraction and amplification was performed as described previously (2). Two randomly selected 
amplified RNA samples {cRNA) were hybridized together on the arrays for intensity-based instead of 
ratio-based analysis of the microarray data (3). cRNA samples (1.5 µg) were labeled with ULS-Cy5 
and ULS-Cy3 labels {BIOKE, Leiden, the Netherlands) and hybridized to 70-mer oligonucleotide 
microarrays ("'35,000 Operon v3.0 probes), manufactured by the Netherlands Cancer Institute (NKI; 
Amsterdam, the Netherlands, http://microarrays.nki.nl). Tumor samples were profiled multiple 
times with a minimum of two hybridizations per sample. Detailed information regarding the number 
of experiments per samples can be found in Supplement Table 1. Samples were hybridized as part of 
a larger study (2) using a randomized design to prevent systematic biases (4-6). Arrays were scanned 
with the Affymetrix GMS428 (Affymetrix, Santa Clara, CA) and expression values were calculated by 
Bluefuse software (BlueGnome, Cambridge, UK). Raw microarray data and accompanying clinical 
data are available at http://www.ncbi.nlm.nih.gov/geo/. 
Preprocessing of m icroarray data 
Quantile normalization was applied to log2 transformed Cy5 and Cy3 intensities (7). Subsequently, 
principal components analysis was performed for quality control. It has been shown that the most 
significant principal component for a gene expression data matrix is frequently a constant pattern, 
which dominates the data (8). So, the first principal component explaining the largest part of the 
variation could be considered as variation that the arrays have in common (9;10). Next, correlation 
with the first principal component (factor loading) was calculated for each individual array. Factor 
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loadings of the first principal component for an individual array can be seen as a quality index, as 
arrays of lesser quality would have lower or distinctly different correlations than arrays of good 
quality. Samples with a factor loading with the first principal components of less than 2 times the 
standard deviation from the mean were excluded as their hybridizations were considered to be of 
low quality (9;10). Based on this approach one sample was excluded (see supplementary Figure 1), 
leaving 54 samples that were available for further analysis. Next, Operon V3.0 probe identifiers were 
converted to official gene symbols using probe annotations provided by the NKI 
(http://microarrays.nki.nl//down1oad/files/operon_hs_060614.xls). A description of the annotation 
methodology used by the NKI is provided on their website 
(http://microarrays.nki.nl/services/blastdata.html). We have only used those oligonucleotides that 
specifically BLAST with a single hit on a gene. Expression values of multiple oligonucleotide probes 
targeting the same gene (identical gene symbol) were averaged, resulting in a total of 15,909 unique 
genes for further analysis. Subsequently, expression data obtained from multiple hybridizations of 
the same tumor sample were averaged resulting in 9 paired pre- and post-chemotherapy profiles. 
Class comparison between pre- and post-chemotherapy samples 
Class comparison was performed using the software package BRB Array Tools 3.6.0, developed by 
the Biometric Research Branch of the US National Cancer Institute (http://linus.nci.nih.gov/BRB­
ArrayTools.html). Differentially expressed genes were identified using a paired t-test with a 
significance threshold of p < 0.01. The significance of individual genes was determined using a 
univariate permutations test based on 10,000 permutations. With each permutation samples were 
randomly assigned to either the pre- or post-chemotherapy class and the t-test statistic was 
recalculated for each gene. The proportion of the permutations giving a paired t-test statistic as 
small as obtained with the true class labels is the univariate permutation p-value for an individual 
gene. Subsequently, average linkage hierarchical clustering using the Euclidean distance metric was 
performed using CLUSTER and TREEVIEW software (11). 
Gene Set Enrichment Ana lysis (GSEA) 
GSEA was performed with the software package GSEA 2.0, developed by the Broad Institute of MIT 
and Harvard (12). For each gene the relative difference in expression between paired pre- and post­
chemotherapy samples was determined using the paired t-test permutation p-value. p-Values were 
log2 transformed and a minus sign was added when the post/pre fold-change was less than one. 
Next, all 15,909 genes were ranked according to their transformed p-values resulting in a ranked list 
where the top genes were significantly up-regulated in post-chemotherapy samples (down­
regulated in pre-chemotherapy samples) and the bottom genes were significantly down-regulated in 
post-chemotherapy samples (up-regulated in pre-chemotherapy). This ranked list was compared 
against a large collection of functional gene sets to determine if there is enrichment of one of these 
functional gene sets at the top or bottom of the ranked list. The GSEA analysis was separately 
performed three times with a total of 166 gene sets as reported in the Kyoto Encyclopedia of Genes 
and Genomes database (KEGG), and 174 gene sets as reported in the Biocarta database 
(http://www.biocarta.com) (13). All gene sets contained a minimum of 10 and maximum of 500 
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genes from the total of 15,909 genes measured within this study. To determine if there is 
enrichment of a functional gene set the list of ranked genes is processed from top to bottom. 
Whenever a gene belonging to the functional gene set is encountered a running enrichment score is 
increased by a certain amount, otherwise the enrichment score is decreased. The enrichment 
statistic (ES) is the maximum deviation of the running enrichment score from zero (both negative 
and positive). A positive ES means that the functional gene set is enriched in the post-chemotherapy 
samples, whereas a negative ES indicated enrichment in pre-chemotherapy samples. Statistical 
significance of the ES was determined using an empirical gene-based permutation test based on 
1,000 permutations. Furthermore, for each functional set the false discovery rate (FDR) was 
calculated. The FDR is the estimated probability that the functional set with a given ES represents a 
false positive finding. Gene sets with an enrichment p-value of less than 0.05 are reported. A gene 
set with an FDR < 0.25 indicates that the result is expected to be valid 3 out of 4 times, and are 
considered most likely to generate interesting hypotheses and drive further research (12). 
Leading-edge subset ana lysis 
The leading-edge subset is defined as the subset of genes in a functional gene set that appears in the 
ranked list of 15,909 genes at, or before, the point where the running enrichment score reaches its 
maximum deviation from zero. The genes within this subset can be interpreted as the most 
important in the enrichment of the functional gene set. Leading-edge subsets were defined for all 
statistically enriched functional gene sets (p < 0.05). Subsequently, the overlap between leading­
edge subsets from significantly enriched functional gene sets from the three databases (KEGG, 
Biocarta and TRANSFAC) was determined. Using this approach, genes could be identified that 
belonged to more than one leading-edge subset and might be considered key regulators. 
I mpact of identified genes on overa l l  surviva l 
For genes with differential expression between pre- and post-chemotherapy samples we 
determined the correlation with survival within a data set of 157 advanced stage serous ovarian 
carcinomas previously profiled by our group (2). The significance of each gene was determined by a 
univariate Cox proportional hazards regression of survival time versus the log expression level and 
genes were selected at a threshold of p < 0.05. This resulted in a subset of genes that were both 
differentially expressed between paired pre- and post-chemotherapy samples and significantly 
correlated with overall survival. Based on fold-changes, this subset was divided into genes that were 
up-regulated or down-regulated in post-chemotherapy samples. Hazard ratios (HR) were log 
transformed, and a two-sample t-test between the mean of the log transformed HRs of the two 
groups was performed. This enabled us to determine the prognostic impact of up- and down­
regulation in post-chemotherapy samples on overall survival. 
Furthermore, from the data set containing the 157 advanced stage serous ovarian cancers genes 
that were significant differentially expressed between pre- and post-chemotherapy samples were 
selected. This subset of genes in combination with the supervised principal components method was 
utilized to construct a predictor model that is capable of assigning risk classes to individual patients 
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(14). Genes included in the model were selected based on univariate correlation with overall survival 
at a significance level of p < 0.05. To give a fair representation of the capability of this predictor 
model for predicting survival risk we applied internal 10-fold cross validation (15). In addition, we 
performed a permutation test based on 1,000 permutations to assess to what degree our model was 
influenced by overfitting (15). 
Additionally, we performed GSEA on the 157 ovarian cancers to determine the association between 
the identified pathways and overall survival. First, the correlation of each gene with overall survival 
was determined by a univariate Cox proportional hazards regression of survival time versus the log 
expression level. p-Values were log transformed and a minus sign was added when the hazard ratio 
was less than one. Next, all 15,909 genes were ranked according to their transformed p-values 
resulting in a ranked list where high expression of the top genes were significantly associated with a 
better prognosis and high expression of the bottom genes were significantly associated with a worse 
prognosis. As previously described, this ranked list was compared against a large collection of 
functional gene sets to determine if there is enrichment of one of these functional gene sets at the 
top or bottom of the ranked list. 
Quantitative RT-PCR 
Differential gene expression was validated using 24 RNA samples previously used for microarray 
analysis (2). For each patient, a minimum of one pre-chemotherapy and one post-chemotherapy 
sample was included. Total RNA, previously extracted and used for the microarray analysis, was 
reverse transcribed into cDNA using MMLV reverse transcriptase and hexameric random primer 
pd(N)G (lnvitrogen, Breda, the Netherlands) as previously described (2). Quantitative RT-PCR (qRT­
PCR) was performed on 1,2 ng of cDNA using Taqman Gene expression assays and Taqman Universal 
PCR master mix (Applied Biosystems, Nieuwekerk a/d IJssel, the Netherlands) on CRSP2 
(Hs00426717 _ml), EGR2 (Hs00166165_ml), LHX1 (Hs00232144_ml), UBLCP1 (Hs00376791_ml) 
and the constantly expressed housekeeping gene GAPDH (Hs02758991_gl) (16). All reactions were 
performed in triplicate using an ABI PRISM" 7900 HT Sequence Detection System according to 
previously described cycling conditions (2). To calculate the relative expression for each gene, the 
mean CT value for GAPDH was subtracted from the mean CT value for the gene of interest 
(comparative threshold cycle [f1CT] method). 
lmmunohistochemical sta in ing for MB1 and IGF-1R 
lmmunohistochemical staining for the proteasome subunit MB1 and /GF-1R was performed on 
tissue microarrays. Tissue microarrays were constructed using primary tumor tissues from all 
consecutive epithelial ovarian cancer patients treated by gynecological oncologists from the 
University Medical Centre Groningen between May 1985 and April 2003. Paraffin-embedded tumor 
tissue was available for 232 patients. Detailed information regarding the patient population and 
tissue microarray construction has been described previously (17;18). 
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lmmunohistochemical staining for the proteasome subunit MBl was performed in 232 stage I/IV 
primary ovarian cancers as part of a previously published study (18). For the present study, we 
analyzed the prognostic value of MBl immunostaining in all 115 patients presenting with stage Ill/IV 
serous disease. lmmunostaining for IGF-lR was newly performed in 165 stage Ill/IV tumors. This 
cohort included 115 patients evaluated for MBl staining and in addition all consecutive epithelial 
ovarian cancer patients with stage Ill/IV serous tumors treated between April 2003 and August 
2006. 
Four µm sections taken from the array block were deparaffinized in xylene and dehydrated with 
alcohol. Antigen retrieval was performed by boiling slides in a microwave in citrate buffer (pH 6.0) 
for 15 min. Endogenous peroxidase was blocked by incubating the slides in 3% hydrogen peroxide 
for 30 min. Sections were incubated with primary antibodies (polyclonal rabbit anti-MBl [Novus 
Biologicals, dilution 1:10] and polyclonal rabbit anti-lGF-lR [Cell Signaling #3027, dilution 1:150]) 
overnight at 4 2c. Detection was by a goat anti-mouse/rabbit secondary antibody conjugated with a 
peroxidase labeled polymer (DAKO EnVision+ system, DAKO, Glostrup, Denmark). Peroxidase activity 
was visualized by incubating the slides with 3,3-diaminobenzidine substrate (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and sections were counterstained with hematoxylin. As a negative 
control, a serial section was processed by replacement of primary antibody with rabbit lgG. Normal 
tissue derived from first trimester placenta served as a positive control (19). The intensity of 
immunostaining was evaluated by two independent observers blinded to the clinical data. MB-1 was 
scored as described previously (18). For IGF-lR, tumors showing moderate or strong membrane 
and/or cytoplasmic staining were considered to show positive expression (20). 
Statistical analysis was performed using the SPSS 16.0 software package. All cases with < 2 evaluable 
core were excluded from the analysis. Associations between IGF-1R staining and clinicopathological 
characteristics were investigated using the Chi-square or Fisher exact test, where appropriate. The 
endpoints that were investigated were progression free survival, defined as the time from primary 
surgery to relapse of the disease, and overall survival, defined as the time from surgery to death of 
ovarian cancer. Univariate survival analysis was performed using Kaplan Meier survival curves and 
the log rank test. For multivariate analysis, Cox proportional hazards model was used. Variables 
included in the multivariate analysis were age (continuous), grade (grade 1/1 1 or grade 
Ill/undifferentiated) and residual disease (< 2 cm. o� 2 cm.) Multivariate analysis was stratified for 
chemotherapy and all variables were entered simultaneously into the model. p-Values < 0.05 were 
considered statistically significant. 
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Figure S1. Correlation of each sample with PCqc. 
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Figure SZ. Scatter Plots Showing the Microarray Expression Signal Versus the LlCt 
Obtained by qRT-PCR for Four Individual Genes. Genes are LHX1, UBLCP1, EGR2, and 
CSRP2. LlCt of the gene is obtained by subtracting the mean Ct value of GAPDH from 
the mean Ct value of the gene. Both axes are on /og2 scale. 
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Table S1. Hybridizations 
Patient ID Number of hybridizations Tissue source 
A 3 pre-chemotherapy 
A 2 post-chemotherapy 
B 2 pre-chemotherapy 
B 2 post-chemotherapy 
C 2 pre-chemotherapy 
C 6 post-chemotherapy 
D 6 pre-chemotherapy 
D 2 post-chemotherapy 
E 4 pre-chemotherapy 
E 3 post-chemotherapy 
F 2 pre-chemotherapy 
F 2 post-chemotherapy 
G 3 pre-chemotherapy 
G 2 post-chemotherapy 
H 3 pre-chemotherapy 





Table S2. Results of leading edge analysis 
KEGG Biocarta 
Gene symbol n gene sets Gene symbol n gene sets 
PIK3R2 7 MAP2K1 8 
AKT2 7 RELA 5 
S0S1 6 S0S1 5 
MAP2K1 5 BAD 5 
MAPK1 5 NFKB1 5 
BAD 5 ELK1 5 
RELA 4 SRC 4 
EGFR 4 /GF-1R 3 
NFKB1 4 IRS1 3 
PDGFRA 4 PTK2 3 
Table S3. Pathways associated with overall survival in the validation set 
Pathway Database p-value FDR***  Enriched in 
IGF-1 pathway * Biocarta < 0.001 0.22 Poor survival 
CDC42RAC pathway Biocarta 0.002 0.24 Poor survival 
MET pathway * Biocarta 0.016 0.39 Poor survival 
ARAP pathway Biocarta 0.018 0.39 Poor survival 
P38MAPK pathway Biocarta 0.022 0.43 Poor survival 
LONGEVITY pathway Biocarta 0.024 0.38 Poor survival 
SALMONELLA pathway Biocarta 0.024 0.61 Poor survival 
INSULIN pathway Biocarta 0.027 0.48 Poor survival 
PROTEASOME pathway * Biocarta 0.029 0.40 Poor survival 
I Ll 7 pathway Biocarta 0.0019 0.16 Better survival 
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Table 53. Continued 
Pathway Database p-value FDR*** Enriched in 
NO2IL12 pathway Biocarta 0.0036 0.16 Better survival 
DC pathway Biocarta 0.0036 0.31 Better survival 
CTL pathway Biocarta 0.0092 0.28 Better survival 
T CYTOTOXIC pathway Biocarta 0.0164 0.26 Better survival 
IL22BP pathway Biocarta 0.032 0.39 Better survival 
T HELPER pathway Biocarta 0.037 0.49 Better survival 
TALLl pathway Biocarta 0.047 0.47 Better survival 
Sulfur metabolism KEGG 0.006 0.53 Poor survival 
N glycan biosynthesis KEGG 0.007 0.29 Poor survival 
TGF beta pathway * KEGG 0.007 0.51 Poor survival 
Glycosylphosphatidylinositol anchor biosynthesis KEGG 0.026 0.46 Poor survival 
Aminoacyl tRNA biosynthesis KEGG 0.028 0.51 Poor survival 
Proteasome pathway * KEGG 0.037 0.52 Poor survival 
Cell cycle ** KEGG 0.048 0.70 Poor survival 
Hematopoietic cell lineage KEGG < 0.001 0.02 Better survival 
Cytokine-cytokine receptor interaction * / ** KEGG < 0.001 0.02 Better survival 
Jak-STAT pathway * / ** KEGG < 0.001 0.16 Better survival 
Neuroactive ligand receptor interaction * KEGG < 0.001 0.20 Better survival 
MAPK pathway **  KEGG < 0.001 0.23 Better survival 
Cell adhesion molecules ** KEGG 0.002 0.21 Better survival 
Linoleic acid metabolism KEGG 0.005 0.12 Better survival 
Natural killer mediated cytotoxicity ** KEGG 0.011 0.23 Better survival 
T cell receptor pathway KEGG 0.011 0.25 Better survival 
ERBB pathway KEGG 0.017 0.28 Better survival 
Pantothenate and CoA biosynthesis KEGG 0.022 0.20 Better survival 
Metabolism of xenobiotics by cytochrome p450 KEGG 0.024 0.27 Better survival 
Antigen processing and presentation KEGG 0.026 0.24 Better survival 
Calcium pathway * / ** KEGG 0.035 0.47 Better survival 
Renin angiotensin pathway KEGG 0.039 0.19 Better survival 
* Also enriched in pre- or post-chemotherapy samples 
** Also associated with overall survival in our previous study (Crijns et al Plos Med 2009} 
*** False discovery rate 
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Table S4. Clinicopathological characteristics 
Characteristic Subcategory MBl cohort (n = 115) IGF-lR cohort (n = 165) 
n or Value % n or Value % 
Age Median, years 61 61 
Range 22 - 81 22-85 
Stage Stage Ill 92 80.00% 129 78.20% 
Stage IV 23 20.00% 36 21.80% 
Tumor type Serous 115 100.00% 165 100.00% 
Tumor grade Grade 1/1 1 29 25.20% 50 30.30% 
Grade 
Ill/undifferentiated 
76 66.10% 102 61.80% 
Missing 10 8.70% 13 7.90% 
Residual tumor < 2 cm 32 27.80% 49 29.70% 
;;? 2 cm 80 69.60% 105 63.60% 
Missing 3 2.60% 11 6.70% 
Overall survival Median 16 16 
Range 0 - 213 0 - 248 
Progression 
free survival 
Median 10 10 
Range 0 - 108 0 - 149 
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Table SS. Results of multivariate analysis for MBl and IGF-lR immunostaining 
Staining Subcategory Progression free survival Overall survival 




1.07 0.62-1.85 0.8 1.84 1.02-3.32 0.044 
expression 
Age 
1.01 0.99-1.04 0.31 1.01 0.99-1.03 0.61 
(continuous) 
Grade Ill / 
undifferentiated 
1.03 0.52-2.04 0.93 2.33 1.24-4.37 0.009 
Residual tumor 
2.28 1.27-4.10 0.006 2.68 1.52-4.72 0.001 








1.01 0.99-1.04 0.3 1.01 0.99-1.03 0.63 
Grade Ill / 
1.05 0.53-2.08 
undifferentiated 
0.9 2.16 1.15-4.06 0.016 
Residual tumor 
2.27 1.26-4.09 0.006 2.70 1.53-4.74 0.001 









0.52 1.01 0.99-1.02 0.6 
Grade Ill / 
1.18 0.74-1.87 
undifferentiated 
0.49 1.25 0.77-2.03 0.38 
Residual tumor 
2.07 1.33-3.20 0.001 2.11 1.35-3.31 0.001 
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Chapter 6 
Abstract 
It has been hypothesized that the net expression of a gene is determined by the combined effects of 
various transcriptional system regulators {TSRs). However, characterizing the complexity of 
regulation of the transcriptome is a major challenge. Principal component analysis on 17,SS0 
heterogeneous human microarray experiments revealed that SO orthogonal factors {hereafter called 
TSRs) are able to capture 64% of the variability in expression in a wide range of experimental 
conditions and tissues. We identified gene clusters controlled in the same direction and show that 
gene expression can be conceptualized as a process influenced by a fairly limited set of TSRs. 
Furthermore, TSRs can be linked to biological functions, as we demonstrate a strong relation 
between TSR-related gene clusters and biological functionality as well as cellular localization, i.e. 
gene products of similarly regulated genes by a specific TSR are located in identical parts of a cell. 
Using 3,934 diverse mouse microarray experiments we found striking similarities in transcriptional 
system regulation between human and mouse. Our results give biological insights into regulation of 
the cellular transcriptome and provide a tool to characterize expression profiles with highly reliable 
TSRs instead of thousands of individual genes, leading to a > S00-fold reduction of complexity with 
just SO TSRs. This might open new avenues for those performing gene expression profiling studies. 
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Introduction 
Biological systems have a layered complexity and it is known that a cell's activity is modulated by a 
network of co-regulated gene clusters (1). Such modules are characterized by clusters of 
transcriptionally correlated genes, most often with related functions (2). A number of studies using 
clustering algorithms based on similar expression patterns provided valuable clues about which 
strongly expressed genes are co-regulated in a small, specific set of experimental conditions (1-3). 
However, clustering algorithms are less effective when applied to large datasets of heterogeneous 
material. Basic clustering algorithms assign each gene to a single cluster of co-regulated genes, 
whereas it is hypothesized that the net expression of a gene is determined by the combined effects 
of various transcriptional system regulators (TSRs) (4-6). In addition, each level of transcriptional 
regulation may only be active in certain phenotypes and the remaining phenotypes will contribute 
to noise (5). In contrast, principal component analysis (PCA) on a large heterogeneous set could 
enable us to use correlation structures of not only strong but also weakly expressed genes and could 
provide a global picture of the dynamics of gene expression on various transcriptional regulation 
levels. It could allow individual genes to be classified into groups that are similarly controlled by a 
specific TSR. 
Unraveling the complexity of regulation of the transcriptome is a major challenge; as in principle an 
infinite number of TSRs could be needed to control the expression of thousands of genes ultimately 
leading to the large diversity seen in cellular phenotypes. In this study we identified a structure of 
transcriptional regulation by analyzing 17,550 heterogeneous microarray experiments. We found 
that the number of orthogonal factors needed to explain most of the variability in expression is fairly 
limited, even in a wide range of experimental conditions, tissues and even across species. 
Furthermore, using several different models, we show that these TSRs have biological relevance and 
yield reliable summary measurements of gene expression that are applicable to different tissue 
types as well as organisms. 
Results 
Transcriptiona l  system regu lators 
Insight into the complexity of the regulation of the transcriptome was revealed by PCA on the 
expression correlation matrix of 13,032 genes in 17,550 human miscellaneous expression arrays. 
PCA demonstrated that 64% of the variance in expression of 13,032 genes was explained by only 50 
orthogonal factors, called TSRs, which means a > 500-fold reduction in complexity (Figure lA). 
Similar results were observed in mice where 50 TSRs explained 71% of the variance in expression of 
9,062 genes in 3,934 arrays (Figure lA). Moreover, Figure lA shows that the pattern of the 
percentage explained variance per TSR is highly similar between human and mouse. Tables Sl and 
S2 contain factor loadings for the first 50 TSRs in human and mouse, respectively. 
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Figure 1. Explained variance and reliability of the first 50 transcriptional system regulators (TSRs). Panel A shows 
the explained variance for the first 50 TSRs in human and mouse. The percentage explained variance is depicted 
for each TSR. The cumulative percentage explained variance for the first 50 TSRs is 64% in human and 71% in 
mouse. Panel B shows a heat map where each box represents the Pearson correlation coefficient between TSRs 
generated from sets A and B, each using half of the data. Correlation coefficients of 0 and 1 are represented by 
black and red, respectively. Panel C shows the split-half correlations for the first 50 TSRs. (A TSR is a weighted sum 
of genes and a so-called TSR score can be calculated for each sample. In the split-half method, genes of a TSR 
score are split into two random parts and the resulting partial TSR scores are correlated (Pearson).) 
Rel iabi l ity of TSRs 
To evaluate whether the identified TSRs depend on the specific set of selected microarray 
experiments, the human microarray data were randomly split into two halves and then two sets (A 
and B) of TSRs were generated, each using only half of the samples. Figure 1B contains a heat map 
showing correlation coefficients between TSRs generated in sets A and B. TSRl generated in set A 
and TSRl in set B correlated significantly (R = .999; p < 1.0xl0-16), indicating highly similar control of 
identical genes by TSRl in both sets. Furthermore, the diagonal line in Figure 1B shows that TSRs 
generated in both sets were highly similar in their control of identical genes. For a few TSRs, the 
relative position in the order they were found was seen to be switched, but the same directions of 
variation were identified. These results indicate that the TSRs were reliably identified and were not 
artifacts due to sample selection. To further investigate whether the identified TSRs were not 
artifacts due to gene selection, we applied the split-half method to each TSR. Figure lC shows the 
split-half correlations for the first 50 TSRs, which were high (> 0.91), indicating their high internal 
consistency. In sum, the identified TSRs were robust and not artifacts due to selection of genes and/ 
or tissues. 
Biologica l significance of TSRs 
To validate that the identified TSRs are not merely mathematical constructs but contain biological 
coherence and to gain more biological insight into the regulation of the transcriptome, we 
performed Gene Set Enrichment Analysis (GSEA). The hypothesis is that our identified TSRs are 
related to known biologically related gene clusters represented by GO ontology's. Here we describe 
the GSEA results for the first, second and fiftieth TSR as examples. GSEA results for the first 25 TSRs 
are available in the supplementary data online. Among the genes most strongly influenced by TSRl, 
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TSR2 and TSRS0, many GO ontology's were significantly enriched (n = 488, n = 1157 and n = 119, 
respectively). Figure 2 shows the most significant biological processes per TSR according to the GO 
ontology classification on either side of it. The graphs show the enrichment score as a function of 
the index in the list (x-axis) of genes ranked according to the correlation between their expression 
and a TSR score (factor loading). Red graphs with a 'mountain-like shape' illustrate a specific GO 
ontology predominantly containing top ranked genes. In contrast, green graphs with a 'valley-like 
shape' illustrate a specific GO ontology predominantly containing bottom ranked genes. When 
genes belonging to a specific GO ontology are not top or bottom ranked but randomly distributed in 
the ranked list the graph will have a 'zigzag' shape. Furthermore, Figure 2 shows that TSRs have the 
capacity to influence the expression of genes involved in specific biological processes in opposite 
directions, e.g. TSRl regulates genes belonging to GO ontology 'progression through M phase' vs. 
'ion transport' , TSR2 genes belonging to GO ontology 'cell cycle checkpoint' vs. 'the cell 
morphogenesis' and TSRS0 genes belonging to GO ontology 'striated muscle contraction' vs. 
'complement activation'. Biological processes represented by GO ontologies can theoretically be 
influenced by more than one TSR; the contrast seen in TSRl 'progression through M phase' vs. 'ion 
transport' was also seen in TSR3 for example. All enrichments for GO ontologies representing these 
six biological processes were highly significant; p < 10-8. In addition, the encoded proteins of genes 
controlled in opposite directions (i.e. top vs. bottom ranked genes) by a TSR are generally located in 
other compartments of a cell (e.g. Golgi, mitochondrion, nucleus, etc. ), as shown for TSRl in Figure 3 
for example. Panel A shows that the encoded proteins of the top-ranked genes of TSRl (the limit of 
200 was arbitrarily chosen) are generally located within the plasma membrane, whereas the 200 
bottom-ranked genes of TSRl are generally located within the nucleus of the cell. This is also 
visualized in Panel B, where the green 'valley-like shape' graph shows that the GO ontology for 
cellular localization 'nucleus' is enriched among the bottom-ranked genes. In contrast the red 
'mountain-like shape' graph shows the enrichment of the GO ontology 'plasma membrane' at the 
top-ranked genes. 
Simi la rities in transcriptional system regu lation between human and mouse 
PCA on the combined two-species dataset consisting of 3,934 human and 3,934 mouse arrays was 
performed to assess the similarity of the structure in transcription regulation between human and 
mouse. PCA revealed that again 50 principal components (PCs) explained ~73% of the total variance 
in combined human and mouse gene expression. In this specific two species dataset the first PC 
(PCl) explained, ~2s% of the total variance in expression. The distribution of PCl scores for human 
samples showed no overlap with PCl scores for mouse samples, suggesting that PCl summarizes 
the variation in expression caused by species differences (Figure S1). Biological processes such as 
RNA processing, ion transport and primary metabolism were enriched in PCl using GSEA analysis. 
Except for PCl, all PCs showed a strong overlap between human and mouse PC scores, suggesting 
that gene expression in human and mouse is similarly influenced by regulatory processes influencing 
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Figure 2. Biological significance of the 
transcriptional system regulators (TSRs). The 
most significant biological processes for either 
side of the respective TSR according to the GO 
ontology classification are shown for TSRl, 
TSR2 and TSRS0 in panels A, 8 and C, 
respectively. Graphs depict the running sum 
statistics when applying gene set enrichment 
analysis. The running sum (y-axis) is shown as a 
function of the index in the list (x-axis) of genes 
ranked in ascending order according to their 
factor loadings within TSR. The red vs. green 
graphs show the biological coherence of 
opposing regulated gene clusters controlled by 
TSRs. 
Figure 3. Relationship between cellular 
localization of genes controlled in opposite 
directions by TSRl. Panel A shows the cellular 
localization of the 400 most strongly controlled 
genes (highest factor loadings). The colors 
represent genes with positive (green) and 
negative (red) factor loadings. Panel 8 shows 
the results of gene set enrichment analysis with 
regard to cellular localization of the gene 
products. Graphs show the running sum 
statistics when applying gene set enrichment 
analysis. The running sum (y-axis) is shown as a 
function of the index in the list (x-axis) of genes 
ranked in ascending order according to their 
factor loadings within a TSR. 
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Mapping human and mouse TSRs 
The results above suggest a high similarity in the structure 
of transcriptional regulation between human and mouse. 
To assess similarities in regulation of biological processes, 
we mapped TSRs generated in the human dataset to TSRs 
generated in the mouse dataset. The Spearman rank 
correlation coefficients between human and mouse TSRs 
showed that human TSRl was most strongly correlated 
with mouse TSR2 (R = .489, p = 1.0xl0-6). Correlation 
coefficients between the first 25 human and mouse TSRs 
are given in Table S3. As an example of the strong 
resemblance in transcriptional system regulation between 
human and mouse, Figure 4 shows that identical biological 
processes are enriched and similarly controlled in one 
direction (human TSRl vs. mouse TSR2). 
Figure 4. Similarities in transcriptional system regulation between 
human and mouse. Panels A and B show the results of gene set 
enrichment analysis for six biological processes for human TSRl 
and mouse TSR2, respectively. Graphs show the running sum 
statistics. The running sum (y-axis) is shown as a function of the 
index in the list (x-axis) of genes ranked in ascending order 
according to their factor loadings with a TSR. The red vs. green 
graphs show the biological coherence of regulated gene clusters 
controlled by TSRs in both species. 
Regional control of chromosomal domains 
Next, in order to further characterize the transcriptional 
system regulation, we assessed whether genes similarly 
controlled by a specific TSR also cluster within 
chromosomal regions. Figure 5 shows regional factor loading profiles for TSRl. GSEA results in terms 
of chromosomal distribution of similarly controlled gene regions for other TSRs are available in the 
supplementary data. An application of a moving median with a window size of 20 genes clearly 
shows differences for the chromosomal regions. The Y-chromosome is not depicted as the number 
of genes in the dataset located on the Y-chromosome was less than 20, so a moving median could 
not be calculated. Several chromosomes (e.g. 1 and 11) have large regions of genes with 
predominantly positive factor loadings, interspersed with regions where genes have predominantly 
negative factor loadings. In contrast, chromosomes 4, 13 and 22 show hardly any regions of genes 
inversely controlled by TSRl, but, more remarkably, all these gene regions seem to be regulated in 
only one direction. 
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Figure 5. Regional factor loading profiles for 23 chromosomes. Factor loadings for TSR1 are shown on 
chromosomes as a moving median with a window size of 20 genes. Chromosome position is depicted on the x-axis 
and factor loadings for gene regions are given on the y-axis. Bars above or below the middle line represent 
inversely regulated chromosomal regions. 
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Gene clustering based on TSR interaction 
We clustered genes based on factor loadings with the first 50 TSRs in order to elucidate the 
dynamics of gene expression regulation, in which individual genes are classified into groups with 
similar regulation patterns. Gene clusters with distinct patterns of regulation were observed; 
clusters predominantly controlled by the first TSRs and clusters with a more diffuse pattern of TSR 
regulation {e.g. genes of which the products are involved in the biosynthesis of proteins from mRNA 
molecules). Furthermore, as functionally related genes often exhibit expression patterns that are 
correlated, we expected to observe clusters of functionally related genes based on TSR interaction. 
For example, Figure 6A and 6B show gene clusters with a strong biological relationship, i.e. the 
human leukocyte antigen system {HLA). All clustering results are available as supplementary data 
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Figure 6. Heat map examples of gene clusters based on factor loadings with the first 50 transcriptional system 
regulators (TSRs). Each box in the heat map represents the factor loading of a gene with one of the TSRs (negative 
= red; positive = green). The first row shows the average factor loadings for the depicted cluster. 
Sam ple clustering based on TSR scores 
Samples from the publicly available human body index were clustered to assess whether similar 
tissue samples have similar patterns in TSR scores. Clustering results for all samples are given in the 
supplementary data. Samples with identical tissue origins showed strong clustering, e.g. Figure 7 
shows clustering of liver tissue samples as well as kidney samples. 
Feta1 Liver BD Normal 
Liver 2 Hormal. 
Liver 1 Hormal. 
Liver 3 Hormal. 
Liver 4 Normal. 
Kidnev BD Normal 
Kidnev Cortex 3 Hormal 
Kidnev Cortex 2 Normal 
Kidnev Cortex 1 Normal 
Kidnev Cortex 4 Hormal 
Kidnev Medu11a 3 Hormal 
Kidnev Medulla 4 Hormal 
Kidnev Medulla 1 !formal 
Kidney Medulla 2 !formal 
Figure 7. Heat map example of sample clusters based on transcriptional system regulator (TSR) scores. Each box 
in the heat map represents the score for a sample (negative = red; positive = green). The first row shows the 




Principal component analysis (PCA) on a large number of heterogeneous microarray experiments 
showed that a maximum of SO statistically independent transcriptional system regulators (TSRs) can 
explain the vast majority of biological variance in gene expression in human as well as in mouse. 
Furthermore, we identified clusters of genes which expression is influenced in the same direction by 
specific TSRs and showed that gene expression can be conceptualized as a process influenced by a 
limited set of TSRs. 
In microarray studies small sample sizes often present a major problem, such as overfitting, i.e. 
finding a discriminatory pattern by chance, which may occur when large numbers of genes are used 
to discriminate a small number of phenotypes (7). Since a TSR is a weighted sum of genes, a TSR 
score can be calculated for each observed expression array. This data reduction allows us to 
characterize the expression profile of an individual microarray with SO highly reliable TSR scores 
(TSR-profiling) instead of using thousands of individual genes (the software to compress expression 
array data in TSR scores is available at the supplementary website). As an example we showed that 
similar tissues clustered together based on the first SO TSR scores (Figure 7). These results strongly 
suggest that the origin of tissues can be uncovered with the use of TSR scores. This could be applied 
for the identification of cancer metastases of unknown origin. The advantage is that a limited set of 
TSRs makes it is possible to analyze even small gene expression datasets with much less danger of 
false-positive results due to overfitting. Furthermore, TSR scores can be used to identify systematic 
changes of expression in gene clusters consisting of genes with small but systematic fold changes 
between phenotypes. This is important as we often do not know whether large fold changes in 
individual genes will have more biological relevance than smaller but coordinate fold changes in a 
set of genes. 
Inherent to microarray experiments the measurement of gene expression is composed of biological 
signals and experimental noise (8). We assumed that at least the first SO TSRs, accounting for , 70% 
of the information present in the entire dataset, capture the majority of relevant biological signals 
and that subsequent ones are likely to consist of noise and experimental artifacts, a principle which 
has also been described by Alter et al (9). Normalizing gene expression data by filtering out these 
latter TSRs enables a meaningful comparison to be made of the expression of different genes across 
different arrays in different experiments (Figure 6). Moreover, in addition to compare genes on the 
basis of their net expression, genes can now also be compared by their similarity in regulation of any 
chosen subset of TSRs. Therefore, the function of genes with a provisional status could be elucidated 
by looking at genes with known biological functions which are similarly influenced by our identified 
TSRs. 
TSRs can also be linked to biological functions as we have shown a strong relation between TSR­
related gene clusters and biological coherence in terms of functionality as well as cellular localization 
(Figures 2 and 3). Genes encoding for proteins located in the nucleus are influenced in opposite 
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directions compared to genes encoding for proteins located in the plasma membrane. This might 
suggest that there is a regulatory process which could down regulate the expression of 'nuclear' 
genes when up-regulating 'plasma membrane' genes and vice versa. However, of note, a biological 
process represented by a GO ontology is not necessarily influenced by one specific TSR alone but can 
be influenced by more than one TSR; e.g. the contrast nucleus vs. membrane was seen in several 
TSRs. Although we do not know the nature of the transcriptional regulatory processes represented 
by our TSRs, this study provides insights into which specific biological processes are influenced in 
opposite directions. Further studies are needed to unravel the underlying nature and interplay of 
these TSRs. 
Expression profiling of relevant disease tissues might help in candidate gene selection. However, 
such studies are often problematic, as relevant human tissue is hard to obtain. To overcome these 
sampling problems, the use of comparable mouse tissues seems a good option. Figure 4 shows a 
highly similar pattern of influence on gene expression between TSRl in human and TSR2 in mice. 
Identical opposing GO ontology's are influenced in the same directions. Our results suggest a high 
homology between the transcriptional regulation of human and mouse. It is noteworthy that the 
first principal component from the PCA on the combined two-species dataset representing species 
differences revealed that GO ontology's such as primary metabolism and RNA processing were 
highly enriched. This is in line with expected metabolic differences between human and mouse. By 
filtering out the first principal component that represents expression differences between the 
species and/or platforms, will enable one with the remaining differences to translate mouse data to 
the human situation and vice versa, because species-specific variance in expression can be 
recognized and eliminated by subtraction. 
So far several levels in transcriptional system regulation have been reported, e.g. classical DNA 
sequence regulators, epigenetic modifications, spatial and temporal organization of nuclear 
processes and chromosomes, organization of chromatin into higher-order domains, transcription 
factors and microRNAs (10-15). These known levels in transcriptional system regulation may be 
represented by a combination of the TSRs identified in this study. In addition, some of the identified 
TSRs may represent other, as yet undiscovered levels of transcriptional system regulation. 
Interestingly, our work demonstrated that TSRs regulate genes from chromosomal regions 
predominantly in the same direction. This observation was most strongly pronounced for TSRl 
(Figure 5), suggesting it is strongly related to chromosomally related transcriptome regulation. A 
higher-order organization of transcriptome regulation in terms of chromosomal domains is also 
suggested by Caron et al (16). 
Our results give biological insights into regulation of the cellular transcriptome and provide a tool to 
characterize expression profiles with highly reliable TSRs instead of thousands of individual genes, 
leading to a .500-fold reduction of complexity with just 50 TSRs. This might open new avenues for 
those performing gene expression profiling studies. 
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Materials and methods 
Data acqu isition 
Publicly available microarray expression data of 17,550 human samples hybridized to HG-U133A or 
HG-U133 Plus 2.0 Genechips (Affymetrix, Santa Clara, California, USA) and 3,934 mouse samples 
hybridized to MG-U74A Genechip (Affymetrix, Santa Clara, California, USA) were obtained from the 
Gene Expression Omnibus (17). These datasets contained a wide range of heterogeneous tissues 
(primary patient material, cell lines, normal tissues, etc. ) and covered a multitude of different 
experimental conditions (transfected/transduced, stimulated or treated cells, etc. ) . For the human 
dataset, probes available on both platforms were selected for further analysis. Then the probes for 
the human as well as the mouse dataset were converted to official gene symbols, averaging log2 
transformed expression values of multiple probes targeting the same gene. This resulted in 13,032 
and 9,062 unique genes for the human and mouse datasets, respectively. Next, quantile 
normalization was applied separately to the log2 transformed expression values in each dataset {18). 
Principal component ana lysis 
Correlations between genes were calculated based on expression patterns across the diverse 
samples in both the human as well as the mouse datasets. Principal component analysis (PCA) was 
performed on the resulting correlation matrices, which is equivalent to factor analysis, leading to 
reduced dimensionality in gene space. We developed software to perform this task based on 
JAMA/C++, a translation of the Java Matrix Library, developed by the Mathworks and NIST, into C++ 
(http://math.nist.gov/tnt/). PCA is a method to condense a multi-dimensional dataset into a set of 
lower dimensions, in order to reveal the simplified linear structure of the data that often underlies it 
(19). In this study PCA represents a transformation of a set of correlated genes into sets of 
uncorrelated linear additions of gene expression signals called principal components (PCs). PCs are 
able to summarize expression information and, for this application, can be interpreted as statistically 
uncorrelated transcriptional system regulators (TSRs) (9). In each TSR all genes are present but the 
weight of individual genes in the linear addition varies among TSRs. TSRs are constructed in such a 
way that the first TSR explains the largest amount of variance in expression and each subsequent 
TSR explains the largest amount of the remaining variance in expression while remaining 
uncorrelated with previously constructed TSRs. Since a TSR is a weighted sum of genes, TSR scores 
can be calculated for each observed expression array (TSR profiling). A TSR score can be seen as the 
degree of activity of the regulator in different cellular states or phenotypes. We provide a software 
tool capable of calculating individual TSR scores for observed expression arrays (see supplementary 
information online). Subsequently, the correlation between individual gene expression and TSR 
scores can be calculated (i.e. a factorloading). A factor loading can be seen as the amount of control 
a specific TSR has on the net expression of a particular gene. A high positive or negative factor 
loading with a TSR indicates that a gene's expression is strongly influenced by this specific TSR. 
Clusters of genes with contrasting factor loading signs (i.e. positive vs. negative) are inversely 
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regulated by a specific TSR. For further reading on PCA we recommend a publicly available tutorial 
(20). 
Rel iab i l ity of transcriptiona l  system regulators 
To investigate whether our method gives results that depend on the presence of specific arrays, we 
randomly divided the human dataset into two equally sized sets and then generated new TSRs using 
PCA, each based on only half of the data. To assess whether these separately generated sets were 
comparable, we calculated Pearson correlations between the factor loadings with TSRs from the two 
separate sets. Furthermore, to validate that the identified TSRs were not artifacts of gene selection, 
we applied the split-half method on each TSR (21). As described above, a TSR is a weighted sum of 
genes and a so-called TSR score can be calculated for each sample. In the split-half method, the 
genes of a TSR score are split into two random partitions and the resulting TSR scores of both parts 
are correlated (Pearson). High correlation indicates that TSR scores can be reliably calculated and 
that information from different genes is indeed identical and indicative of the same underlying TSR 
score. 
Gene set enrichment ana lysis (GSEA) 
To investigate whether our identified statistically uncorrelated TSRs are related to biologically 
related gene clusters represented by known GO ontologies we used GeneTrail, a software program 
recently developed by a German team (http://genetrail.bioinf.unisb.de) (22). This web-based 
application scores a sorted list of genes with respect to their enrichment of functional categories 
(23). For each TSR we ranked the genes according to ascending factor loadings, i.e. from most 
negative to most positive factor loading. A factor loading is the correlation between individual gene 
expression and a specific TSR score (degree of regulator activation). The ranked list of genes, of 
which some belong to a functional set S, is then processed from top to bottom. Genes at the top and 
bottom (i.e. genes with high negative and positive factor loadings respectively) are genes most 
strongly controlled by our defined TSR. Whenever a gene belonging to the functional set S is found, 
an enrichment statistic (ES) is increased by a certain amount, otherwise the ES is decreased. This ES 
is depicted in graphs showing whether the genes that comprise a functional set S are accumulated at 
the top (red graph) or bottom (green graph) of the ranked list (see Figs 2 and 4). The red vs. green 
graphs show the biological coherence of opposing regulated gene clusters controlled by TSRs, i.e. 
gene clusters with positive vs. negative factor loadings. The minimum and maximum of this ES are 
used to estimate the significance of the enrichment; the more significant a functional set S is, the 
more important a TSR is in regulating the expression of genes belonging to S (22). To adjust for 
multiple testing problems, we tested for the false discovery rate (FDR) according to Benjamini and 
Hochberg's method (24). A significance threshold of p < 0.05 after FDR correction was maintained. 
Although GeneTrail reveals many biological categories, we focused our analysis on Gene Ontology 
(GO) and chromosomal location (25). We analyzed 5,760 GO categories containing more than two 
genes and also assessed 24 chromosomes (including X and Y) for enrichment in co-regulated genes. 
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Simila rities i n  transcri ptiona l  system regu lation between  human and mouse 
To assess the similarity of the structure in transcription regulation between human and mouse, we 
applied a PCA to a combined two-species dataset containing 3,934 mouse arrays and 3,934 
randomly selected human arrays. Expression data of 6,610 orthologus genes between human and 
mouse was selected for this dataset. If the structure of transcriptional regulation is similar between 
human and mouse, we would expect a similar, limited number of TSRs to be needed to summarize 
the same amount of variance in total expression as seen in the PCA performed on human and mouse 
expression data separately. 
Mapping human and mouse TSRs 
To map TSRs identified in 17,SSO human and 3,934 mouse arrays separately, in order to assess 
similarities in regulation of biological processes between human and mouse, we selected the factor 
loadings of the first SO TSRs for 6,610 identified homolog genes, based on similar gene symbol 
identifiers. Then we calculated Spearman rank correlations between factor loadings from human 
and mouse TSRs. High correlation between a human- and a mouse TSR indicates that these TSRs 
control identical gene clusters in human and mouse in the same way. 
Gene clustering based on gene-TSR corre lation 
In microarray experiments, gene expression is  composed of biological signals and experimental 
noise (8). In our model the first SO TSRs capture most of the biologically relevant signals and 
subsequent TSRs capture noise and experimental artifacts. Clustering genes according to their factor 
loadings with the first SO TSRs instead of net expression patterns, of which a part is experimental 
noise, might be a more robust approach and could give more insight into the dynamics of gene 
expression regulation, in which individual genes are classified into multiple groups of similar 
regulation. We used average linkage hierarchical clustering according to the Euclidean distance 
measure (square root of the sum of the squared differences in each dimension) by using the Cluster 
3.0 software (26). 
Sample c lustering based on TSR scores 
Since a TSR is a weighted sum of genes, a so-called TSR score can be calculated for each individual 
sample. To assess whether similar tissue samples have identical TSR scores, we applied average 
linkage hierarchical clustering according to the Euclidean distance measure on the first SO TSR 
scores. We selected 621 samples, representing over 90 distinct tissue types from the publicly 
available human body index dataset from the Gene Expression Omnibus (Accession number: 
GSE7307). 
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Sum mary, general d iscussion 
and future perspectives 
Chapter 7 
Summary 
Standard treatment of patients with advanced stage ovarian cancer is surgical debulking followed by 
the combination of a platinum compound and paclitaxel. The 5-year survival rate of patients with 
advanced-stage disease is around 20%-30%. Recently, large clinical trials with different 
combinations and sequences of classic cytotoxic drugs indicated that further significant 
improvement in prognosis by this type of drugs is not to be expected. Therefore the ceiling seems to 
be reached for these conventional chemotherapeutic drugs, indicating that a paradigm shift is 
needed. Instead of treating all patients according to standard guidelines, we need to identify 
subgroups of patients that may benefit from targeted innovative molecular therapy. Utilizing gene­
expression profiling might enable us to classify ovarian carcinomas into such clinically relevant 
subtypes. Furthermore, gene-expression profiling might provide us with more insights into tumor 
aggressiveness and drug resistance, yielding potential new molecular targets for therapy. 
This thesis focuses on the identification of gene-expression profiles, biological pathways and 
transcription factors that are associated with survival and chemo-resistance in ovarian cancer. 
Following a brief introduction and outline of this thesis in chapter 1, a literature overview of 
microarray studies that have studied prognostic and/or predictive gene expression profiles in 
advanced stage ovarian cancer is presented in chapter 2. Three of the seven microarray studies 
described aimed to predict survival / clinical outcome. In addition to these three prognostic studies, 
four other studies are discussed that tried to identify a profile predictive of response to platinum­
based therapy. 
In addition, we address several methodological issues that may explain the limited overlap between 
the prognostic and predictive profiles reviewed in this chapter. Because the numbers of samples 
included in the seven prognostic and/or predictive microarray studies are all of limited size in 
comparison with the numbers of features on the microarrays, all studies are at risk for overfitting. 
Overfitting means that a prognostic or predictive profile includes accidental findings that do not 
generalize to independent data sets. 
Furthermore, studies differ with respect to microarray platforms and probes types (short­
oligonucleotide, long-oligonucleotide, cDNA, etc. ), production methods (in situ polymerization, 
spotting, microbeads, etc.), and labeling methods. The problem of non-reproducibility of prognostic 
or predictive profiles related to these technical differences has been addressed in several studies. 
Some studies found that the concordance of results across expression analysis platforms was low, 
while other studies concluded the opposite. 
In microarray experiments the intensities observed are composed of signal (gene-expression level) 
and experimental noise (e.g. sample collection, sample labeling, hybridization, and the analysis). 
Within a single tissue type, the differences in gene expression between two classes of interest may 
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not be large in relation to the experimental noise. This explains the difficulty to identify a few 
relevant genes from a background of many more genes with substantial random variation. 
We have described two major new strategies that may assist in defining new molecular subgroups 
within advanced stage ovarian cancer at the level of biological pathways. Bild et al. experimentally 
generated expression signatures that reflect the activation of various oncogenic signaling pathways. 
These expression signatures could then be used to assess the activation of these oncogenic 
pathways in individual tumor samples. In contrast to these experimentally derived signatures 
Subramanian et al. described a computational approach called gene set enrichment analysis (GSEA). 
In this method, genes that are differentially expressed between two phenotypic classes are 
compared according to rank against a large collection of functional groupings, such as pathway 
definitions. This is done to determine enrichment for one or more of these functional groupings 
within a phenotype. 
In chapter 3 we used a large set of expression data from 13,629 publicly available samples from a 
wide variety of different human tissues hybridized to Affymetrix HG-U133A and HG-U133 Plus 2.0 
GeneChips (Affymetrix, Santa Clara, California, USA) and investigated the stability in gene expression 
levels in order to identify the most stable expressed housekeeping genes. The stability in expression 
of 13,037 genes is measured as the variance divided by the mean intensity (coefficient of variance, 
CV) of log2 transformed intensity data after quantile normalization. With this strategy we identified 
15 top candidate housekeeping genes. All 15 genes had a CV beneath the 4% level, reflecting the 
minor variation in expression of those candidate housekeeping genes within the large data set. 
Thirteen of these top 15 genes encode for ribosomal proteins involved in protein biosynthesis. 
Furthermore, the stability in expression of commonly used housekeeping genes was determined, 
such as actin beta (ACTB), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) and beta-2-microglobulin (82M). The expression levels of 
these genes fluctuated dramatically and only one of 12 commonly used housekeeping genes (ACTB) 
showed a CV beneath the 5% level. Remarkably, none of the classical housekeeping genes ranked 
among the top 50 identified candidate housekeeping genes. In addition, using expression data of 
21,377 unique genes in a set of 2,543 publicly available mouse samples hybridized to Affymetrix 
Mouse Genome 430 2.0 GeneChips (Affymetrix) we validated the enhanced stability of the identified 
novel candidate housekeeping genes. This data set comprises a wide variety of different mouse 
tissues and varying experimental conditions. Within the mouse data set, genes encoding for 
ribosomal proteins were the most stable expressed genes. 
In chapter 4 we used currently available methods for predictive gene profiling identification, 
resulting in an 86-gene profile that was associated with overall survival. The profile was derived 
from 157 advanced stage serous ovarian cancers analyzed in duplicate with ~35K 70-mer 
oligonucleotide microarrays. Although the profiling methods used addressed problems of multiple 
testing and overfitting, we added an additional validation step by assessing the performance of the 
profiling methods on randomized phenotypes. The 86-gene prediction model was able to 
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discriminate between patients with unfavorable and favorable prognosis (median survival, 19 versus 
41 months, respectively; permutation p-value of log-rank statistic = 0.015) and maintained its 
independent prognostic value in multivariate analysis, adding other predictors (p = 0.008; HR = 1.94; 
95% confidence interval 1.19-3.16). The prognostic value of 57 out of the 86 genes we had 
identified was univariately validated on a fully independent, publicly available data set of 118 well­
defined primary serous ovarian cancers. With these 57 genes a prediction model was built using the 
same methodology, that was able to discriminate between patients with unfavorable and favorable 
prognosis within this independent data set (median survival, 33 versus 108 months, respectively; 
permutation p-value of log-rank statistic = 0.007). To further validate our overall survival profile we 
performed qRT-PCR for 31 total RNA samples that had been included in the microarray analysis on 
four genes from the 86-gene profile: Fibroblast growth factor binding protein 1 (FGFBP1), FK506 
binding protein 7 (FKBP7), transmembrane protein 45A (TMEM45A), and chemokine (C-C motif) 
ligand 28 (CCL28). A strong correlation between qRT-PCR and microarray signal intensities was 
observed for all four genes. 
Our overall survival profile contains several interesting genes that offer potential insight into 
mechanisms associated with tumor behavior. High expression of the pro-apoptotic BAX gene was 
associated with improved prognosis in our study, which was also reported by others. High 
expression of Ras inhibitor 1 (RIN1) and low expression of Ras-like without CAAXl (RIT1) were 
associated with better overall survival, which is in agreement with previous work by others showing 
that activated Ras contributes to the maintenance and growth of ovarian carcinomas. Furthermore, 
Oncostatin M (05M), Janus kinase 2 (JAK2), and ciliary neurotrophic factor receptor (CNTFR) are 
components of the Jak/STAT signaling pathway, which can stimulate cell proliferation, 
differentiation, cell migration, and apoptosis. OSM has individually been identified as a potent 
suppressor of tumor cell proliferation and inducer of differentiation in multiple tissues. FGFBP1 and 
fibroblast growth factor receptor 1 (FGFR1) interact with fibroblast growth factors FGF1 and FGF2, 
and it has been suggested that fibroblast growth factors could serve as inducers of an angiogenic 
switch in human cancer. FK506 binding protein 7 (FKBP7), with the highest hazard ratio for individual 
genes in our study, appears to be especially of interest because FKBPs can be targeted with 
mammalian target of rapamycin (mTOR) inhibitors. 
A functional class scoring analysis revealed 17 pathways to be related to survival, of which 16 were 
validated in the independent data set. For example, cell cycle, Wnt, Jak-STAT, and MAPK pathways, 
playing a role in apoptosis, proliferation, differentiation, and/or cell cycle, were identified. Aberrant 
signaling of these pathways has been proposed as contributing to ovarian carcinogenesis. 
In addition, 13 transcription factors were associated with overall survival in our data set, of which 12 
were validated in the independent data set. For example, A2P-2alpha and c-Ets-1, which have 
previously been associated with poor prognosis in ovarian cancer, were identified. Furthermore, 
several identified E2F transcription factors, members of the C/EBP family, and CREB were 
demonstrated to play an important role in ovarian carcinogenesis. 
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Finally, we assessed the activation status of five oncogenic signaling pathways based on the 
activation observed in a mammalian cell line following transfection of adenovirus expressing human 
c-Myc, activated H-Ras, human c-Src, human E2F3, or f3-catenin. None of these five oncogenic 
pathways activation profiles showed a significant association (as individual pathways and/or in 
combination) with overall survival in our data set. 
In chapter 5 we aimed to identify genes and pathways associated with platinum resistance. Nine 
paired stage Ill/IV serous ovarian cancers obtained at primary surgery and after chemotherapy were 
profiled using oligonucleotide microarrays. A total of 272 genes were differentially expressed 
between pre- and post-chemotherapy samples. From these 272 genes, a subset of 24 genes was 
univariately associated with overall survival in a large series of 157 advanced stage ovarian tumors 
previously profiled (chapter 4). Moreover, high expression of genes up-regulated in post­
chemotherapy samples was associated with poor overall survival. In addition, a predictor model 
based on these 24 genes was capable of reflecting patients' overall survival. 
To validate that microarray expression measurements reflect true differences in expression, 4 genes 
differentially expressed between pre- and post-chemotherapy samples were selected for qRT-PCR 
analysis: cysteine and glycine-rich protein 2 (CSRP2), early growth response 2 (EGR2), LIM homeobox 
1 (LHX1), and ubiquitin-like domain containing CTD phosphatase 1 (UBLCP1). A strong correlation 
between tiCT values obtained from qRT-PCR and microarray signal intensities was observed for 
three out of four genes. In addition, qRT-PCR signal intensities for UBLCP1 could significantly 
discriminate between samples obtained prior to and following chemotherapeutic treatment. 
Among the 24 genes there are several genes previously described to be involved in (ovarian) 
carcinogenesis and tumor progression, for example ring finger protein 7 (RNF7) and EGR2. RNF7 was 
first identified as a stress-responsive gene that plays a role in ubiquitination and subsequent 
degradation of caspase 3 (CA5P3), jun oncogene (c-Jun) and hypoxia inducible factor 1, alpha subunit 
(HIF-1a), thereby protecting tumor cells from apoptosis. EGR2 was identified as a component of the 
phosphatase and tensin homolog (PTEN) pathway and was shown to be down-regulated in ovarian 
cancer cell lines compared to corresponding normal ovarian tissues. Functional studies revealed that 
EGR2 functions as a key mediator of PTEN-induced growth inhibition and cell cycle arrest, making it 
an attractive target for therapy. 
In addition to single gene analysis, GSEA revealed well-known and novel pathways enriched in pre­
or post-chemotherapy samples. Several of these pathways were also associated with survival in the 
validation set. For example, GSEA revealed that the proteasome pathway was highly enriched in pre­
chemotherapy samples and also associated with overall survival in the validation series. Consistent 
with GSEA results, immunostaining of the proteasome subunit MB1 showed that nuclear MB1 
staining was independently associated with poor disease-specific survival. Furthermore, results from 
GSEA suggest that deregulation of genes belonging to the insulin-like growth factor ( IGF) axis 
contributes to platinum resistance and survival of ovarian cancer patients. The insulin-like growth 
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factor 1 receptor {IGF-1R) pathway was enriched in pre-chemotherapy samples, whereas 
deregulated insulin-like growth factor 1 (/GF-/) signaling was related to poor overall survival. 
lmmunohistochemical staining for JGF-1R in a large series of 165 advanced stage serous ovarian 
tumors showed that 50% of ovarian cancers exhibited high expression of the JGF-1R, rendering the 
receptor an attractive therapeutic target. Furthermore, univariate survival analysis revealed that 
tumors exhibiting enhanced /GF-1R expression had a longer progression free survival. This did 
however not translate into better overall survival. 
In chapter 6 we show that gene expression can be conceptualized as a process influenced by a fairly 
limited set of Transcriptional System Regulators (TSRs). Principal component analysis on the 
expression correlation matrix of 13,032 genes in 17,550 microarray experiments of heterogeneous 
human tissues (primary patient material, cell lines, normal tissues, etc. ) revealed that 50 orthogonal 
factors (TSRs) are able to capture 64% of the variability in expression in a wide range of 
experimental conditions and tissues. Split-half tests revealed that TSRs were reliably identified and 
were not artifacts due to sample or gene selection. GSEA as discussed above validated the TSR's as 
having strong biological correlates. 
Similar results were observed in mice where 50 TSRs explained 71% of the variance in expression of 
9,062 genes in 3,934 arrays. By mapping TSRs generated in the human data set to TSRs generated in 
the mouse data set we show that there are striking similarities in regulation of biological processes. 
Finally, we show that an expression profile of an individual microarray can be fairly well predicted 
from only 50 TSR scores (TSR profiling), summarizing the signal of thousands of individual genes in 
just 50 component scores. As an example application we showed that similar tissues clustered 
together based on the first 50 TSR scores. 
General discussion and future perspectives 
In microarray studies the performance of an expression profile to predict survival / clinical outcome 
is best assessed by applying the prediction rule created on a training data set to an independent 
validation set. We attempted to perform such a validation of our overall survival prediction profile in 
chapter 4. However, differences in platform did not allow one-to-one validation of the underlying 
predictive algorithm. We, therefore, applied a 10-fold cross validation within our own data set. 
Cross-validation provides an estimate of the misclassification error rate one can expect when 
applying the predictor to independently collected data. It is important to note that 10-fold cross­
validation alone was not sufficient to assess the performance of our prognostic profile. A large log­
rank statistic in our study is still subject to inflation due to overfitting and the performance did not 
guarantee that the classification of patients in risk groups could be generalized. Because of the high 
dimensionality of our gene expression data, it may be possible to achieve a relatively large log-rank 
statistic even for random data, due to overfitting. Various solutions have been proposed to estimate 
the degree of overfitting. Especially the shrinking methods developed by van Houwelingen and Le 
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are an important contribution (1). We have applied a different method to estimate the degree of 
overfitting by applying a phenotype permutation test to assess the significance of the log-rank 
statistic for the Kaplan-Meier survival curves of the predicted overall survival risk classes. The idea 
behind this permutation test is: under the null hypothesis that there is no association between gene 
expression and overall survival, it can be assumed that assignment of patients to the overall survival 
risk classes based on their gene expression profiles is purely coincidental. The number of classifiers 
after phenotype permutations that have a log-rank statistic beyond the log-rank statistic obtained 
for the real data is the permutation significance level for testing the null hypothesis that there is no 
relation between the expression data and survival. 
Despite the validation steps of 1O-fold cross-validation and correction for overfitting based on 
phenotype permutation, further empirical validation of the clinical applicability of our overall 
survival predictor is mandatory, as, following Dr. Richard Simons, our study might be considered a 
phase II study in which we constructed an expression profile associated with overall survival (2). The 
next step would be to validate the prognostic value of our profile in a large independent set of 
prospectively collected ovarian cancers to reach level 2 or 1 clinical evidence (3). 
In chapter 6 we have introduced the concept of TSR-profiling that might improve the performance 
of predictive profiles. We demonstrated that SO uncorrelated transcriptional system regulators 
(TSRs) can explain the majority of biological variance in gene expression correlation in humans and 
mice. Since a TSR is a weighted sum of genes, a TSR score can be calculated for each observed 
expression array. These TSRs allow us to characterize the expression profile of an individual 
microarray with SO TSR scores instead of using ten thousands of individual genes. This leads to a 
SOO-fold reduction of complexity, thus avoiding the problem of overfitting. Because the number of 
genes expected to be differentially expressed between two classes of interest within a single cancer 
histiotype is probably small, and the differences in expression may not be large in relation to 
experimental noise (2), there is a second advantage of TSR-profiling. When signals of multiple genes 
are added to calculate TSR-scores the signal-to-noise ratio improves because noise cancels out. In 
addition, we have demonstrated that TSRs are internally reliable, which means that TSR scores 
produced from random subsets of genes are highly correlated. Therefore, TSR-scores are more 
reproducible input variables for prediction models than expression signals of selected individual 
genes. 
In principle, reliable expression based gene profiles may exist that are not a linear function of the 
major TSR's we have identified. It will, however, be difficult to identify such profiles, as it would 
require large disease specific datasets (in the order of the size of the datasets we used for TSR 
identification) to reliably estimate disease specific correlation between transcripts. Considering that 
such datasets do not currently exist, the second best option is to use the expression correlation 
present in the many, often unrelated, sets currently available in the large web based repositories. 
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In the future, we are planning to optimize our TSR-profiling by including more samples and more 
genes in our analysis to extend the TSRs. Any future genetic profile capable of prediction prognosis 
or response to chemotherapy should best be constructed with TSR-scores as input variables. 
It is noteworthy that the studies performed in chapter 3 and 6 could not be performed without the 
scientific community uploading their microarray data to the public domain. This emphasizes the 
importance of microarray repositories such as the Gene Expression Omnibus (4) which supports 
microarray data submission according to the MIAME standard. MIAME describes the Minimum 
Information About a Microarray Experiment that is needed to enable the interpretation of the 
results of the experiment unambiguously and potentially to reproduce the experiment. 
Expression analyses in this thesis were done with gene expression microarrays, which are at the 
present time the standard for analyzing the transcriptome. However, gene expression microarrays 
suffer from background and cross-hybridization problems and measure only the relative abundances 
of transcripts. Recently, "new generation" sequencing technologies have become available, that 
enable gene expression analysis by direct shotgun sequencing of complementary DNA synthesized 
from RNA samples (5). In contrast to microarrays, sequencing technologies do not depend on 
predefined sequences, thus allowing for detection of, for example, new splicing variants or single­
nucleotide polymorphisms. Furthermore, recent sequencing-based expression analysis studies have 
demonstrated excellent specificity, sensitivity, and reproducibility that systematically improve with 
increasing sequencing depth. Moreover, the quantitative accuracy compares favorably with DNA 
microarrays and quantitative RT-PCR (6). These results indicate that sequence based expression 
analysis will replace microarray based analysis in the near future as the technique of choice for 
analyzing the transcriptome. 
In addition to mRNA expression profiles, studies have tried to link single-nucleotide polymorphisms, 
epigenetics, miRNA expression, and proteomics to clinical outcome. Integrating information from 
these different molecular levels will even further advance our knowledge and understanding of 
(cancer) cell biology. For example, Breitling et al. showed by integrating genotype data and mRNA 
expression data from individual samples, that single nucleotide polymorphism (SNP) leads to 
widespread downstream changes in the expression of distant genes (7). SNPs associated with the 
expression of distant genes are called quantitative trait loci (eQTLs). In addition, Wu et al. 
demonstrated that these eQTLs are biologically coherent by showing that in about 25% of cases, the 
genes associated with a single eQTL are enriched for functional gene sets derived from Gene 
Ontology, the KEGG pathways database, and the Ingenuity Pathways Knowledge Base. These 
findings suggest that integrating information from different molecular levels might enable us to 
better infer biological pathways and signaling cascades within a cell. Furthermore, we can envision 
that in the future prognostic or predictive models will integrate the different molecular profiles (i.e. 
mRNA, miRNA, epigenetics, and proteomics) of a tumor sample to give better predictions. 
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Gene-expression profiling as performed in chapter 4 and 5 might provide us with more insights into 
tumor aggressiveness and drug resistance with ovarian cancer, yielding potential new molecular 
targets for therapy. Because of the multiple-testing problem in high dimensional data sets it is 
important to further validate the identified genes to rule out false positive findings. For example, 
immunohistochemical staining could be performed to determine the clinical relevance in large 
cohorts of ovarian patients on the protein level. Furthermore, studies in ovarian cancer cell lines 
should be performed to assess the functionality and therapeutic potential of the individual genes 
identified. 
Although such individual genes may prove to be relevant for tumor behavior, we also stated that it is 
often not known in ovarian and other cancers whether large fold-changes in individual genes will 
have more biological relevance than smaller but coordinated fold-changes in a set of genes along a 
single biological pathway. Therefore, we have emphasized integrating individual genes in functional 
sets (GSEA) to reveal the biological pathways associated with ovarian tumor behavior. A 
disadvantage of GSEA is that it does not take in account the interaction between the genes 
belonging to a functional gene set and is therefore not able to assess the activation status of 
pathways in an individual tumor sample. In the future we would like to create pathway models, 
capable of predicting the activation status of relevant pathways in individual tumor samples. This 
might enable us to identify patients who will benefit from potentially novel therapeutic options 
specifically targeting these activated pathways. Furthermore, pathway models might permit us to 
monitor the efficacy of the targeted therapy, as the probability of activation will either increase or 
decrease under the influence of a molecular targeted drug. In addition, one can envision in the 
future a database of pathway prediction models that can be used to screen for relevant pathways by 
linking pathway activations status to clinicopathological data in the future. 
Bild et al. described one possible approach to create such pathway prediction models (8). They used 
recombinant adenoviruses to express various oncogenic activities in otherwise quiescent cells, 
thereby isolating the subsequent events as being defined by the activation/deregulation of that 
single (oncogen-dependent) pathway. Subsequently, significantly differentially expressed genes 
between the quiescent and infected cells were used to train a prediction model capable of assessing 
the activation status of a pathway. In our opinion it is probably best to create these pathway models 
in cell lines derived from the same tissue origin as the pathway activation status will be studied in. 
This policy should prevent large differences in gene expression between the cell line and tissue 
under examination, which may result in erroneous pathway activation probabilities. A disadvantage 
of the Bild approach is that no prior information of the pathway of interest is used in defining the 
model. All significant differentially expressed genes are used as input variables in their prediction 
models, even those that are differentially expressed purely by chance, by the process of 
transfection, or other unknown systematic disturbance. These genes in fact are not relevant for the 
pathway of interest and could potentially lead to erroneous activation probabilities when 
incorporated in the pathway model. Using the expression signals of the subset of genes known, a 
priory, to be involved in the pathway of interest from, for example well defined pathway databases 
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such as KEGG or Biocarta, may substantially advance these models. As mentioned above TSR­
profiling using only this subset of genes will potentially further improve the accuracy of prediction, 
as the signal-to-noise ratio increases and overfitting is avoided. 
Besides over-expression or knock-down / suppression of key genes from a relevant pathway, recent 
results with Poly(ADP-ribose) polymerase (PARP) inhibitors suggest another interesting strategy that 
can be pursued. PARP inhibitors induce in cell lines with BRCAl and BRCA2 mutations cell cycle 
arrest and apoptosis. Early clinical testing indicates that PARP inhibitors are extremely well tolerated 
and exhibit antitumor activity as single agent in the subgroup of ovarian cancer patients that are 
BRCAl or 2 mutation carriers and extensively pretreated. By comparing wild-type with BRCA­
deficient cell lines one could define the subsequent events of a BRCA mutations on gene expression 
levels. These altered gene expression levels in combination with TSR-profiling could again serve as 
input to a prediction model. This prediction model should in theory be able to predict the sensitivity 
for PARP inhibitors for patients, even if they do not have a deficient BRCA gene. This strategy could 
be extended to other molecular targeted drugs that also rely on mutations or deregulated pathways 
for their therapeutic efficacy. 
In conclusion, this thesis provides insights into molecular changes in genes, pathways, and 
transcription factors that are relevant for ovarian cancer behavior and that should therefore be 
exploited in the search for new treatment strategies towards patient-tailored therapy. 
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Chapter 8 
Samenvatting 
De standaardbehandeling voor patienten met een hoog stadium ovariumcarcinoom is debulking 
chirurgie, gevolgd door combinatiechemotherapie met cisplatine (of carboplatine) en paclitaxel. De 
vijfjaarsoverleving van patienten met gevorderde stadia van deze ziekte is ongeveer 20 tot 30 
procent. Onlangs hebben grote klinische trials aangetoond dat verdere significante verbetering van 
de prognose, doormiddel van verschillende combinatie en schema's van conventionele 
chemotherapie, niet te verwachten is. Het plafond voor deze conventionele chemotherapie lijkt dus 
bereikt te zijn en een paradigmaverschuiving in het denken is nodig. In plaats van, zeals nu alle 
patienten volgens de standaardrichtlijnen te behandelen, zouden we patienten moeten kunnen 
selecteren die mogelijk baat hebben van gerichte innovatieve moleculaire therapieen. Gen­
expressieprofielen zouden ons in staat moeten kunnen stellen om dergelijke klinisch relevante 
subtypes binnen het ovariumcarcinoom te identificeren. In aanvulling daarop zouden gen­
expressieprofielen ons meer inzicht in tumoragressiviteit en therapieresistentie kunnen verschaffen, 
waardoor we eventuele nieuwe potentiele therapeutische opties kunnen ontdekken. 
In dit proefschrift ligt de nadruk op het identificeren van gen-expressieprofielen, intracellulaire 
routes en transcriptiefactoren die geassocieerd zijn met overleving of chemoresistentie in het 
ovariumcarcinoom. 
Hoofdstuk 1 bevat een korte inleiding en een overzicht van dit proefschrift. De literatuurstudie in 
hoofdstuk 2 beschrijft een overzicht van zeven microarray studies waarin prognostische en/of 
voorspellende gen-expressieprofielen voor gevorderd stadium ovariumcarcinomen. Drie van deze 
studies waren gericht op gen-expressieprofielen met prognostische waarde. De vier overige studies 
streefden naar het identificeren van een profiel dat in staat is om te voorspellen of tumoren 
gevoelig zijn voor een op platinum gebaseerde therapie. 
In dit hoofdstuk worden verschillende methodologische problemen besproken die mogelijk de 
beperkte overlap tussen de zeven prognostische en voorspellende profielen kunnen verklaren. Deze 
microarraystudies zijn allen onderhevig aan 'overfitting' door het geringe aantal tumoren in 
verhouding tot het aantal gemeten genen op de microarray. Overfitting betekent dat een 
voorspellend expressieprofiel toevallige bevindingen bevat die zich niet laten vertalen naar een 
andere onafhankelijke dataset. 
Verder verschillen de studies met betrekking tot microarrayplatform en probes (korte 
oligonucleotide, lange oligonucleotide, cDNA, etc.), productiemethoden (in situ polymerisatie, 
spotting, microbeads, etc.) en methode van labellen. In hoeverre deze technische verschillen 
verband houden met de niet-reproduceerbaarheid van voorspellende expressieprofielen is 
onderzocht in verschillende studies. Uit sommige van deze studies bleek dat de correlatie tussen de 
expressie uitkomsten van verschillende microarrayplatformen laag was, terwijl andere studies juist 
het tegenovergestelde concludeerden. 
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De intensiteiten van iedere spot, die gemeten warden in microarrayexperimenten bestaat voor een 
deel uit signaal {werkelijke gen-expressie) en experimentele ruis {bijvoorbeeld ge"introduceerd door 
mRNA extractie, labeltechniek, hybridisatie en data-analyse). Het verschil in gen-expressie tussen 
twee relevante groepen binnen hetzelfde type weefsel is meestal niet groat in verhouding tot de 
experimentele ruis. Dit verklaart waarom het moeilijk is om enkele relevante genen te identificeren 
tegen een achtergrond van een overgrote meerderheid van genen met aanzienlijke willekeurige 
variatie. 
Hiernaast beschrijft hoofdstuk 2 twee belangrijke· nieuwe strategieen die kunnen bijdragen aan de 
identificatie van nieuwe moleculaire subgroepen binnen het hoog stadium ovariumcarcinoom op 
het niveau van intracellulaire routes. Bild e.a. hebben experimenteel gen-expressieprofielen 
ontwikkeld die de activatiestatus voor verschillende intracellulaire oncogene routes in individuele 
tumoren kunnen voorspellen. In tegenstelling tot deze experimentele benadering beschrijven 
Subramanian e.a. een computationele methode die zij 'Gene Set Enrichment Analysis' {GSEA) 
noemen. Hierin warden genen gerangschikt op basis van de mate van differentiele expressie tussen 
twee fenotypen en vervolgens vergeleken met een grate verzameling van functionele groepen van 
genen {bijvoorbeeld een groep van genen behorende tot dezelfde intracellulaire route). Op deze 
manier kan bepaald warden of een functionele groep van genen geassocieerd is met een fenotype. 
In hoofdstuk 3 hebben we gebruik gemaakt van publiekelijk beschikbare expressiedata van een 
heterogene groep van 13.629 humane weefsels die gehybridiseerd zijn op de Affymetrix HG-U133A 
of HG-U133 Plus 2.0 GeneChips {Affymetrix, Santa Clara, California, USA). In deze dataset hebben we 
gekeken welke genen stabiel tot expressie kwamen om zo huishoudgenen te kunnen identificeren. 
Na log2 transformatie en quantile normalisatie van de intensiteitsdata, werd de stabiliteit in 
expressie voor 13.037 genen bepaald door de variantie te delen door de gemiddelde intensiteit 
{variatiecoefficient, CV). Met deze strategie zijn 15 top kandidaat huishoudgenen geidentificeerd. 
Alie 15 genen hadden een CV onder de 4 procent als gevolg van de geringe variatie in expressie in de 
grate dataset. Dertien van de 15 genen coderen voor ribosomale eiwitten die betrokken zijn bij de 
biosynthese van eiwitten. Verder is de stabiliteit in expressie bepaald voor veelgebruikte 
huishoudgenen, zoals beta-actin (ACTB), glyceraldehyde-3-fosfaat dehydrogenase (GAPDH), 
hypoxanthine fosforibosyl 1 (HPRTl) en beta-2-microglobuline {82M). De expressieniveaus van deze 
genen schommelden dramatisch in deze grate dataset en slechts een van de 12 veelgebruikte 
huishoudgenen (ACTB) toonde een CV onder de 5 procent. Opmerkelijk is dat geen enkel 'klassiek' 
huishoudgen voorkwam in de top 50 van geidentificeerde kandidaat huishoudgenen. Daarnaast is de 
stabiliteit van de ge'identificeerde kandidaat huishoudgenen gevalideerd door te kijken naar de 
expressie van 21.377 unieke genen in een eveneens publiekelijk beschikbare expressie dataset van 
2.543 heterogene muisweefsels (gehybridiseerd op de Affymetrix Mouse Genome 430 2.0 
GeneChips van Affymetrix). Oak in deze dataset waren genen die coderen voor ribosomale eiwitten 
de meest stabiel tot expressie gebrachte genen. 
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In hoofdstuk 4 hebben we een robuuste methodologie voor het ontwikkelen van prognostische gen­
expressieprofielen toegepast. Dit heeft geleid tot een 86-genen profiel dat geassocieerd is met 
overleving. Dit profiel werd ontwikkeld op een groep van 157 hoog stadium sereuze 
ovariumcarcinomen waarin gen-expressie werd gemeten met behulp van een 35.000 70-mer 
oligonucleotide microarray {in tweevoud). De door ons toegepaste analysemethoden hielden zoveel 
mogelijk rekening met statistische problemen die kunnen optreden zoals 'overfitting' en 'multiple 
testing'. In aanvulling hierop hebben we een extra validatie stap uitgevoerd door te kijken hoe onze 
methodologie zou presteren op gerandomiseerde fenotypes. Het 86-genen profiel was in staat 
onderscheid te maken tussen patienten met een ongunstige en gunstige prognose {mediane 
overleving respectievelijk 19 versus 41 maanden; permutatie p-waarde van log-rank test = 0,015) en 
hield een onafhankelijke prognostische waarde in een multivariate analyse met andere predictoren 
(p = 0,008; HR = 1,94; 95% betrouwbaarheidsinterval 1,19-3,16). De prognostische waarde van 57 
van de 86 genen werd gevalideerd op een volledig onafhankelijke en publiekelijk beschikbare 
dataset van 118 goed gedefinieerde primaire sereuze ovariumcarcinomen. Met deze 57 genen werd 
een predictiemodel gebouwd volgens dezelfde methodologie als die toegepast werd op het 86-
genen profiel. Dit model was in staat onderscheid te maken tussen patienten met een ongunstige en 
gunstige prognose binnen deze onafhankelijke dataset {mediane overleving van respectievelijk 33 
versus 108 maanden; permutatie p-waarde van log-rank test = 0,007). 
Voor verdere validatie van het prognostisch profiel is qRT-PCR uitgevoerd op totaal RNA van 31 
tumoren, die tevens opgenomen waren in de microarray analyse voor 4 genen uit het 86-genen 
profiel: 'Fibroblast growth factor binding protein 1' {FGFBPl), 'FK506 binding protein 7' {FKBP7), 
'transmembrane protein 45A' {TMEM45A), en 'chemokine {C-C motif) ligand 28' {CCL28). Voor alle 
vier de genen werd een sterke correlatie tussen de qRT-PCR en microarrayresultaten waargenomen. 
Het ge'identificeerde 86-genen profiel bevat een aantal interessante genen die kunnen leiden tot 
meer inzicht in tumorgedrag. Hoge expressie van het pro-apoptotische 'BCL2-associated X protein' 
{BAX) gen is geassocieerd met een betere prognose in onze studie. In voorgaande studies is reeds 
een dergelijke verband tussen BAX en prognose aangetoond. Daarnaast werd hoge expressie van 
'Ras inhibitor 1' {R/Nl) en lage expressie van 'Ras-like without CMXl' {R/T1) in onze studie in 
verband gebracht met een betere prognose. Dit is in overeenstemming met eerdere studies die 
laten zien dat geactiveerd Ras bijdraagt aan het onderhouden en de groei van ovariumcarcinomen. 
Verder is beschreven dat Oncostatin M {05M), Janus kinase 2 {JAK2) en ciliary neurotropic factor 
receptor {CNTFR) deel uitmaken van de intracellulaire Jak/Stat route, die celproliferatie, 
differentiatie, migratie en apoptose kan stimuleren. Tevens is OSM individueel ge'identificeerd als 
een krachtige onderdrukker van celproliferatie en draagt OSM bij aan differentiatie in meerdere 
weefseltypes. Ook is bekend dat FGFBPl en 'fibroblast growth factor receptor 1' {FGFRl) een 
interactie aangaan met fibroblast groeifactoren FGFl en FGF2. Er is gesuggereerd dat fibroblast 
groeifactoren kunnen dienen als een schakelaar voor angiogenese in tumoren. Daarnaast is 'FK506 
binding protein 7' {FKBP7) interessant, aangezien het de hoogste hazard ratio heeft in onze studie en 
er medicijnen zijn zoals rapamycin' {mTOR), die specifiek gericht zijn tegen FKBPs. 
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Analyses hebben aangetoond dat 17 intracellulaire routes geassocieerd zijn met prognose. Van deze 
routes lieten er 16 ook in de onafhankelijke dataset een associatie met prognose zien. Enkele 
interessante routes die werden ge"identificeerd waren: 'cell cylcle', 'Wnt', 'Jak-STAT' en de 'MAPK' 
route. Oeze intracellulaire routes spelen een rol in apoptose, proliferatie en differentiatie. Het is 
eerder beschreven dat afwijkende activatie van deze intracellulaire routes bijdraagt aan het 
ontstaan van het ovariumcarcinoom. 
Verder waren 13 transcriptiefactoren geassocieerd met prognose in onze dataset, waarvan er 12 
tevens gevalideerd konden warden in de onafhankelijke dataset. Enkele interessante 
transcriptiefactoren, zoals A2P-2alpha en c-Ets-1, werden ge'identificeerd. Voor deze 
transcriptiefactoren is eerder een verband beschreven met een slechte prognose in 
ovariumcarcinoom. Daarnaast werd voor enkele ge'identificeerde transcriptiefactoren, zeals E2Fs, 
leden van de C/EBP familie en CREB, aangetoond dat deze mogelijk een belangrijke rol spelen in de 
ontwikkeling van het ovariumcarcinoom. 
Tot slot hebben wij de activatiestatus van 5 intracellulaire oncogene routes beoordeeld in 
individuele tumoren. Deze intracellulaire routes waren gedefinieerd aan de hand van de 
expressieverschillen in een cellijn na transfectie van een adenovirus, dat humane c-Myc, H-Ras, C­
Src, E2F3 of (3-catenin tot expressie bracht. Geen enkele van deze 5 intracellulaire oncogene routes 
bleek een significante associatie (individueel of in combinatie) te hebben met prognose in onze 
dataset. 
Het doel in hoofdstuk S was om genen en intracellulaire routes te identificeren die geassocieerd zijn 
met verworven platinumresistentie. Met behulp van oligonucleotide microarrays werd het gen­
expressieprofiel bepaald van 9 gepaarde stadium I l l/IV sereuze ovariumtumoren. Deze tumoren zijn 
verkregen tijdens de primaire operatie en na chemotherapie. In totaal kwamen 272 genen 
differentieel tot expressie tussen de pre- en post-chemotherapie tumoren. Van deze 272 genen 
waren er 24 univariate geassocieerd met overleving in een grote validatieset van 157 hoog stadium 
ovariumtumoren, waarvan eerder het expressieprofiel bepaald was (hoofdstuk 4). Bovendien was 
toename van expressie geassocieerd met een slechtere overleving voor de genen die ook hoog tot 
expressie kwamen in de post-chemotherapie tumoren. Daarnaast was een predictiemodel, 
gebaseerd op deze 24 genen, in staat de overleving voor patienten te weerspiegelen. 
Voor qRT-PCR analyse werden 4 genen geselecteerd die differentieel tot expressie kwamen tussen 
pre- en post-chemotherapie tumoren om daarvoor de microarray metingen te valideren. Deze 
genen waren: 'cysteine and glycine-rich protein 2' (CSRP2), 'early growth response 2' (EGR2), 'LIM 
homeobox 1' (LHX1), en 'ubiquitin-like domain containing CTD phosphatase 1' (UBLCP1). Voor 3 van 
de 4 genen werd een sterke correlatie gevonden tussen de qRT-PCR tiCT waarden en de 
intensiteiten gemeten op de microarray. Bovendien kon met qRT-PCR voor UBLCP1 significant 
onderscheid gemaakt worden tussen de 9 tumoren verzameld voor en na chemotherapie. 
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Onder de 24 genen bevonden zich enkele genen, waarvan bekend is dat ze betrokken zijn bij 
(ovarium) carcinogenese en tumorprogressie, zoals 'ring finger protein 7' (RNF7) en EGR2. RNF7 
werd ten eerste ge'identificeerd als een stressresponsief gen dat een rol speelt in de ubiquitinatie en 
de daaropvolgende afbraak van 'caspase 3' (CASP3), 'jun oncogene' (c-Jun) en 'hypoxia inducible 
factor 1, alpha subunit' (HJF-1a). Hierdoor voorkomt RNF7 dat tumorcellen in apoptose gaan. EGR2 
werd ge'identificeerd als een onderdeel van de 'phospatase and tensin homolog' (PTEN) 
intracellulaire signaleringsroute, waarvoor werd aangetoond dat deze minder tot expressie komt in 
ovariumtumor cellijnen in vergelijking met overeenkomstig normaal ovarium weefsel. Uit 
functionele studies bleek dat EGR2 een belangrijke rol speelt in PTEN-ge'induceerde groei inhibitie 
en celcyclus arrest, waardoor EGR2 een aantrekkelijk doelwit voor therapie zou kunnen zijn. 
GSEA liet, in aanvulling op de individuele genanalyse, zien dat zowel bekende als nieuwe 
intracellulaire routes geassocieerd waren met pre- of post-chemotherapie tumoren. Een aantal van 
deze intracellulaire routes waren tevens geassocieerd met overleving in de validatieset. Uit de GSEA 
bleek bijvoorbeeld dat de genen behorende tot de proteasoomroute hoger tot expressie kwamen in 
de post-chemotherapie tumoren en dat de proteasoomroute bovendien geassocieerd was met een 
slechtere overleving in de validatieset. Uit immunokleuring van het 'proteasoom subunit MBl' bleek 
dat nucleaire MBl kleuring onafhankelijk geassocieerd was met een slechtere ziektespecifieke 
overleving, wat in overeenstemming was met de GSEA resultaten. 
GSEA resultaten suggereerden bovendien dat ontregeling van genen, behorende tot de 'insuline-like 
growth factor' (IGF) intracellulaire route, een rol speelt in platinumresistentie en de overleving van 
ovariumkankerpatienten. De 'insulin-like growth factor 1 receptor' (JGF-1R) route was geassocieerd 
met pre-chemotherapie tumoren, terwijl de 'insuline-like growth factor 1' (JGF-1) intracellulaire 
route was geassocieerd met een slechtere prognose. lmmunokleuringen voor /GF-1R in een grate 
serie van 165 hoog stadium sereuze ovariumtumoren lieten zien dat /GF-1R in 50% van de tumoren 
hoog tot expressie kwam. Hierdoor kan deze receptor mogelijk een aantrekkelijke therapeutische 
optie zijn. Bovendien liet een univariate overlevingsanalyse zien dat tumoren met een verhoogde 
JGF-1R expressie een langer ziektevrij interval hadden. Dit liet zich echter niet vertalen in een betere 
overleving. 
In hoofdstuk 6 tonen we aan dat gen-expressie kan warden geconceptualiseerd als een proces dat 
be'invloed wordt door een vrij beperkte set van zogenaamde 'Transcriptional System Regulators' 
(TSR's). Principale componenten analyse, over de expressie correlatiematrix van 13.032 genen in 
17.550 microarray experimenten van heterogene humane weefsels (primair patient materiaal, 
cellijnen, normale weefsels, enz.), liet zien dat 50 orthogonale factoren (TSR's) in staat zijn om 64% 
van de expressie variabiliteit te vangen in een brede verzameling van experimentele condities en 
weefsels. Een 'split-half test liet zien dat deze TSR's betrouwbaar werden ge'identificeerd en niet 
gevoelig waren voor selectie van experimenten of genen. GSEA toonde aan dat de TSR's sterk 
gecorreleerd waren met biologische processen. 
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Soortgelijke resultaten werden waargenomen in muizen data, waarbij 50 TSR's 71 procent van de 
variabiliteit in expressie van 9.062 genen in 3.934 arrays verklaarden. Door de humane TSR's te 
koppelen aan en te vergelijken met de muis TSR's konden we aantonen dat er opvallende 
gelijkenissen zijn in de regulatie van biologische processen tussen mens en muis. 
Tot slot laten we zien dat het expressieprofiel van een individuele microarray voorspeld kan worden 
op grond van slechts 50 TSR scores (TSR-profiling). Hierdoor kan het signaal van duizenden 
individuele genen in slechts 50 TSR scores samengevat worden. Als voorbeeld laten we zien dat 
soortgelijke weefsels samenvallen wanneer er geclusterd wordt op basis van de eerste 50 TSR 
scores. 
Algemene discussie en toekomstvisie 
In microarraystudies kan men een expressieprofiel, dat in staat is om overleving / klinische uitkomst 
te voorspellen, het beste valideren door de op de trainingsset gebaseerde predictieregel toe te 
passen op een onafhankelijke validatieset. Een dergelijke validatie hebben wij getracht toe te passen 
op het prognostische gen-expressieprofiel in hoofdstuk 4. Door platformverschillen waren wij echter 
niet in staat om een-op-een validatie te doen van het onderliggende predictieve algoritme. Om deze 
reden hebben wij een 10-voudige kruisvalidatie toegepast binnen onze eigen dataset. Kruisvalidatie 
geeft een verwachtingswaarde voor het percentage misclassificaties dat men kan verwachten 
wanneer het predictieve model toegepast zou worden op onafhankelijk verzamelde data. Het is 
hierbij belangrijk op te merken dat een 10-voudige kruisvalidatie niet toereikend was om de 
prestatie van ons prognostisch profiel te bepalen. In onze studie kan een grote log-rank statistiek 
nog steeds deels gebaseerd zijn op 'overfitting', waardoor classificatie van patienten in 
risicogroepen mogelijk niet generaliseerbaar is. Er zijn meerdere oplossingen voorgesteld om een 
schatting te kunnen maken van de mate van 'overfitting', waarbij de 'shrinking' methodes, 
ontwikkeld door van Houwelingen en Le, een goed voorbeeld zijn (1). Wij hebben een andere 
methode toepast om de mate van 'overfitting' te kunnen schatten. Door het toepassen van een 
fenotype permutatietest, dus het loskoppelen van een patient aan de bij die patient behorende 
microarraydata, waren wij in staat om de significantie te bepalen van de log-rank statistiek voor de 
Kaplan-Meier overlevingscurven van de voorspelde overlevingsrisicogroepen. De gedachte achter 
deze permutatietest is dat, ender de nulhypothese dat er geen associatie is tussen gen-expressie en 
overleving er vanuit kan worden gegaan dat toewijzing van patienten tot overlevingsrisicogroepen 
op basis van hun gen-expressieprofiel gebaseerd is op toeval. Het aantal predictiemodellen dat na 
fenotype permutaties gevonden kon worden met een betere log-rank statistiek dan de log-rank 
statistiek gebaseerd op de werkelijke data, is de permutatie significantie voor het testen van de 
nulhypothese dat er geen relatie is tussen de expressiedata en overleving. 
Ondanks het toepassen van de 10-voudige kruisvalidatie en fenotype permutatietest is aanvullende 
empirische validatie van het prognostisch profiel voor eventuele klinische toepasbaarheid 
noodzakelijk. In navolging van Dr. Richard Simons kan onze studie gezien worden als een fase 2 
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studie waarin wij een expressieprofiel hebben geconstrueerd dat geassocieerd is met overleving (2). 
Validatie van ons profiel in een grote set van onafhankelijke, prospectief verzamelde ovarium 
tumoren zou de tweede stap zijn om het klinische bewijs naar niveau 2 of 1 te halen (3). 
In hoofdstuk 6 introduceerden wij 'TSR-profiling' als een concept om de prestaties van predictieve 
profielen te verbeteren. We lieten zien dat SO ongecorreleerde 'transcriptional system regulators' 
(TSR's) in staat waren om het overgrote deel van de biologische variatie in de correlatiestructuur 
tussen genen in mens of muis te verklaren. Aangezien een TSR een gewogen som is van gen­
expressie signalen kan er een TSR-score berekend worden voor iedere geobserveerde expressie 
array. Deze TSR's stellen ons in staat om het expressieprofiel van een individueel microarray te 
karakteriseren met SO TSR-scores in plaats van expressiesignalen van tienduizenden individuele 
genen. Het probleem van 'overfitting' wordt hierdoor verminderd, aangezien er een SOO-voudige 
reductie in dimensionaliteit optreedt. Omdat het aantal genen dat differentieel tot expressie komt 
tussen twee fenotypen binnen hetzelfde kankerweefsel type waarschijnlijk gering zal zijn en het 
verschil in expressie in verhouding tot experimentele ruis klein kan zijn (2), resulteert 'TSR-profiling' 
in een tweede voordeel: om TSR-scores te berekenen wordt het expressiesignaal van meerdere 
genen opgeteld, waardoor de ruis weggedrukt wordt en de signaal-ruis-verhouding verbetert. 
Tevens hebben wij aangetoond dat TSR's robuust zijn door te laten zien dat TSR-scores, berekend op 
willekeurige subsets van genen, hoog correleren. Daarom kunnen TSR-scores gezien worden als 
beter reproduceerbare input variabelen voor predictiemodellen dan expressiesignalen van 
geselecteerde individuele genen. 
In principe zouden er betrouwbare, op expressie gebaseerde genprofielen kunnen bestaan die geen 
lineaire functie zijn van de belangrijkste, door ons ge"identificeerde TSR's. Het zal echter moeilijk zijn 
om dergelijke profielen te identificeren, aangezien er dan grote ziektespecifieke datasets nodig zijn 
(in de orde van grootte zeals de dataset gebruikt voor het identificeren van de TSR's) om 
betrouwbaar ziektespecifieke correlaties tussen transcripten te kunnen schatten. Overwegende het 
feit dat dergelijke grote datasets nog niet bestaan, is de beste optie gebruik te maken van de 
expressie correlaties in de vele, vaak niet gerelateerde, datasets die op dit moment beschikbaar zijn 
in de grote publiekelijk beschikbare web databases. 
Op den duur hopen wij onze 'TSR-profiling' te optimaliseren door het aantal weefsels en genen in de 
analyse uit te breiden, zodat het aantal betrouwbare TSR's toe zal nemen. In de toekomst kan men 
genetische profielen, die in staat zijn prognose of respons op chemotherapie te voorspellen, het 
best baseren op TSR-scores als input variabelen. 
Het is goed om te benoemen dat de studies die uitgevoerd zijn in hoofdstuk 3 en 6 niet uitgevoerd 
konden worden zonder de wetenschapsgemeenschap die haar microarray data publiekelijk 
beschikbaar stelde. Dit benadrukt hoe belangrijk microarray web databases, zeals 'Gene Expression 
Omnibus' (4), zijn in het ondersteunen van de MIAME standaard voor het opslaan van microarray 
138 
Summary in Dutch (samenvatting) 
expressiedata. MIAME beschrijft de minimale informatie die nodig is om het resultaat van een 
microarrayexperiment ondubbelzinnig te interpreteren of mogelijk te reproduceren. 
Expressie analyses in dit proefschrift zijn uitgevoerd met gen-expressie microarrays die op dit 
moment gelden als de standaard voor het analyseren van het transciptoom. Gen-expressie 
microarrays hebben echter last van achtergrondsignalen en kruis-hybridisatie en meten slechts het 
relatieve verschil in aantal transcripten. Onlangs is een nieuwe generatie sequentie methodes 
beschikbaar gekomen die het mogelijk maakt om gen-expressie analyses uit te voeren doormiddel 
van 'direct shotgun sequencing' van complementair DNA gesynthetiseerd uit RNA monsters (5). In 
tegenstelling tot de microarray technologie zijn deze sequentie analyse methoden niet afhankelijk 
van vooraf gedefinieerde probe sequenties, waardoor deze methodes in staat zijn om bijvoorbeeld 
nieuwe 'splicing variants' of 'single-nucleotide polymorphisms' te ontdekken. Tevens tonen recente 
studies aan dat deze sequentie analyse methode uitstekende specificiteit, sensitiviteit en 
reproduceerbaarheid laat zien, die systematisch verbeteren met toenemende sequentie diepte. 
Daarboven is the kwantitatieve nauwkeurigheid beter in vergelijking met DNA microarrays en qRT­
PCR (6). Deze resultaten geven aan dat in de nabije toekomst, voor het bestuderen van het 
transcriptoom, microarray gebaseerde analyse vervangen zal worden door op sequentie gebaseerde 
expressie analyse. 
Verder hebben studies in aanvulling op mRNA expressieprofielen geprobeerd om 'single-nucleotide 
polymorphisms', epigenetica, miRNA expressie en proteomics te relateren aan klinische uitkomst. 
Het integreren van deze verschillende moleculaire niveaus zal onze kennis uitbreiden en een beter 
begrip opleveren in het gebied van (kanker)celbiologie. Breitling e.a. hebben door integratie van 
genotype en mRNA expressie data laten zien dat een 'single nucleotide polymorphism' (SNP) leidt 
tot grootschalige verandering in expressie van verafgelegen genen (7). SNPs die geassocieerd zijn 
met de expressie van verafgelegen genen worden zogenaamde 'quantitive trait loci' (eQTL"s) 
genoemd. In aanvulling hierop hebben Wu e.a. laten zien dat deze eQTLS biologisch coherent zijn, 
doordat in 25 procent van de gevallen functionele gensets uit de 'Gene Ontology', de KEGG 
intracellulaire routes en de 'Ingenuity Pathways Knowledge Base' oververtegenwoordigd waren in 
de genen die geassocieerd waren met een eQTL. De bevindingen suggereren dat integratie van 
verschillende moleculaire niveaus ans beter in staat kan stellen om biologische routes en 
signaleringscascades te definieren. Bovendien kunnen we ans voorstellen dat in de toekomst 
prognostische of predictieve modellen de verschillende moleculaire profielen (bijvoorbeeld mRNA, 
miRNA, epigenetica en proteomics) van een tumor integreren om zo tot een betere voorspelling te 
komen. 
Gen-expressie analyses, zoals ze uitgevoerd zijn in hoofdstuk 4 en 5, kunnen ons meer inzicht geven 
in tumor agressiviteit en therapieresistentie in ovarium tumoren, waardoor we eventuele nieuwe 
potentiele therapeutische opties kunnen ontdekken. Door het 'multiple-testing' probleem in hoog 
dimensionale datasets is het belangrijk om verdere validatie uit te voeren voor gei"dentificeerde 
genen om mogelijk fout-positieve bevindingen te voorkomen. Er zouden bijvoorbeeld 
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immunohistochemsiche kleuringen uitgevoerd kunnen warden om de klinische relevantie in een 
groat cohort te bepalen op het eiwitniveau. Verder zouden studies gedaan kunnen warden met 
ovariumtumorcellijnen om de functionaliteit en mogelijke therapeutische relevantie voor individuele 
genen te bepalen. 
Hoewel dergelijke individuele genen relevant kunnen zijn voor het gedrag van tumoren hebben wij 
ook aangegeven, dat het vaak niet bekend is of in ovarium- en andere tumoren een grate 
verandering in expressie van individuele genen biologisch belangrijker is dan de gecoordineerde 
kleine veranderingen in expressie van genen die behoren tot dezelfde intracellulaire route. Daarom 
hebben wij de nadruk gelegd op het integreren van individuele genen in functionele sets (GSEA) om 
de biologische routes te identificeren die geassocieerd zijn met het gedrag van ovariumtumoren. 
Een nadeel van GSEA is dat het geen rekening houdt met de interactie (positieve of negatief) tussen 
genen die deel uitmaken van een functionele genset, waardoor het niet mogelijk is om de 
activatiestatus van een intracellulaire route te bepalen in individuele tumoren. In de toekomst willen 
wij modellen creeren van intracellulaire routes die in staat zijn om de activatiestatus van relevante 
routes te bepalen in individuele tumoren. Dit kan ons in staat stellen om patienten te identificeren 
die mogelijk baat hebben bij nieuwe potentiele therapieen die specifiek op deze geactiveerde 
intracellulaire routes gericht zijn. Bovendien zouden dergelijke intracellulaire route modellen ons in 
staat moeten stellen om de werkzaamheid van gerichte moleculaire therapieen te screenen. De kans 
op activatie van een route zal toenemen of afnemen onder invloed van een moleculair gerichte 
therapie. Verder kunnen wij ons voorstellen dat in de toekomst een database van intracellulaire 
predictiemodellen gebruikt kan warden om te bepalen welke routes relevant zijn door de 
activatiestatus te correleren met klinische pathologische data. 
Bild e.a. beschrijven een methode om dergelijk intracellulaire routes te modelleren. Doormiddel van 
recombinante adenovirussen werd in niet-delende cellen de activiteit van verschillende oncogenen 
verhoogd. De hierop volgende verandering in expressie werd toegewezen aan de 
activatie/deregulatie van de intracellulaire (oncogen-afhankelijke) route. Vervolgens werden de 
genen, die significant differentieel tot expressie kwamen tussen de niet-delende originele en de met 
een oncogen ge'infecteerde cellen, gebruikt om een predictiemodel te trainen dat in staat was om 
de activiteit van de intracellulaire route te bepalen. Naar onze mening is het beter om dergelijke 
intracellulaire routes te definieren met cellijnen die afkomstig zijn van hetzelfde type weefsel als 
waarin de activatie later bepaald zal warden. Deze benadering zal voorkomen dat grate gen­
expressie verschillen tussen de cellijn en het weefsel dat geanalyseerd wordt, resulteren in onjuiste 
voorspelling van de activatie. Een nadeel van de benadering van Bild e.a. is dat er geen vooraf 
bekende informatie over de intracellulaire route gebruikt wordt voor het definieren van het model. 
Alie genen die significant differentieel tot expressie komen, warden als input variabelen gebruikt in 
de predictieve modellen. Daartussen zitten ook genen die differentieel tot expressie komen op basis 
van toeval, het transfectie proces of een andere onbekende systematische verstoring. Deze genen 
zijn niet relevant voor de intracellulaire route en kunnen in het model mogelijk leiden tot foutieve 
voorspellingen van de activatie. 
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De predictiemodellen zouden verbeterd kunnen worden door gebruik te maken van expressie 
signalen van een subset van genen, waarvan men al weet, op basis van goed gedefinieerde 
databases zoals KEGG of Biocarta, dat ze betrokken zijn bij de intracellulaire route. Zoals boven 
reeds beschreven, kan voor deze subset van genen 'TSR-profiling' worden toepast waardoor de 
signaal-ruis-verhouding zal toenemen en 'overfitting' wordt vermeden. Dit zou mogelijk kunnen 
leiden tot nauwkeurigere voorspellingen. 
Naast het tot over-expressie brengen of remmen van sleutelgenen in een relevante intracellulaire 
route, suggereren recente resultaten met Poly{ADP-ribose) polymerase {PARP) remmers dat een 
andere interessante strategie toegepast kan worden. In cellijnen met een BRCAl of BRCA2 mutatie 
induceren PARP remmers celcyclus arrest en apoptose. lnitiele klinische studie lieten zien dat PARP 
remmers uiterst goed verdragen werden en antitumor activiteit lieten zien als een monotherapie in 
de subgroep van reeds uitgebreid behandelde ovariumkankerpatienten, die dragers zijn van een 
BRCAl of BRCA2 mutatie. Door cellijnen met een normale en een afwijkende sequentie van het 
BRCA gen te vergelijken, kan men de gevolgen definieren van BRCA mutaties op gen-expressie 
niveau. De afwijkende gen-expressies in combinatie met 'TSR-profiling' kunnen weer dienen als 
input variabelen voor een predictiemodel. Een dergelijk predictiemodel zou, in theorie, in staat 
moeten zijn om de sensitiviteit van patienten voor PARP onderdrukkers te voorspellen, zelfs als zij 
niet dragers zijn van een BRCA mutatie, maar wel een tumor genexpressie profiel hebben dat lijkt op 
dat van een BRCAl of BRCA2 mutatie dragers. Een dergelijke strategie zou uitgebreid kunnen 
worden naar andere moleculair gerichte therapieen die voor hun therapeutische werking tevens 
afhankelijk zijn van mutaties of ontregelde intracellulaire routes. 
Concluderend biedt dit proefschrift nieuwe inzichten in de moleculaire verandering op gen, 
intracellulaire route en transcriptiefactor niveau die relevant zijn voor het gedrag van 
ovariumtumoren. Deze inzichten zouden verder benut moeten worden in de zoektocht naar nieuwe 
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